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3 Summary 
Memo was recently identified in a screen for proteins required for ErbB receptor induced cell 
migration. Encoded by a single-copy gene present in all branches of life, it is ubiquitously expressed 
during all stages of embryogenesis and in adult tissues. This study aimed to investigate the 
physiological role of Memo. Initially, we generated a conventional knock out of Memo, which was 
embryonic lethal between E12.5 to E14.5. We subsequently generated a mouse strain to allow temporal 
control of Memo deletion by crossing a mouse strain harboring a homozygous floxed Memo allele 
(Memofl/fl) with pCX-CreERTM transgenics, where the ubiquitous actin promoter drives the Cre 
recombinase. Following tamoxifen treatment, Memo was deleted in all organs (Memo null mice). 
Knock out of Memo in mice at the age of 2 to 14 weeks revealed a severe premature aging phenotype 
accompanied by alterations in insulin and glucose metabolism. The phenotype of the Memo null mice, 
especially the metabolic phenotype, revealed an interesting similarity to the Klotho and FGF23 mutant 
mice. In particular, insulin and glucose metabolism was very similar to the phenotype shown by both 
Klotho mutant and FGF23 knock-out mice. To investigate this phenotype further, and as Klotho is 
mainly expressed in the renal tubular cells, we generated a mouse model, which lacked Memo 
specifically in the kidney. We chose a Pax8 promoter system to delete Memo in the renal tubular cells 
(1). Kidney specific Memo knock-out mice were generated by crossing Memo floxed (Memofl/fl) mice 
with a mouse line expressing the tetracycline-sensitive transactivator rtTA under control of the Pax8 
promoter, and a mouse line harboring Cre recombinase under a promoter that contains a tetracycline-
responsive promoter element. In these mice doxycycline treatment induced loss of Memo in renal 
tubular epithelial cells. 
By investigation of the Memo null and kidney-specific Memo KO mice we found that only the Memo 
null mice showed premature aging symptoms. However, both KO models showed deregulation of the 
FGF23-Klotho axis measuring expression of enzymes involved in vitamin D metabolism and phosphate 
reabsorption. Moreover, blood analysis of both models showed renal insufficiency and hypercalcemia. 
For the kidney-specific Memo KO animals we also performed analysis of the urine and found 
hypercaliuria. Surprisingly, for both models there was no difference in serum phosphate levels, which 
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has earlier been shown by others to be causative for the premature aging syndrome. 
In conclusion, we found that deletion of Memo in the full body or specifically in the kidney induces 
renal insufficiency and hypercalcemia. Furthermore, Memo deletion in the full body results in severe 
premature aging symptoms that cannot be explained by elevated serum phosphate levels. To date, it is 
not clear how hypercalcemia and hypercalciuria affects Memo mice and what specifically induces the 
premature aging in Memo null animals. 
To investigate the function of Memo in vitro we isolated and immortalized mouse embryonic 
fibroblasts (MEFs) from Memofl/fl embryos. These cells were then infected with a Cre recombinase 
containing vector, which following 4-hydroxytamoxifen treatment ablated Memo expression (KO 
MEFs). Our studies showed that signaling downstream of FGF2 was reduced in activity and duration in 
Memo KO MEFs and furthermore that Memo was associated with the FGFR signaling complex 
(FGFR-FRS2-GRB2-GAB1). In addition, we tested mammary carcinoma cells (4T1) for sensitivity to 
FGFR inhibition and revealed lower sensitivity to FGFR inhibition in Memo downregulated cells. To 
investigate the role of Memo in the metabolic signaling we used HEK293 cells that are stably 
transfected with Klotho or βKlotho and therefore responsive to FGF19, 21 and 23. We found that in 
Memo downregulated HEK293-Klotho and –βKlotho cells, FGFR signaling activity after stimulation 
with FGF23 and FGF19 was affected.  
In summary, this study provides evidence for a physiological role of Memo downstream of the FGFR 
pathway. We show that Memo is part of the FGFR signaling complex. Loss of Memo affects the 
intensity and duration of the FGFR signaling and modulates sensitivity to FGFR inhibition and to 
oxidative stress. Furthermore, we uncovered an important role of Memo in renal physiology that 
contributed to a premature aging phenotype, which is similar to that observed in Klotho mutant or 
FGF23 knock out animals. 
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4 Introduction 
4.1 Memo (Mediator of ErbB2 driven cell motility) 
4.1.1 The ErbB family 
The ErbB2 receptor family has been shown to be very important in a wide range of physiological 
processes as well as in disease. The family consists of four ErbB receptors, EGFR/ErbB1, ErbB2, 
ErbB3 and ErbB4. Their extracellular region consists of four domains (I-IV); Domain I and III are 
important for peptide binding, while domain II is important for receptor-receptor interaction. Upon 
activation of the receptor homo- and heterodimers are formed. ErbB1, ErbB3 and ErbB4 bind their 
ligands leading to activation, while ErbB2 does not bind a ligand, but is a preferred binding partner of 
the other receptors and is activated by crossphosphorylation. 
The Erb receptor ligands are expressed by 10 different genes (2) and include EGF, betacellulin (BTC), 
transforming growth factor-alpha (TGF-α), heparin-binding EGF-like growth factor (HB-EGF), 
epiregulin, amphiregulin (AREG) and four neuregulins (NRG 1-4). The ligand family members are 
expressed as transmembrane precursor protein molecules, which possess a conserved epidermal growth 
factor (EGF)-like domain (3), and undergo ectodomain proteolytic cleavage by a procession of 
different ADAMs to release the mature active growth factors. 
Upon activation of the receptors different downstream pathways are activated, including the mitogen-
activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K)-AKT pathways. 
Furthermore, activation of signal transducer and activator of transcription proteins (STATs), SRC 
tyrosine kinase and the mammalian target of rapamycin (mTOR) can be observed. The EGFR pathway 
is important for a wide range of physiological processes, as such the constitutive knock out of EGFR in 
mice results in death during the first postnatal week. ErbB2, ErbB3 and ErbB4 have been shown to 
have an essential role in cardiac development and in disease, such as in breast cancer where it has been 
found that about 30% human breast cancers show overexpression of ErbB2 (4). 
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4.1.2 Memo (Mediator of ErbB driven cell motility) 
Much research has focused on understanding tumor etiology and developing strategies for therapeutic 
elimination of primary tumors. However, as up to 90% of tumor related mortality is related to 
metastatic disease rather than a consequence of the primary tumor, research in the field of tumor 
metastasis has become increasingly important. Metastasis formation is a multi-step process, consisting 
of extravasation, migration and intravasation. Our group was interested in the process of cancer cell 
migration and aimed at finding binding partners of ErbB2 which were relevant for migration. They 
showed that mainly two phosphorylation sites of ErbB2 are relevant for migration; Tyr1201 and 1227. 
Based on this, the focus was set on proteins that bind to peptides containing Tyr1201 or Tyr1227. 
Binding proteins were identified by liquid chromatography-tandem mass spectrometry (LC-MSMS). In 
this screen several known binding partners were confirmed and in addition a novel 32kDa protein was 
found and named Memo (Mediator of ErbB driven cell mo
4.1.3 The structure of Memo 
tility). Memo is a 297-amino-acid protein. A 
single protein is encoded in the human genome, and Memo homologs are found in all branches of life. 
Boyden chamber migration assays have shown that down-regulation of Memo in human cancer cells 
interferes with cell migration. In addition, it has been shown that not only migration downstream of the 
ErbB pathway, but also downstream of the FGFR pathway was affected by Memo down-regulation. 
In collaboration with the group of Daniel J. Leahy we investigated the structure and possible function 
of Memo (5) and the Leahy group determined the 2.1 A crystal structure of human Memo. We showed 
that Memo is structurally homologous to ligB, a member of the class II of bacterial non-heme iron 
dioxygenase. The active site of ligB family members is formed by two histidines and glutamine. Memo 
contains the two histidines, but the glutamine is replaced by a cysteine.  This exchange does not 
necessarily imply loss of metal binding, but it was not possible to detect any metal binding in the 
structure or enzymatic activity of Memo. While we published earlier that in cellular lysates Memo 
binds Tyr1201 of ErbB2 via Shc (6), it was shown here that Memo can directly bind the phospho-
peptide as well, although the dissociation constant for this interaction is relatively high in the range at 
kD=32 µM. Therefore, in vivo it is likely that Memo uses other factors which enhance its binding to the 
receptor, e.g. shc. More recently, it has been shown that Memo binds with its vestigial active site to a 
16 amino acid helical structure of the phospho-peptide (7). In addition, there is evidence that 
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phosphorylation of Tyrosine 8 of the phospho-peptide is important for Memo binding. Furthermore, 
three asparagine-sites proofed to be essential. In Memo the three hisitines as well as the cystein, 
described earlier (5), are important for the interaction with the phospho-peptide. This data suggest that 
Memo contains a novel phosphotyrosine motif, different to the known SH2 and PTB domains. 
4.1.4 Memo and migration 
Memo positively affects migration downstream of heregulin and FGF2 stimulation (6) and affects the 
formation of short-lived adhesion sites and outgrowth of microtubules, resulting in a defect in 
migration. Memo-RhoA-mDia1 signaling coordinates the organization of the lamellipodial actin 
network (8). Memo is also specifically important for directionality (9) and we demonstrated that Memo 
is important for PLCγ activation by showing that in Memo knock-down T47D cells phosphorylation of 
PLCγ is impaired (9). Our data suggest that Memo cooperates with PLCγ in the migration process; both 
Memo knock-down cells and PLCγ knock-down cells show impaired directional migration in T47D 
cells. Furthermore, our data shows that Memo interacts with cofilin, an actin severing and depolarizing 
protein and that in F-actin polymerizinging assays Memo binds F-actin, therefore in cells Memo may 
enhance PLCγ activation via altering the actin cytoskeleton (9). 
4.2 The Fibroblast Growth Factor (FGF) tyrosine kinase receptor family 
The FGF superfamily has been shown to be important in normal physiology, both during development 
and in the adult organism, and as well in disease. During embryonic development, FGF receptor 
(FGFR) signaling orchestrates a multitude of processes. FGFRs are master regulators of mesenchymal-
epithelial communication and thus are required for organogenesis and pattern formation (10, 11). They 
have been shown to be relevant for the formation of the nervous system, the limbs, midbrain, and the 
lungs (12). Furthermore, FGFR signaling also plays a key role in the induction and development of the 
embryonic mammary gland (13-16). In the adult, FGFs continue to regulate tissue homeostasis but also 
play important roles in wound healing, tissue repair, cholesterol metabolism (17, 18) and serum 
phosphate regulation (19-24). They have also been shown to have a role in angiogenesis and 
neovascularization, although FGFR signaling is thought to mainly play an indirect role by influencing 
other growth factors such as the vascular endothelial growth factor (VEGF) and hepatocyte growth 
factor (HGF) (25). Imbalances in FGF signaling cause a wide spectrum of human pathological 
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conditions, including skeletal syndromes (26), olfactory syndromes (27), phosphate wasting disorder 
(28, 29), and cancer (30-32). 
4.2.1 The FGF receptors 
4.2.1.1 The structure 
The FGF superfamily consists of four different FGF receptors (1-4) of which there exist various splice 
variants of receptors 1-3. Like all receptor tyrosine kinases, they are composed of an extracellular 
ligand binding domain, a single transmembrane domain and a cytoplasmic domain containing the 
catalytic protein tyrosine kinase core as well as additional regulatory sequences (33, 34). 
The extracellular ligand-binding domain of FGFR is composed of three immunoglobulin (Ig) like 
domains, designated D1-D3; the stretch of D1 and D2 contains an “acid box” consisting of 7-8 acidic 
residues that link D1 and D2 and a conserved positively charged region in D2 that serves as a binding 
site for heparin (35). The third of the IgG loops can be alternatively spliced resulting in different 
isoforms of the receptors 1-3. The isoforms arise by two alternative exons, IIIb and IIIc, which are 
spliced to the common exon IIIa in a mutually exclusive fashion. These isoforms are expressed by 
different cell types and tissues and are referred to in the literature as ‘c’ for mesenchymal and ‘b’ for 
epithelial (Figure 4-1). 
The cytoplasmic juxtamembrane domain of FGFRs is considerably longer than that of other receptor 
tyrosine kinases. This region contains a highly conserved sequence that serves as a binding site for the 
phosphotyrosine binding (PTB) domains of the two members of the FRS2 family of docking proteins, 
FRS2α and FRS2β (36, 37). In FGFR1, seven tyrosine residues have been identified as the major 
autophosphorylation sites: Tyr463, 583, 585, 653, 654, 730, and 766. (38, 39). 
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Figure 4-1 Structure of the FGF receptors 
FGFRs 1-3 are alternatively spliced. The first half of the third Ig is encoded by exon IIIa. This exon is spliced to either exon 
IIIb or IIIc. Epithelial tissues predominantly express the isoform IIIb and mesenchymal tissues express the isoform IIIc.  
This alternative splicing also influences ligand-binding specificity. Adapted from Turner et al. 2010 
4.2.1.2 Mutations of the FGF receptors 
The knock-out of Fgfr1 and 2 are embryonic lethal. 
Mutation of Fgfr1: leads to growth retardation and defect of mesodermal patterning lethal at E7.5-9.5 
(40, 41) 
Mutation of Fgfr2: is lethal at E4.5-5.5 (42) 
Knock-out of Fgfr3 results in bone over growth and inner ear defect (43, 44). 
Mice with a knock-out of Fgfr4 look morphologically normal, but their liver function is decreased 
(depleted gallbladders, elevated bile acid pool and excretion of bile acids) and those mice are sensible 
to xenobiotics (CC14). (45, 46) 
Mutations of the FGF receptors cause many different diseases, showing the importance of these 
receptors in normal physiology. Mutations are known for receptors 1-3, Table 4-1. 
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Table 4-1 Birth defects associated with mutations in FGF receptors 
Adapted from Burke et al. 1998 
4.2.2 The FGFR ligands 
There are 22 identified FGFs which are widely expressed in embryonic and adult tissues and have 
various biological activities both in vivo and in vitro, including roles in angiogenesis, mitogenesis, 
cellular differentiation, cell migration and tissue-injury repair. The diversity of the FGF gene family 
was generated both by gene and chromosomal duplication and translocation during evolution.  
4.2.2.1 Structure of the FGFs 
Although FGFs vary in size from 17 to 34 kDa, all members of the family share a conserved sequence 
of 120 amino acids that show 16-65% sequence identity (47). They have a homologous core region that 
consists of 120-130 amino acids ordered into 12 anti-parallel β-strands (β1−β12), flanked by divergent 
amino and carboxyl termini. In general, primary sequence  variation of the N- and C-terminal tails of 
FGFs accounts for the different biology of the ligands (48). The heparan sulphate glycosaminoglycan 
(HSGAG) binding site (HBS) which is composed of the β1−β2 loop and parts of the region spanning 
β10 and β12 is in the FGF core. For paracrine FGFs, the elements of the HBS form a contiguous, 
positively charged surface. In contrast, the HBS of the FGF19/endocrine subfamily contains ridges 
formed by the β1−β12 loop and the β10−β12 region, which sterically hinders HSGAG binding to the 
core backbone of the FGFs thus, leading to the endocrine nature of this subfamily (49). Most of the 
FGF ligands contain a non-cleavable N-terminal hydrophobic sequence which is required for their 
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secretion, although there are exceptions as FGF 9, 16 and 20. They lack such a signal sequence but are 
secreted nevertheless. FGF1 and FGF2 also lack these signal peptides, however, they are not secreted 
but can be released from damaged cells or by an exocytotic mechanism that is independent of the 
endoplasmic reticulum-Golgi pathway (47). The 22 known FGF ligands are divided into seven 
subgroups (Figure 4-2).  
 
 
Figure 4-2 The evolutionary relationships within the human FGF gene family (Itoh et al. 2004) 
22 genes have been identified. Phylogenetic analyses suggest grouping of those genes into seven subfamilies, each 
containing two to four members. Branch lengths are proportional to the evolutionary distance between each gene. The value 
at each branch-point indicates the percentage of times that a node was supported in 1000 bootstrap pseudoreplications. 
Fgf15 is the mouse gene that is the ortholog to the human fgf19. 
 
• FGF1 subfamily (FGF1 and FGF2) 
The exact physiological roles of FGF1 and FGF2 are still unclear. However, it is likely that they play a 
part in the maintenance of vascular tone, as administration of FGF1 and FGF2 lowers blood pressure in 
rats (50) and can restore nitric oxide synthase activity in spontaneously hypertensive rats (51). The 
angiogenic properties of FGF2 are well known: exogenous FGF2 stimulates migration and proliferation 
of endothelial cells in vivo (52), it has anti-apoptotic activity (53) and it stimulates mitogenesis of 
smooth muscle cells in fibroblasts, which induces the development of large collateral vessels with 
adventitia (54). However, the physiological relevance of these effects is uncertain. Evidently, there is a 
high level of compensation among the growth factors mediating angiogenesis (55). 
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• The FGF4 subfamily (FGF4, FGF5, FGF6) 
FGF4 has wide-ranging functions in development, including cardiac valve leaflet formation (56) and 
limb development (57), and it is as well important for trophoblast proliferation (58). 
Thus far, roles for FGF5 in the negative regulation of the hair follicle growth cycle (59) and for FGF6 
in myogenesis (60) have been elucidated. 
 
• The FGF7 subfamily (FGF3, FGF7, FGF10, FGF22) 
FGF7 is also known as keratinocyte growth factor (KGF). It is expressed specifically in the 
mesenchyme. Its levels are increased by up to 150-fold in the skin after cutaneous injury (61), and are 
also increased after bladder or kidney injury (62, 63).Homozygous deletion of FGF3 was shown to 
cause hereditary deafness, leading to total inner ear agenesis in humans (64). While FGF10 knock-out 
mice lack limbs and the pulmonary structures (65). In addition, they also exhibit defects in all other 
branching organs.FGF22, along with FGF7 and FGF10, are presynaptic organizers with roles in vesicle 
clustering and neurite branching (66). 
 
• The FGF8 subfamily (FGF8, FGF17, FGF18) 
FGF8 is involved in brain, limb, ear and eye development (67) and, along with FGF17, is crucial for 
forebrain patterning (68). FGF8 knock-out mice do not undergo gastrulation (69). FGF17 knock-out 
mice exhibit abnormalities in the development of cerebral and cerebellar structures (70) while FGF18 
knock-out mice have decreased expression of osteogenic markers and delayed long-bone ossification 
(71, 72). 
 
• The FGF9 subfamily (FGF9, FGF16, FGF20) 
FGF9 knock-out mice demonstrate male-to-female sex reversal and lung hypoplasia that quickly leads 
to postnatal death (73). Importantly, the FGF9 subfamily, which signals from the epithelium to the 
mesenchyme, functions in a reciprocal way to the FGF7 subfamily, which signals from the 
mesenchyme to the epithelium. FGF9 stimulates mesenchymal proliferation, and the mesenchyme in 
turn produces ligands of the FGF7 subfamily. Accordingly, knocking out FGF9 disrupts the 
mesenchymal-epithelial signaling loop that helps to regulate these FGFRb-binding ligands. And the 
concomitant reduction in production of the FGF7 subfamily ligands is the proximate cause of the 
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observed lung hypoplasia (74). FGF16 knock-out mice exhibit significant cardiac defects (75). 
 
• The FGF19 subfamily (FGF19/15, FGF21, FGF23) 
This family is also called the endocrine family, as this is the way these FGFs function. FGF15 is the 
mouse ortholog of the human FGF19. The members of the FGF19 subfamily do not bind Heparin/HS, 
but interact with the Klotho family as coreceptors, which are discussed in more details in chapter 4.4.2 
FGFR pathway & Metabolism. 
 
As detailed above, the functions of the various FGF ligands are diverse and very important. Therefore, 
it is not surprising that null mutations in these genes lead to severe phenotypes, many of which are 
summarized in Table 4-2. 
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Table 4-2 FGF knock-out mice (Ornitz et al. 2001) 
4.2.2.2 FGF-FGFR specificity 
 
FGF signaling is in general important for the reciprocal communication between mesenchymal and 
epithelial tissue, although ligands, such as FGF1, pose exceptions to this general rule by promiscuously 
binding to both the b and c isoforms of certain FGFRs. (Figure 4-3). Pathological states can result from 
a breakdown in binding specificity, as is common in cancers in which FGFs are overexpressed (76). 
Structural studies of FGF1, 2, 8 and 10 with their cognate FGFRs show that sequence diversity at the 
FGF N-termini, variation in β1 strand length and the alternatively spliced regions in D3 dictate binding 
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specificities. 
 
Figure 4-3 FGFR specificity for ligand binding (Turner et al. 2010) 
Ligand specificity shown on the example of FGFR IIIb and IIIc.  
4.2.2.3 Modulators of FGF signaling 
There are two known factors that facilitate specific ligand activity: 
• FGF-binding protein (FGFBP): activates FGFs by releasing them from the extracellular matrix, 
where they are bound by Heparan sulfate glucosaminoglycans (HSGAGs) (77).  
• Fibronectin leucine-rich transmembrane protein 3 (FLRT3): facilitates FGF8 activity through the 
MAPK pathway (78). 
4.2.3 The FGF coreceptors: Heparin/Heparan sulfate proteoglycans and the Klotho family 
FGF ligands show low affinity for their receptors therefore binding of the ligands with their receptors is 
greatly enhanced by binding to coreceptors. For most of the ligands, with the notable exception of the 
three metabolic ligands, Heparin/Heparan sulfate proteoglycans (HS) serve as coreceptors and stabilize 
the FGF ligand/receptor complex. The three metabolic ligands on the other hand interact with members 
of the Klotho family.   
4.2.3.1 Heparin/Heparan sulfate proteoglycans (HS) 
Heparin and HS are heterogeneously sulfated linear polymers containing repeating disaccharide 
subunits of hexuronic acid (iduronic or glucuroinic acid) and D-glucosamine (79). It has been shown 
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that, although there is formation of a minimal FGF/FGFR complex in the absence of heparin/HS (80), 
Heparin/HS are essential for high affinity binding of the FGFs to their receptors. High affinity binding 
between the receptors and their ligands is important to induce signaling. Heparin/HS are found in the 
extracellular matrix adjacent to cell surfaces and as integral components of the plasma membrane (81, 
82). Their binding of the FGFs keeps these ligands and their effects close to the secreting cell. 
Heparin/HS were proposed to: (i) stabilize and protect FGFs from thermal, proteolytic, or pH-
dependent degradation (83, 84), (ii) function as storage reservoirs from which FGFs can be liberated 
for interaction with FGFRs (85-89), or (iii) facilitate FGF-FGFR encounters by limiting the diffusion of 
the FGF ligands (90). Finally, Heparin/HS also facilitate FGFR clustering, as they are able to 
simultaneously bind multiple FGF ligands. Moreover, heparin degrading enzymes (heparanases) 
release soluble FGF/HS complexes and therefore inhibit FGFR signaling. Another function of 
heparanases is to reduce adherence of cells (91).  
4.2.3.2 The Klotho family 
The Klotho family consists of two distinct members, named Klotho and βKlotho, which are encoded by 
two genes. They are both type I membrane proteins and have a single membrane-spanning region with 
a short intracellular tail (92, 93). And they both share structural similarity to family 1 glucosidase 
members (92, 94, 95). In contrast, for Klotho, but not for βKlotho a secreted form has been found (93). 
Members of the FGF19 subfamily show very little affinity for their cognate FGFRs in the absence of 
Klotho, therefore, FGF23 uses Klotho as coreceptor and FGF19 and 21 βKlotho. The extracellular 
domain of Klotho proteins was demonstrated to bind directly to multiple FGFRs (96, 97).  
Klotho is discussed in more detail in chapter 4.4.2. 
 
4.2.4 Signaling of the FGFR pathway 
4.2.4.1 FRS2 dependent signaling 
The FGFR is constitutively associated with FGFR substrate 2 (FRS2), a key adaptor protein that is 
largely specific to FGFRs although it can also bind other tyrosine kinase receptors, such as 
neurotrophic tyrosine kinase receptor type 1 (NTRK1) (36, 98), RET (99-101) and anaplastic 
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lymphoma kinase (ALK) (102). In contrast to FGFRs, RET and the neurotrophin receptors TrkA and 
TrkB bind only the phosphorylated form of FRS2 (36, 100). 
FRS2 proteins contain myristyl anchors and PTB domains in the N-termini and a large region with 
multiple tyrosine phosphorylation sites at their C-termini (103, 104). They contain four binding sites 
for the adaptor protein GRB2 and two binding sites for the protein tyrosine phosphatase SHP2. The 
FRS2 family consists of two members, FRS2α and FRS2β, which are structurally very similar. 
Expression of FRS2α begins in the early stages of development, whereas expression of FRS2β begins 
at mid-gestation, predominantly in tissues of neuronal origin (98). The different expression patterns of 
FRS2α and β suggest specific, nonoverlapping roles for each docking protein. 
FRS2 is bound constitutively to the receptor but phosphorylation occurs only upon ligand binding to 
the receptor, dimerization and autophosphorylation of the receptor at different tyrosines. Subsequent to 
its phosphorylation it recruits different FRS2-dependent adaptor proteins, such as son of sevenless 
(SOS) and growth factor receptor-bound 2 (GRB2) to activate RAS and the downstream RAF and 
MAPK pathways (105). A separate complex involving GRB2-associated binding protein 1 (GAB1) that 
is recruited to GRB2, stimulates PI3K and the AKT pathway (106). Adaptor proteins or enzymes, 
which are FRS2-independent,
Figure 4-4
 are directly recruited to the receptor tyrosine sites, as for example PLCγ 
is recruited to Tyr766.  
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Figure 4-4 The FGFR signalosome 
 
FRS2 is responsible for the assembly of both positive (i.e. SOS, PI3K) and negative (i.e. CBL), 
signaling proteins resulting in a balanced FGF signal transduction (105). 
In addition, while tyrosine phosphorylation of FRS2 by the receptor induces positive signaling, 
threonine phosphorylation of FRS2 by ERK affects signaling negatively. In FGFR signaling this allows 
a negative feedback loop between activated ERK and FRS2. In contrast, signaling downstream of 
Insulin, EGF, and PDGF induces only threonine phosphorylation of FRS2 via ERK and always results 
in a negative outcome of the signaling downstream of FRS2 in response to Insulin, EGF and PDGF 
(107, 108).     
4.2.4.2 FRS2 independent signaling 
Autophosphorylation on Tyr766 in the C-terminus of FGFR1 creates a specific-binding site for the SH2 
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domain of phospholipase PLCγ (39). Upon complex formation of Tyr766 with PLCγ, the phospholipase 
is activated and phosphatidylinositol-biphosphate (PIP2) is hydrolysed leading to the generation of the 
two second messengers, diacylglycerol (DAG) and phosphatidylinositol-3,4,5-triphosphate (PIP3) 
(109). DAG activates among others, protein kinase C (PKC), which partly reinforces the activation of 
the MAPK pathway by phosphorylating RAF-1 (c-raf). (Figure 4-5) 
Membrane recruitment of PLCγ is aided by binding of the pleckstrin homology domain of PLCγ to 
PIP3 molecules that are generated in response to PI3K stimulation (110).  
 
Figure 4-5 FGFR signaling (Turner et al. 2010) 
 
Several other pathways are also activated by FGFRs depending on the cellular context, including the 
p38 MAPK and Jun N-terminal kinase (JNK) pathways, signal transducer and activator of transcription 
(STAT) signaling (111) and ribosomal protein S6 kinase 2 (112). 
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4.2.4.3 Negative regulators of FGFR signaling 
The mechanisms of attenuation and negative feedback control of FGFR signaling are only partly 
understood.  
• CBL 
Cells that are stimulated by FGF2 induce not only activation of many pathways, but as well FGFR 
degradation via GRB2 dependent binding of CBL, an ubiquitin ligase, to FRS2 (113, 114). GRB2 and 
CBL are constitutively associated. Upon stimulation GRB2/CBL and GRB2/SOS compete for binding 
to FRS2. GRB2/SOS induces positive signaling while GRB2/CBL induces internalization and 
ubiquitination of the receptor, followed by lysosomal degradation. CBL is responsible for the main bulk 
of degradation, although there are also other processes that may involve other members of the CBL 
family that induce degradation (114).  
• Negative feedback loop 
MAPK signaling, particularly ERK1 and ERK2 signaling, has been shown to phosphorylate FRS2 on 
multiple threonine residues (canonical ERK phosphorylation sites (PXTP motif)), inhibiting the 
recruitment of GRB2. This inhibition is induced by a variety of ligands, FGF, insulin, EGF and PDGF 
(107). 
• Phosphatases 
Downstream signaling can be attenuated through the induction of MAPK phosphatases such as MAPK 
phosphatase 3 (MKP3). MKP3 dephosphorylates ERK1 and ERK2 to attenuate MAPK signaling (115). 
 
• Sprouty (SPRY) and SEF 
Sprouty proteins (116, 117) and SEF (similar expression to fgf genes) (118, 119) family members 
modulate receptor signaling at several points in the signal transduction cascade (120). Sprouty proteins 
are thought to function in either a dominant-negative fashion, by competing for GRB2 binding and 
thereby preventing SOS-mediated RAS activation, or by directly binding to RAF and blocking 
subsequent MAPK signaling (116, 117). Similarly, SEF encodes a conserved protein that shares 
sequence similarities with the intracellular domain of the interleukin 17 receptor. SEF is a member of 
the FGF synexpression group and its expression is regulated by FGF. It acts similarly to sprouty, it 
functions at multiple levels and has a transmembrane form that can directly interact with FGFRs; both 
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the transmembrane form and a splice variant that is confined to the cytoplasm seem to be capable of 
inhibiting ERK phosphorylation (121). 
• Receptor recycling 
Receptor recycling is a mechanism to ensure prolonged activation of the receptor and to enable 
dynamic regulation of signaling. NCAM has been identified as a non-canonical ligand for FGFR1. It 
induces internalization of the receptor to the endosome, but prevents CBL binding and thus 
ubiquitination and degradation. Instead the receptor is recycled to the membrane via Rab11-positive 
vesicles resulting in sustained signaling and cell migration (122). While FGF2 stimulated ERK 
activation is Ras dependent, stimulation with NCAM probably triggers an integrin-FAK-Src-ERK1/2 
pathway. 
4.2.5 FGFRs and cancer 
FGFR signaling has been found to be altered in several cancers. Excessive signaling may cause; 
increased proliferation, enhanced survival, migration/invasion or angiogenesis. 
Excess FGFR signaling can be caused by several mechanisms. Gene amplification, activating 
mutations, and chromosomal rearrangements in the genes encoding FGFRs can give rise to receptors 
with altered signaling activities. Other mechanisms involve higher ligand availability, switching of 
alternatively spliced isoforms, germline single nucleotide polymorphism (SNP) and inability to 
terminate FGFR signaling.  
4.2.5.1 Excessive FGFR signaling 
• FGFR gene amplification 
Elevated levels of FGFRs have been found in numerous human cancers such as cancer of the brain, 
head and neck, lung, breast, stomach, and prostate and in sarcomas and multiple myeloma (123-130). 
However, an elevated level of a protein in cancer cells does not necessarily mean that this protein plays 
a role in carcinogenesis. 
Amplifications of both FGFR1 and FGFR2 have commonly been described, while amplification of 
FGFR3 has only been rarely described in cancers (131) 
Amplification of FGFR1: 
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Amplification of the chromosomal region 8p11-12, the genomic location of FGFR1, is one of the most 
common focal amplifications in breast cancer (132-134), and occurs in approximately 10% of breast 
cancers, predominantly in oestrogen receptor (ER)-positive cancers (132). FGFR1 amplifications have 
also been reported in oral squamous carcinoma (129) and are found at a low incidence in ovarian 
cancer (135), bladder cancer (136) and rhabodomyosarcoma (137). Nevertheless, the role of FGFR1 in 
the amplicon is debated, because the 8p11-12 region contains many genes and FGFR1 is not always 
overexpressed when it is amplified. Even though Reis-Filho and colleagues showed that the FGFR1-
amplified cell line MDA-MB-134 is dependent on FGFR1 for proliferation (134), it is not universally 
accepted that FGFR1 is a driver of cancer harboring 8p11-12 amplification. 
Amplification of FGFR2: 
Approximately 10% of gastric cancers show FGFR2 amplification. There is a correlation of FGFR2 
amplification and poor prognosis of diffuse-type gastric cancers (138, 139), which is a cancer type that 
consists of poorly differentiated tumor cells. The stomach wall is often thick and rigid, caused by 
diffuse infiltration of tumor cells and extensive fibrosis. 
• Activating mutations 
Mutated forms of FGFRs have been identified in cancer of the brain, head and neck, lung, stomach, 
prostate, colon uterus, and bladder as well as in cancer of white blood cells (140-154). 
Many of the identified mutations give rise to more active forms of the receptors. Some mutations have 
also been shown to induce dimerization of the receptor and thereby leading to constitutive activation of 
the receptor kinase domain. Furthermore, mutations of the intracellular domain give rise to 
constitutively active kinase domains or impaired termination of FGFR signaling. 
Mutated FGFR1: 
Mutations of the kinase domain of FGFR1 have been found in glioblastomas (140). 
Mutated FGFR2: 
Mutations of FGFR2 are frequently extracellular and identical to the activating germline mutations 
found in craniosynostosis syndromes (155). Mutations have been described in 12% of endometrial 
carcinomas (151). 
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Mutated FGFR3: 
Bladder cancer has the most established link to FGFR mutations. Overall about 50% of bladder cancers 
have somatic mutation in the FGFR3-coding sequence (156). FGFR3 mutations have also been 
identified in many other cancer types, including cervical cancers (157), multiple myeloma, prostate 
cancer (150) and spermatocytic seminomas (158). 
In contrast to the EGFR gene, in which activating mutations occur almost exclusively in the kinase 
domain, more than half of the mutations in FGFR3 occur at a single position in the extracellular 
domain (S249C). This mutation leads to the formation of an aberrant intermolecular cysteine disulphide 
bridge, which results in constitutive dimerization and activation of the receptor (159, 160). Mutations 
are also commonly found in the transmembrane domain, as well as less common kinase domain 
mutations. 
FGFR4: 
Several mutations in FGFR4 were identified in approximately 7% to 8% of rhabdomyosarcoma (RMS) 
tumors (161). 
• FGFR fusion proteins/chromosomal rearrangements 
At least 11 fusion partners have been identified for FGFR1 (eg. ZNF198, FOP, and BCR 108). In the 
fusion proteins, the tyrosine kinase domain of the FGFR is typically juxtaposed to a dimerization 
domain from the partner gene, inducing constitutive dimerization and activation of the tyrosine kinase 
(162). Most of the FGFR fusion proteins are identified in patients with the myeloproliferative disorder 
stem cell leukemia/lymphoma syndrome (SCLL) also known as the 8p11 myeloproliferative syndrome 
(163).  
Some of the strongest evidence linking FGF signaling to oncogenesis has come from the study of 
haematological malignancies, in which translocations involving the FGFRs have been identified. 15% 
of multiple myeloma cases harbor a t(4;14) translocation, that links FGFR3 at 4p16.3 to the 
immunoglobulin heavy chain locus at 14q32. FGFR3 translocation in multiple myeloma is associated 
with a poor prognosis and is rarely found in a precursor condition of multiple myeloma, which suggests 
that FGFR3 translocations promote a rapid conversion to full multiple myeloma (164). 
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• Ligand availability 
Increased ligand availability likely leads to increased FGFR signaling. Inappropriate expression or 
release of FGFs from the extracellular matrix by malignant cells or cells of the tumor environment may 
lead to increased ligand availability.  
Elevated levels of FGF8 have been reported in human breast and prostate cancer (126, 165-167), and 
elevated levels of FGF8, FGF3, and FGF4 have been identified as mammary proto-oncognes in mouse 
mammary tumor virus (MMTV)-infected mice (168-170). In prostate cancer, several FGFs, including 
FGF2 (171) and FGF6 (172), are upregulated. It has been proposed that these changes in prostate 
cancer may result in androgen independence (126). As in prostate cancer, the expression of FGF1, 
FGF2 and FGF7 is higher in breast cancer stroma than in normal breast stroma (173, 174). FGF19 is 
overexpressed in a subgroup of liver, colonic and lung squamous carcinomas (175), while elevated 
levels of FGF2 might also play an important role in cancer progression. FGF2 is a potent angiogenic 
factor, and antisense-mediated inhibition of FGF2 in human melanoma xenografts led to tumor 
regression and block of intratumoral angiogenesis (176). Six different somatic mutations in FGF9 
leading to loss of function have been identified in colorectal and endometrial cancer (177). 
It’s not only the stromal cells that secrete FGF ligands. The first strong evidence for autocrine FGF 
signaling driving human tumorigenesis comes from studies of melanoma, which expresses high levels 
of FGFR1 and FGF2. Frequent amplification of FGF1, resulting in increased FGF1 expression, has also 
been reported in ovarian cancer and is associated with poor survival (178). An autocrine FGF2-FGFR1-
IIIc feedback loop has also been reported in non-small-cell lung cancer cell lines that show resistance 
to the EGFR antagonist gefitinib (179). 
• Switching between alternatively spliced isoforms 
Several reports have indicated different oncogenic potential of the various isoforms of the FGFRs (139, 
180-183). A shift in splicing generating more oncogenic isoforms during carcinogenesis could thus 
promote tumor growth, while a switch from one isoform to another can lead to autocrine signaling. 
Exon switching in epithelial cells from the FGFR2IIIb isoforms to the mesenchymal FGFR2IIIc 
isoforms by alternative splicing has been described in a rat model of prostate and bladder cancer (184-
186). So far it is not clear whether alternative splicing of the third Ig-like domain contributes to 
carcinogenesis in humans (126). 
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• Germline single nucleotide polymorphism (SNP) 
SNPs are the most common type of genetic variation among humans. There are roughly 10 million 
SNPs in the human genome. Most of them are silent mutations. But dependent on their location they 
can lead to disease susceptibility. 
FGFR2 has been identified as breast cancer susceptibility gene (187, 188). Interestingly, the SNP seems 
to appreciably increase the risk of developing ER-positive breast cancer only, with little or no effect on 
ER-negative breast cancer (189). 
A SNP for FGFR4, G388R, has also been found. This SNP does not seem to increase the incidence of 
cancer, but has been reported to associate with poor prognosis in multiple cancer types, including breast 
cancer, colon cancer (190) and lung adenocarcinoma (191). 
• Prolonged activation of FGFR signaling 
There are several possibilities to attenuate FGFR signaling, e.g. the activity of the sprouty (192) and 
SEF (193) proteins. The protein expression of SEF is decreased in intermediate or high-grade tumors 
originating from the breast, ovary, thyroid, and prostate (194). Loss of SEF is correlated with increased 
FGF2, FGF8, and FGFR4 expression in metastatic prostate tumors (167). 
4.2.5.2 Oncogenic mechanisms of FGF signaling 
• FGF and proliferation 
FGF10 overexpression has been found in the stromal compartment of the murine prostate, resulting in 
epithelial hyperproliferation, concomitant with the upregulation of the androgen receptor (195). PTEN 
(phosphatase and tensin homolog) a counterplayer of PI3K, has been found to be deficient in prostate 
epithelium synergized with autocrine overexpression of FGF8, leading to prostate adenocarcinoma 
(196). 
• FGF and survival 
Several studies have suggested that FGF2 mediates a cytoprotective effect by upregulating the 
expression of the anti-apoptosis proteins BCL-2, BCL-X, X-linked inhibitor of apoptosis (XIAP) and 
inhibitor of apoptosis 1 (IAP1) through an S6 kinase (S6K2 and RSK2)-mediated pathway, therefore 
promoting resistance to chemotherapy (197-199). 
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• FGF and migration/invasion 
It has been shown that invasion of pancreatic cancer is FGF10- and FGFR2-IIIb dependent (200). 
Pancreatic cancer cells express FGF10 which induces migration and invasion by interacting with 
FGFR2-IIIb expressed by the stromal cells. 
One study has shown that constitutive FGFR1 signaling led to the loss of polarity and the gain of a 
matrix metalloproteinase 3 (MMP3)-dependent invasive phenotype (201). In addition, another study 
showed that FGFR1 dependent epithelial-mesenchymal-transition (EMT) occurs. The EMT phenotype 
was accompanied by upregulation of both Sox9, an FGF target gene associated with EMT (202), and 
the pro-angiogenic factor angiopoeitin 2 (ANG2) (203). 
• FGF and angiogenesis 
Angiogenesis is the process of new blood vessel formation from pre-existing vessels. It plays a key role 
in various physiological and pathological conditions, including embryonic development, wound repair, 
inflammation, and tumor growth (204). Numerous inducers of angiogenesis have been identified, 
including members of the FGF family. They affect angiogenesis via different mechanisms: 
- Experimental evidence indicates that different members of the FGF family, but mostly FGF1 
and FGF2, can induce in vitro a “pro-angiogenic phenotype” in endothelial cells (205). 
- Activation of FGFR1 or FGFR2 by angiogenic FGFs (including FGF1, FGF2, and FGF4) leads 
to endothelial cell proliferation (206). 
- FGF/FGFR activity leads to upregulation of VEGF expression in tumors (207). Exogenous 
FGF2 induces VEGF expression in endothelial cells (208). 
- FGF/FGFR signaling results in expression of matrix metalloproteinases (MMPs) that allow 
mobilization of angiogenic growth factors from the extracellular matrix (ECM) of tumor and 
stromal cells by degeneration of the ECM (207). The plasmin-plasminogen activator system and 
MMPs cooperate in this degradation (209). 
- FGF1, FGF2 (210, 211), the FGF8b isoforms (212), and FGF10 (213) stimulate chemotaxis 
and/or chemokinesis in endothelial cells. 
- FGFs can promote both endothelial cell scattering, that is required during the first steps of the 
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angiogenic process, and the formation of the cell-cell interactions required for vessel maturation 
(214). 
4.2.5.3  FGFR signaling and tumor suppression 
FGFRs have also been suggested to have tumor suppressor activity, which is best illustrated by studies 
of FGFR2. Reduced expression of FGFR2 has been reported in several human cancers, such as bladder, 
liver, salivary gland, and prostate cancer (215-217). In addition several loss-of-function mutations in 
FGFR have been identified in melanoma (218). 
4.3 Aging and Premature aging 
Aging is a natural process that is not influenced by selection. Aging is associated with a number of 
events at the molecular, cellular and physiologic levels that influence carcinogenesis and subsequent 
cancer growth in both humans and laboratory animals. Therefore the study of cancer and premature 
aging syndromes has become increasingly important to gain a clearer understanding of these events. It 
is evident that the mechanisms underlying cancer and premature aging are often similar and affect 
mainly DNA instability. All of the premature aging diseases found in humans so far are related to DNA 
instability, the main cause for development of cancer.  
Most of the conditions with errors in genome maintenance fall into three classes: 
- Many attributes of ageing are accelerated but cancer incidence is reduced 
- Specific cancer types are enhanced 
- Incidence of both cancer and segmental progeria is increased. 
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Table  List of syndromes carrying defects in genome maintenance 
 
From Garinis et al. 2008. Abbreviations: TC-NER: transcription-coupled nucleotide excision repair, GG-NER: global 
genomic nucleotide excision repair (repair of damage in transcribed and untranscribed DNA strands in active and inactive 
genes throughout the genome), COFS: cerebro-oculo-facio-skeletal syndrome, HR: homologous recombination, ICL: 
interstrand crosslinks, DSB: double-strand break, XFE: Epf-Errcc1 syndrome. 
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4.3.1 Different Models of premature aging 
The mutations leading to DNA instability are various. There are mutations in telomerases (eg. Werner 
Syndrome) or mutations in proteins important for nucleus stability and shape (Laminopathies, eg. 
Hutchinson-Gilford progeria syndromes). More recently it has been shown that mutations affecting the 
metabolism (eg. affecting the serum level of phosphate) can also promote aging. 
• DNA instability 
e.g. Werner Syndrome: 
The gene on chromosome 8p12, the Werner gene (WRN) was identified in 1996 by positional 
cloning and encodes a 162 kDa RecQ helicase protein (219). The human RecQ helicase family 
consists of five proteins, of which only WRN possesses 3’->5’ exonuclease activity and 3’->5’ 
helicase activity (220, 221). All of the disease-associated WRN mutations (222, 223) confer a 
common biochemical phenotype: they lead to truncation or, in one instance, apparent 
destabilization and loss of WRN protein from patient cells (224, 225). In mammalian cells the 
function of WRN is limiting genetic instability and cell death. It does so by repairing DNA-strand 
beaks that arise from replication arrest. WRN also has an important role in the maintenance of 
telomere length and the suppression of telomere sister-chromatid exchanges (226-230). In the 
absence of WRN function cells accumulate potentially toxic DNA intermediates or critically short 
telomeres that can trigger genetic instability, DNA damage and apoptotic response pathways (226, 
230, 231). So far, three different Werner-syndrome mouse models have been developed; 1) mouse 
strain expressing a mutant WRN protein that is truncated in the middle of the helicase region, 
resulting in mice that are functionally null (WRN-/-) (232). This mutation resembles many of the 
mutations in WS patients. MEFs showed accelerated replicative senescence, and this was enhanced 
in cells from mice on a Bloom’s syndrome (BLM) +/- background. Histopathological studies failed 
to show any unusual lesions in these mice up to the age of seventeen month. 2) a mouse strain with 
an in-frame deletion of the helicase domain (which leads to a truncated protein that retains 
exonuclease activity) (233). MEFs showed a progressively reduced growth rate with increased 
passage number. The mice itself exhibited a normal phenotype until the age of twelve month. Mice 
with either a deletion or a truncation in the WRN helicase domain showed gross abnormalities 
when they were crossed to mice on a p53 -/- background. WRN +/- mice showed increased rates of 
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mortality, as assessed by both median survival and maximum survival. Interestingly, the mice with 
the in-frame deletion on a p53 -/- background exhibited increased numbers of tumors, and a larger 
variety of tumor types at an earlier age, as compared to WRN +/+;p53 -/- mice (234). This suggests 
that WRN and p53 play a synergistic role in the maintenance of genomic stability. 3) transgenic 
expression of a human Lys577Met WRN variant protein that lacks helicase activity and ATP-ase 
activity in a background of normal murine WRN protein (235). Tail fibroblasts showed reduced 
replicative lifespan. The mice did not show any histopathological abnormalities until the age of 
eighteen month.  
To date, there is no animal model of WS that accurately mimics the human disease.  
• Nucleus stability and shape 
e.g. Laminopathies: 
Laminopathies include at least ten distinct diseases, each caused by dominant missense mutations in 
LMNA (236), the single locus that encodes lamin A, B and C through alternative splicing (237). 
Lamins are intermediate filament proteins and lamin A and C are components of the nuclear lamina. 
The ability of lamins to multimerize into filaments lends both rigidity and elasticity to the nuclear 
lamina (238). Lamin A and C have been implicated in the regulation of transcription, DNA 
replication, cell-cycle control and cellular differentiation (239-242).  
The Lamin A protein is synthesized as a 664-amino-acid precursor protein, called prelamin A (243). 
Prelamin A contains a C-terminal CAAX amino-acid motif that undergoes franesylation at the 
cysteine residue. Farnesylated prelamin A undergoes two cleavages; the first takes place C-terminal 
to the modified Cysteine, whereas the second removes 15 C-terminal residues, including the 
farnesyl-Cysteine.  
The most famous laminopathy is the Hutchinson-Gilford progeria syndrome (HGPS): 
HGPS is the most severe of the progeroid syndromes; affected individuals have a mean lifespan of 
only 13 years (244). The disease was first described in 1886 (245), and is rare: there are currently 
fewer than 150 documented cases of HGPS worldwide. HGPS patients generally appear normal at 
birth, but prematurely develop several features that are associated with ageing. Death in patients 
with HGPS frequently results from stroke or coronary failure. 
The genetic basis of HGPS was uncovered in 2003, when it was found that most cases of the 
disease are associated with a single nucleotide substitution that leads to aberrant splicing of LMNA 
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(246-248). The most common HGPS-associated mutation, Gly608Gly, causes 150 nucleotides 
encoded in exon 11 to be spliced out of the final mRNA and results in a protein that lacks 50 amino 
acids. This protein was named progerin and retains its C-terminal CAAX motif but lacks sequences 
that are required for complete processing and is, therefore, uncleaved (prelamin A) and stably 
farnesylated. 
Deletion of the endopeptidase-encoding gene Zmpste24 has also been found. It results in a block of 
both prelamin A cleavage events and the production of mature lamin A. The resulting protein that 
accumulates is farnesylated, uncleaved prelamin A (249). 
• Metabolism 
Accumulating evidence has demonstrated that inorganic phosphate has a significant impact on glucose 
metabolism and oxidative stress, which potentially affects aging processes of any organism from yeast 
to human (250). This is discussed in greater detail in the following chapter. 
4.3.2 Aging and Metabolism 
It has been shown that the FGF23-Klotho-FGFR1 pathway in the kidney regulates serum levels of 
vitamin D, phosphate and calcium. Disruption of this pathway leads to hypervitaminosis and 
hyperphosphatemia and ultimately to a premature aging phenotype (23, 92, 251). Klotho and FGF23 
mutant mice that were fed with low-vitamin D or low-phosphate diet, showed rescue of the premature 
aging phenotype: 
o High levels of vitamin D were reduced by placing the animals on a vitamin D deficient diet. 
This not only restored serum phosphate and calcium levels to normal but also rescued several 
aging-like phenotypes in both Klotho and FGF23 mutant mice (252, 253). 
o Ablation of vitamin D action in Klotho and FGF23 mutant mice via disruption of either the 
Cyp27B1 (251, 254) or vitamin D receptor gene (255) also rescued the hyperphosphatemia, 
hypercalcemia, and the premature-aging syndrome. 
o Low phosphate diet rescued the premature aging phenotype even though the vitamin D and 
calcium levels were upregulated (252, 256). 
o Double knock-out mice of Klotho and the renal sodium phosphate cotransporter (Na-Pi2a) 
(Klotho-/- Na-Pi2a-/- mice) are rescued from hyperphosphatemia and premature aging signs. 
Nevertheless, when challenged with a high phosphate diet the premature aging signs observed 
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in the Klotho mutant mice reappeared (257). 
Thus, data provided by the last two points suggest that elevated phosphate, rather than calcium or 
vitamin D, is primarily responsible for the aging-like phenotypes (250, 257). Nevertheless, it is 
possible and likely that low vitamin D diet and ablation of vitamin D activity rescues accelerated 
aging by contributing to the reduction of phosphate levels. 
• Phosphate and aging 
A major question is how phosphate can cause aging: 
There is still little known about the direct effects of phosphate on aging, however, accumulating 
evidence suggests that inorganic phosphate significantly impacts glucose metabolism and oxidative 
stress, potentially affecting the aging processes of any organism from yeast to human (250). 
- Glucose metabolism 
The effect of phosphate on metabolism is apparently conserved from yeast to human. In yeast it 
has been shown that low phosphate induces similar metabolic changes as caloric restriction, 
which is also called glucose restriction (258-260). It has been shown in mammals that diet 
restriction and a low phosphate diet cause similar metabolic changes. Animals under diet 
restriction reduce blood insulin levels to adapt to the reduced carbohydrate availability. In 
addition, they alter the expression of insulin-responsive genes, leading to changes in glucose 
metabolism, including increased gluconeogenesis and decreased glycolysis (261-265). Although 
reduced blood insulin levels are not a consequence of the low phosphate diet, the diet alters the 
expression of insulin-responsive genes similar to diet restriction (266, 267), also resulting in 
increased gluconeogenesis and decreased glycolysis. Adequate suppression of the insulin-like 
signaling pathway is an evolutionarily conserved mechanism for anti-aging and life span 
extension in Caenorhabditis elegans and Drosophila (268-272). 
- Oxidative stress 
In addition to its involvement in glucose metabolism and insulin sensitivity, inorganic 
phosphate has been shown to increase oxidative stress both in vivo and in vitro (273, 274). 
Inorganic phosphate enters cells and gets transported into mitochondria where it functions as a 
substrate of ATP synthase and as a key regulator of oxidative phosphorylation. The 
mitochondrial potential increases proportionally to the extra-mitochondrial phosphate 
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concentration (275) and is known to correlate with ROS production in the electron transport 
chain (276). Thus, inorganic phosphate plays multiple roles in the regulation of oxidative stress 
and mitochondrial function in health and disease, which potentially affect aging processes. 
• Hypoglycemia 
Most models for premature aging exhibit a diabetes-like phenotype and insulin resistance. The FGF23 
and Klotho deficient mouse models are an exception to this, as they both manifest hypoglycemia and 
increased insulin sensitivity (23, 92, 277). To date these are the only two premature aging models 
described that present with postprandial hypoglycemia and high insulin sensitivity due to the high 
phosphate levels.  
4.4 Phosphate homeostasis 
There are several organs and pathways which contribute to phosphate homeostasis. Phosphate is taken 
up via nutrition and enters the blood stream in the gut. In the kidney excess phosphate gets excreted, 
while enough is reabsorbed to ensure steady levels of phosphate in the blood. Parathyroid hormone 
(PTH), secreted by the parathyroid gland, and FGF23 secreted by the bone influence the activity of 
uptake, excretion and reabsorption of phosphate (Figure 4-6).  
 
Figure 4-6 Regulation of phosphate homeostasis (Bergwitz et al. 2010) 
Phosphate (P) is absorbed from the diet in the gut, stored in the skeleton, and excreted by the kidneys. Active vitamin D 
(1,25(OH)2D) stimulates absorption of phosphate from the diet. FGF23 increases renal phosphate clearance, suppresses 
synthesis of 1,25(OH)2D, and may decrease parathyroid hormone (PTH). PTH increases renal phosphate clearance and 
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stimulates synthesis of 1,25(OH)2D. DMP1: Dentin Matrix Protein-1, PHEX: phosphate regulating gene with homologies to 
endopeptidases on the X chromosome, Na-Pi2: sodium phosphate cotransporter, Pit-2: a type III Na-Pi cotransporter, that 
belongs to the SLC20 gene family, KL: Klotho, PTHR1: parathyroid hormone receptor 1 
 
Important players of these processes are: 
- FGF23, a member of the endocrine FGFs 
- Klotho 
- The FGF receptors 
- Vitamin D (and Cyp27B1/Cyp24A1) 
- The sodium phosphate cotransporters Na-Pi2a and Na-Pi2c 
- The parathyroid hormone (PTH) 
4.4.1 FGF23, a member of the endocrine FGF family 
The members of the FGF19/endocrine subfamily are also called the metabolic FGFs as they have 
important functions in metabolism. The family consists of three members FGF15/19, FGF21 and 
FGF23. These ligands require specific coreceptors, the Klotho family, to bind to their cognate FGFRs. 
FGF23 binds to Klotho and FGF15/19 and 21 bind to βKlotho. The expression of these receptors is 
limited, which ensures organ specificity for these ligands. 
4.4.1.1 FGF15/19 
FGF19 is the human orthologue of the murine FGF15 and was cloned by homology to mouse FGF15 
(278). FGF15/19 is produced by the intestine and is involved in bile acid synthesis and gallbladder 
filling. FGF15 knock-out mice were reported to display contracted gallbladders (279) and enhanced 
bile acid synthesis due to high expression levels of cholesterol 7α-hydroxylase (CYP7A1) in the liver 
(280). Cyp7A1 encodes for the key rate-limiting enzyme for the bile acid synthesis pathway. There is 
strong evidence that FGF15/19 signals via FGFR4 and binds βKlotho as a coreceptor, based on the 
similar phenotype of FGFR4 (280) or βKlotho (281) knock-out models and FGF15 knock-out mice.   
4.4.1.2 FGF21 
FGF21 is a 209 amino-acid protein including a 28 amino-acid signal peptide (282). It is mainly 
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expressed in the liver and was shown to be involved in carbohydrate and fat metabolism (283). 
Furthermore, it has been reported that FGF21 is involved in the response to fasting (284, 285). βKlotho 
and FGFR1 have been reported to be essential for these effects of FGF21 (286, 287). 
4.4.1.3 FGF23 
FGF23 is the third endocrine FGF ligand. It is secreted primarily from the bone and acts on several 
organs, including the kidney where it inhibits phosphate reabsorption and vitamin D biosynthesis (288, 
289). FGF23 was originally identified as a gene mutated in patients with autosomal dominant 
hypophosphatemic rickets (ADHR), one of the rare hereditary disorders that exhibit renal phosphate 
wasting (290). The stimuli for FGF23 synthesis and secretion are phosphate and active vitamin D 
levels. 
• The structure 
The FGF23 gene encodes a 32kDa secreted protein that has N-terminal FGF homology to other FGFs 
and a unique 71-amino-acid C-terminal domain (291, 292). 
• Function 
The principal actions of FGF23 are to inhibit sodium-dependent phosphate reabsorption and 1α-
hydroxylase activity in the proximal tubule of the kidney, leading to phosphaturia and suppression of 
circulating active vitamin D (1,25(OH)2D) levels. 
• Production 
FGF23 is predominantly produced by osteocytes in bone; however, the exact mechanism controlling its 
expression is still unclear. Based on studies of mutations leading to diseases in human, it is known 
which factors play important roles: 
PHEX (phosphate regulating gene with homologies to endopeptidases on the X chromosome): 
Inactivating mutations of PHEX (hyp mice) lead to upregulated levels of FGF23. PHEX is mutated in 
XLH patients, patients with X-linked hypophosphatemic rickets. (See also further down). 
DMP1 (Dentin Matrix Protein-1): 
DMP1 is an acidic noncollagenous extracellular matrix protein and belongs to the SIBLING (small 
integrin binding ligand N-linked glycoprotein) family. Mutations in DMP1 lead to increased production 
of FGF23 (293, 294). Mutation of DMP1 in humans leads to autosomal recessive hypophosphatemic 
rickets (ARHR). (See also further down). 
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The mechanisms how PHEX and DMP1 regulate the level of FGF23 is so far unknown. 
GALNT3 (UDP-N-acetyl-α-D-galactosamine/polypeptide N-acetylgalactosaminyl transferase 3): 
This enzyme is responsible for the initiation of O-linked glycosylation (295). Loss-of-function 
mutations in GALNT destabilize FGF23 and/or impair its secretion. This results in low levels of intact 
FGF23 but high levels of biologically inactive C-terminal FGF23 fragments in the serum (296). 
Mutation of GALNT3 in humans leads to hyperostosis-hyperphosphatemia syndrome (HHS). Patients 
with HHS are characterized by hyperphosphatemia, inappropriately normal or elevated vitamin D and 
cortical hyperostosis. 
• Knock-out of FGF23 
FGF23 knock-out mice showed hypercalcemia, hyperphosphatemia, growth retardation, ectopic 
calcifications, severe osteoidosis, skin atrophy, and renal dysfunction (23). This phenotype is very 
similar to the Klotho mutant phenotype (see below). Therefore, it was hypothesized that FGF23 and 
Klotho may share the same pathway (96). It has since been revealed that both FGF23 and Klotho 
regulate vitamin D, phosphate and calcium levels by controlling the Klotho-FGFR1 pathway in the 
kidney. This is also referred to as the FGF23-Klotho axis. Although FGF23 and Klotho cooperate in 
controlling phosphate and calcium levels, there are also independent activities.  
• Signaling in the kidney 
FGF23 binds FGFR1 in the renal proximal tubule of the nephron with the help of the coreceptor 
Klotho. The FGF23-Klotho axis controls the levels of vitamin D, phosphate and calcium.   
o Vitamin D 
The level of vitamin D is controlled by the vitamin D converting enzyme 1α-hydroxylase encoded by 
Cyp27B1 and the vitamin D catalyzing enzyme 24-hydroxylase encoded by Cyp24A1. 1α-hydroxylase 
synthesizes the active form of vitamin D (1,25-dihydroxyvitamin D3) from its inactive precursor (297). 
24-hydroxylase catalyses active vitamin D and 25-dihydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 
(298).  FGF23-Klotho signaling inhibits transcription of Cyp27B1, and upregulates transcription of 
Cyp24A1.  Klotho mutant mice show decreased levels of Cyp27B1 and Cyp24A1 RNA (299).  
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Figure 4-7 Vitamin D metabolism 
 
o Phosphate 
Sodium phosphate cotransporters Na-Pi2a and 2c are expressed in the brush border membranes 
(BBMs) of the renal tubular cells. FGF23-Klotho signaling controls the levels of expression of these 
transporters as well as their internalization. Klotho mutant mice show lower levels of expression of Na-
Pi2a and 2c (300) but higher activity and localization to the BBM of the expressed transporters (301). 
This leads to more reabsorption of phosphate from the urine and results in hyperphosphatemia found in 
the Klotho mutant mice. 
o Calcium 
Calcium is reabsorbed from the urine into the blood by Calcium specific transport proteins. These 
proteins are transcribed by vitamin D mediated gene transcription. Therefore, active FGF23-Klotho 
signaling regulates Calcium reabsorption indirectly via control of the level of active vitamin D (302-
306). 
• Vitamin D independent functions of FGF23 
FGF23 may directly modulate trafficking of the Na-Pi2a transporter from the apical membrane to the 
intracellular organelles (307, 308). 
So far, the role of FGF23 in calcium regulation has not been investigated in great detail as 
administration of FGF23 did not affect the serum calcium level in normal mice (24).  
 
• FGF23 and disease  
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o Autosomal dominant Hypophosphatemic rickets/ostomalacia (ADHR) (309) 
ADHR was first described in 1971 as a phosphate wasting disease with an autosomal dominant 
inheritance (310). It is characterized by a missense mutation in either the Arg176 or Arg179 site, 
resulting in a FGF23 protein that is not recognized or cleaved by furin (311). This results in high 
serum levels of full-length FGF23 protein, causing the phenotype of hypophosphatemia, renal 
phosphate wasting, inappropriately low or normal levels of 1,25dihydroxyvitamin D3 along with 
skeletal defects that include rickets/osteomalacia, fractures, and dental abscess. 
o Tumor-induced rickets/osteomalacia (TIO) (21) 
TIO is an acquired paraneoplastic disorder characterized by tumors that are mainly of mesenchymal 
origin and which produce excessive amounts of phosphaturic peptides (20, 312-315). It has been 
shown that they secrete excessive levels of FGF23 (19-21, 313), MEPE (a gene expressed in the 
bone marrow and tumors causing osteomalacia) (316), FGF7 (317), and sFRP-4 (318). Tumors 
causing TIO are usually benign and of mesenchymal origin, and the majority can be classified as 
phosphaturic mesenchymal tumors with a mixed connective tissue variant (319, 320). 
o Autosomal recessive hypophosphatemic rickets (ARHR) 
ARHR shares a similar phenotype with ADHR (321, 322). Patients with ARHR have 
hypophosphatemia, phosphaturia, low or inappropriately normal levels of 1,25dihydroxyvitamin 
D3, high serum alkaline phosphatase, and evidence of skeletal defects (rickets/osteomalacia). The 
genetic defect for ARHR has been identified and shown to be caused by a homozygous inactivation 
mutation of the DMP1 (Dentin matrix acidic phosphoprotein 1) (293, 294). 
o Fibrous dysplasia (FD) 
FD is characterized by fibrous skeletal lesions and mineralization defects of the bone. 
o X-linked hypophosphatemic rickets (XLH) 
It is the most common form of inherited rickets with an incidence of 1:20,000. Patients with this 
disorder have severe hypophosphatemia due to renal phosphate wasting that is not caused by 
hyperparathyroidism, and vitamin D levels are not elevated as predicted, but are abnormally normal 
or low for their level of hypophosphatemia. These abnormal vitamin D levels are due to both: low 
1α-hydroxylase activity (323-325) and increased 24-hydroxylase activity (326). 
o Familial tumoral calcinosis 
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This is an autosomal recessive condition characterized by painful depositions of calcium and 
phosphate in the joints and soft tissues (327-329). Mutations in GALNT3 and in the fgf23 gene 
have been identified to cause this disease. 
o Chronic kidney disease (CKD) 
CKD is very common. 1 out of 10 will develop CKD; in young adults only 1 out of 50 will be 
affected, in elderly people (over 75 years) 1 out of 2 is affected. But not all of them will ever 
require dialysis or a kidney transplant. A CKD patient is at higher risk of heart attack or stroke. 
Patients suffering from CKD have hyperphosphatemia as a result of kidney failure. In early stages 
of CKD, serum FGF23 is elevated to maintain normal serum phosphate levels by promoting urinary 
phosphate excretion and decreasing the levels of vitamin D to lower phosphate absorption in the 
gut. In the beginning of the disease this is a helpful compensation, but in advanced stages overt 
phosphate loading may overcome such compensation and the elevated FGF23 levels result in 
decreased renal production of vitamin D, worsening secondary hyperparathroidsm (330). Patients 
with more advanced CKD exhibit impaired urinary phosphate excretion despite extremely high 
FGF23 levels. FGF23 is increased about 1000 fold compared to healthy individuals. In late stage 
CKD the parathyroid gland develops resistance against FGF23 by downregulating the FGFR1c-
Klotho complex on the cell surface. While in healthy individuals FGF23 suppresses secretion of 
PTH (331), in late stage CKD, PTH secretion remains stimulated despite extremely high FGF23 
levels as the parathyroid glands becomes FGF23 insensitive (332, 333). Therefore, PTH levels 
decrease and patients develop secondary hyperparathyroidism. Furthermore, high levels of FGF23 
cause cardiovascular disease. Thus, FGF23 is a bad prognosis factor in CKD. A possible approach 
for therapy could be to apply a low phosphate diet in a stage of the disease before the initial rise of 
FGF23 levels. 
 
4.4.2 Klotho 
The Klotho family consists of two members: Klotho and βKlotho, which share a 41% amino acid 
identity. 
• The structure 
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The mouse Klotho gene is composed of 5 exons and 4 introns and resides on chromosome 13q12 with a 
size over 50kb (92). The transcript of the mouse Klotho gene is about 5.2kb. Its promoter lacks a 
TATA-box and contains four potential binding sites for Sp1 (334). In the third exon, there is an 
alternative splicing at an internal splice donor site. Therefore, two transcripts arise from the template by 
alternative RNA splicing: a transmembrane and a secreted form of the Klotho protein (334-336). The 
transmembrane form of Klotho is produced from the full length transcript and encodes 1014 amino 
acids. The extracellular domain of Klotho can be shed from the cell surface and is detected in the blood 
and cerebrospinal fluid in mice and humans (337).  
Klotho and βKlotho have two β-glucosidase-like domains in the extracellular regions. However, it has 
been unclear whether Klotho and βKlotho actually function as β-glucosidases in vivo.  
• The expression of Klotho and βKlotho 
Klotho is expressed in several tissues including kidney, parathyroid gland and choroid plexus (338). 
Kidney is the organ with the highest expression of Klotho. For several years it is known that Klotho is 
expressed in the distal convoluted tubules, but more recently, applying more sensitive techniques 
Klotho has been found also in the proximal tubules. Klotho is transcribed and expressed in those two 
segments of the nephron (339). βKlotho is expressed in adipose tissue, liver and pancreas (93).  
• Function of Klotho 
- Coreceptor for endocrine FGFs: 
Klotho is an essential coreceptor for FGF23 signaling in the kidney (96) and in the parathyroid 
gland. βKlotho functions as coreceptor for FGF15/19 in the liver and FGF21 in the adipose tissue 
(287). 
- Klotho as a calcitonin 
The regulation of Calcium reabsorption is depicted in Figure 4-8: 
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Figure 4-8 Regulation in active renal Ca2+ reabsorption (from de Groot et al. 2008) 
TRPV5 is a tetrameric channel. TRPV5 is sorted by the Golgi apparatus and integrated into the plasma membrane of the 
nephron. The function of TRPV5 is to allow influx of Ca2+. Following entry of Ca2+ into the cell, Ca2+ binds to calbindin-
D28K and diffuses to the basolateral side of the cell, where it is transported out of the cell into the blood stream with the help 
of NCX1, a sodium-calcium transporter, and to a lesser extent PMCA1b. To recycle or degrade TRPV5, the channel is 
internalized through dynamin- and clathrin-dependent processes shortly after arrival in the plasma membrane. Internalized 
TRPV5 is either degraded or recycled via endosomes. By interaction with Rab11a proteins in the endosome TRPV5 
channels can re-translocate to the plasma membrane and undergo another round of Ca2+ influx. (340) 
It has been shown that Klotho has sialidase activity and that it activates ‘plasma membrane resident 
transient receptor potential vanilloid 5’ (TRPV5) ion channels by removing the terminal sialic acids 
from their glycan chains (341). TRPV5 is a calcium channel expressed in epithelial cells of distal 
convoluted tubules. However, sialidase activity is not the only way Klotho affects calcium levels, as it 
has been reported that Klotho also interacts with the Na+, K+ ATPase to regulate calcium homeostasis 
(342). 
- Klotho as phosphatonin: 
It has been reported that Klotho has a glycosidase function. The two external domains of Klotho 
share 20-40% amino acid sequence similarity with members of the glycosidase family, including β-
glucosidase, β-glucuronidase, and glycosidase (92, 343). While the sequence of Klotho is missing 
the critical catalytic glutamic acid residues (92), studies by the Nabeshima group have shown that 
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Klotho in vitro hydrolyzes β-glucosides and β-D-glucuronide, and this effect is inhibited by a β-
glucuronidase inhibitor (343). 
In vivo evidence for β-glucuronic activity has been shown by the group of Orson Moe (301). Na-
Pi2a and 2c function as sodium-phosphate cotransporters in the kidney and are essential for 
reabsorbtion of phosphate. Na-Pi2 is a highly glycosylated protein (344) with conserved 
asparagine-linked glycosylation sites (343). Therefore Na-Pi2 could be a substrate of Klotho. Hu et 
al. showed that injection of recombinant mouse extracellular domain of Klotho into mice and rats 
induced an inhibition of phosphate uptake from the urine into the blood. This block has shown to be 
a biphasic process. Thus far regulation of Na-Pi2a activity was believed to occur exclusively via 
changes in protein trafficking in the first phase (345) and via protein degradation in the second 
phase (346). Here Hu et al. showed that the first phase is independent of Na-Pi2a internalization. 
Only during the second phase Na-Pi2a was internalized. While in the first phase there was a shift of 
full length Na-Pi2a expression to N-terminal fragments. Nevertheless, the presence of a protease 
inhibitor had no effect of Klotho induced inhibition of Phosphate uptake, whereas the presence of a 
β-glucuronic inhibitor abolished the block of Klotho. This suggests that the Klotho induced 
deglycosylation from N-glycan is sufficient to suppress Na-dependent Pi transport and does not 
require proteolysis (301).  
- Inhibitor of the insulin and IGF-1 pathway 
There are data that show the secreted form of Klotho has humoral functions and inhibits the 
insulin/IGF-1 pathway. The first evidence was given by Kurosu et al. that showed that mice 
overexpressing the soluble form of Klotho lived longer than wild type mice (347). By showing that 
those mice are insulin resistant they indicated in vivo a link of Klotho to the IGF-1/insulin pathway. 
Furthermore, they crossed the Klotho knock out mouse line to the IRS-1 loss of function line and 
found enhanced survival in the double transgenic mice. Studies in C.elegans show also that Klotho 
interacts with the insulin pathway to prolong survival (348). In parallel, they showed in vitro in 
myoblastic cells (L6) that Klotho binds to the surface of target cells and inhibits 
autophosphorylation of the IGF-1 and insulin receptor (347).  
But there is also contradictory in vitro data provided by other groups in HEK293, L6 and HepG2 
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cells (349). Thus, the function of the secreted form of Klotho has not been fully elucidated. 
However, it has also been shown that soluble Klotho inhibited the insulin and IGF-1 pathway in the 
MCF-7 and MDA-MB-231 human cancer cells (350). In addition it has been shown in the same 
publication that Klotho inhibited the activation of the FGF pathway in HEK-293 cells, but 
enhanced its activation in MCF-7 and MDA-MB-231 cells. Nevertheless, Klotho does not affect the 
epidermal growth factor pathway and had not been described to influence the activities of hormone 
receptors (350). In conclusion, role for soluble klotho is cell type and receptor dependent. 
- Klotho and oxidative stress: 
It has been discussed (see above) that high phosphate levels induce oxidative stress in vivo and in 
vitro. In addition, it has been shown that mice which lack Klotho expression show more activated 
ASK complex and sustained activated p38 MAPK (351), which indicates high oxidative state of the 
cell. The mechanism of p38 MAPK activity regulation in response to mitochondrial generated ROS 
involves activation of the ASK1-signalosome, a ROS-sensitive signaling complex composed of 
inhibitor and activator proteins (352-354). Reduced thioredoxin Trx(SH)2 interacts with the N 
terminal domain of ASK1 and inhibits ASK1 activity and thereby p38 MAPK activation (353, 355). 
The ROS-mediated oxidation of ASK1-bound Trx(SH)2 stimulates dissociation of the complex 
thereby allowing activation of the ASK1 and p38 MAPK (353, 355-357).  
- Klotho and acute kidney injury (AKI)/chronic kidney disease (CKD) 
AKI arises from ischemia or nephrotoxins and can lead to CKD. AKI and CKD are a state of 
drastically reduced Klotho levels in serum, urine and kidney. Reduction of Klotho levels takes place 
very rapidly, as soon as 3 hours after the injury. Therefore, Klotho is a marker for AKI and CKD. It 
comes up earlier and more strongly than the commonly used marker: Neutrophil gelatinase-
associated lipocalin (NGAL). Klotho is not only a marker for AKI and CKD but also has 
neuroprotective therapeutic potential. In AKI and CKD patients the values for blood urea nitrogen 
and creatinine were upregulated.  Upon intraperitoneal injection of Klotho (soluble extracellular 
domain of the protein) in mice and rats suffering from AKI or CKD all the blood and urinary 
parameters return to nearly basal. Treatment with Klotho is most effective when started less than 60 
minutes after the injury, which rarely happens in the clinic.  
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• Klotho mutants 
The Klotho gene was originally identified as a gene mutated in a transgenic mouse strain (homozygous 
for the mutated Klotho) that developed multiple aging-like phenotypes (92). This mouse strain carries 
an insertional mutation from a transgene that disrupted the 5’-flanking region of the Klotho gene, 
resulting in a strong hypomorphic allele. Later, a conventional knock-out mouse was generated (358). 
Mice homozygous for the mutation are defective in Klotho gene expression. The hypomorphic model 
as well as the knock-out model (collectively referred to as ‘Klotho mutant models’) exhibit a syndrome 
resembling human aging, including; short life span, hypoactivity, muscle atrophy, skin atrophy, atrophy 
of outer genital organs, impaired maturation of gonadal cells, sterility of both sexes, arteriosclerosis, 
impaired glucose metabolism (92), cognition impairment (273), hearing disturbance (359), motoneuron 
degeneration (360), atrophy of thymus (361), osteopenia (362), vascular calcification, soft tissue 
calcification and pulmonary emphysema (363-365). 
• Klotho overexpressing mice 
It has been shown that mice overexpressing Klotho lived longer than wild-type mice and had higher 
blood insulin levels. In addition, Klotho overexpression induces resistance to insulin and IGF-1(347). 
Presumably, it is the effect of Klotho on the insulin IGF-1 signaling that results in longevity. 
• Klotho and breast cancer 
It has been shown by immunohistochemistry analysis that Klotho is highly expressed in normal breast 
but very low in breast cancer (detected with antibody directed against the intracellular domain of the 
transmembrane form of Klotho) (350). The physiological function of Klotho in the normal mammary 
gland has not yet been elucidated. Wolf and colleagues propose that the soluble form of Klotho acts as 
a tumor suppressor, by inhibiting insulin and IGF-1 signaling in breast cancer cells and that Klotho 
binds to the respective receptors. Nonetheless, it has also been shown earlier that binding of Klotho to 
these receptors is not needed to inhibit their signaling (347). Thus, the mechanism by which Klotho 
affects insulin and IGF-1 signaling needs to be further explored. Klotho-induced inhibition of IGF-1 
signaling might also affect expression of the transcription factors CCAAT/enhancer-binding protein 
(C/EBP) α and β. These factors are downregulated by the IGF-1 pathway and have been identified as 
breast cancer growth suppressors (366-368).  
It is very well known that germ-line mutations in BRCA1 and BRCA2 genes substantially increase 
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lifetime risk of breast- and ovarian cancers. Klotho and BRCA2 are located on 13q12. More recently it 
has been shown that there is a linkage disequilibrium between a functional variant of Klotho that shows 
reduced activity and a BRCA2 mutation (369). The biological interaction between Klotho and BRCA1 
is not known yet. Recent data also indicate an association between mutations in BRCA1 and BRCA2 
and the IGF-1 pathway in breast cancer. IGF-1 levels are increased in cancers from carriers of BRCA1 
and BRCA2 mutations, and levels of the IGF-1 receptor are increased in breast cancer from BRCA1 
carriers (369). In addition, intact BRCA1 protein can lower IGF-1 receptor protein levels in breast 
cancer cells (370, 371). Thus, a possible explanation of our observation is the combination of increased 
activation of the IGF-1 pathway because of BRCA1 mutation and reduced inhibition of klotho. 
• Klotho in C.elegans 
Klotho has two known functions in C.elegans: promotion of longevity and resistance against oxidative 
stress. There exist two redundant homologues of Klotho in C.elegans, C50F7.10 and E02H9.5. They 
encode predicted proteins homologues to the β-glucosidase-like KL1 domain of mammalian Klotho.  
C.elegans Klotho has been shown to promote survival in an EGL15(FGFR)/EGL17(FGF ligand) 
dependent way. In addition, the survival promoting function of Klotho is dependent on the daf2/daf16 
pathway (daf2 – insulin receptor; daf16 – FOXO) (348). 
Klotho has been shown to increase resistance against oxidative stress via the EGL15/EGL17 pathway 
and dependent on daf16, but independent of daf2 (348).  
• Klotho in humans 
o A homozygous missense mutation in the Klotho gene causes decreased Klotho levels resulting 
in tumoral calcinosis, analogous to the tumoral calcinosis seen in patients with decreased 
FGF23 levels (327).  
4.4.3 FGF receptors 
FGFR1 is the predominant receptor for the hypophosphatemic action of FGF23, while FGFR4 may 
also play a minor role. This has been shown by characterizing phosphate homeostasis in FGFR4 ko and 
FGFR1 conditional knock-out mice where Cre recombinase was expressed in the metanephric 
mesenchyme, driven by the Pax3 promoter (372). 
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Another study showed that phosphate homeostasis controlled by FGF23/Klotho/FGFR1 signaling is 
mediated by MEK/ERK1/2 signaling. This has been established by characterizing phosphate 
homeostasis in hyp mice (inactivating mutations of PHEX) that were treated with a MEK inhibitor, 
PD0325901 (373).  
4.4.4 Vitamin D  
• Vitamin D Metabolism 
There are two sources of vitamin D (chalciferol). Either it is taken up by diet (fortified dairy 
products or fish oils) or it is produced from 7-dihydrocholesterol. 7-dihydrocholesterol resides in 
the skin where it is modified by UV irradiation. Subsequently, Cholecalciferol (pre-vitamin D) is 
transported in the blood, where it binds the vitamin D binding protein and reaches the liver. In the 
liver cholecalciferol gets hydroxylated at C25 by one or more cytrochrome P450 vitamin D 25 
hydroxylases, e.g. Cyp27A1, resulting in the formation of 25-hydroxyvitamin D3 (25(OH)D3). 
25(OH)D3 is the major circulating form of Vitamin D. It is bound to the vitamin D binding protein 
and gets transported to the kidney where it gets internalized by magalin, a member of the LDL 
receptor family. In the kidney 25(OH)D3 gets hyroxylated by the 1α-hydroxylase at the position of 
carbon 1 of the A ring, which results in the hormonally active form of vitamin D, 1,25-
dihyodroxyvitamin D3 (1, 25(OH)2D3). 1α-hydroxylase is encoded by the gene Cyp27B1. It is a 
cytochrome P450 monooxygenase found mainly in the kidney, but also present in some extrarenal 
sites including placenta, monocytes and macrophages (374-377). 
Vitamin D exerts its functions by interacting with the high-affinity vitamin D receptor (VDR), 
which is a ligand-dependent transcription factor (378). VDR is a member of the nuclear receptor 
superfamily. It forms heterodimers with the retinoid receptor (RXR) to regulate gene transcription 
by binding to vitamin D responsive elements (VDREs) in the promoter region of target genes.  
• Vitamin D and premature-aging 
In the premature aging models of FGF23 or Klotho mutant hypervitaminosis is found, because 
there is no longer inhibition of the renal 1α-hydroxylase in these animals. High levels of vitamin D 
affect aging by building up high levels of phosphate. Vitamin D induces uptake of phosphate from 
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the gut.  
• Vitamin D and cancer 
Clinical studies have been performed which show that there might be a correlation between levels 
of vitamin D and cancer risk. It was shown for colorectal- (379), pancreatic- (380), gastrointestinal- 
(381), and breast-cancer (382) that high levels of vitamin D may be beneficial. Vitamin D is not the 
only tumor suppressor in this system. Klotho has also been found to have a positive effect in 
relation with cancer. In addition, there were vitamin D response elements (VREs) identified in the 
vicinity of mouse and human Klotho (383). Nonetheless, thus far it is not clear if there is a link 
between the tumor suppressor function of vitamin D and Klotho.  
4.4.5 The sodium phosphate co-transporters Na-Pi2a and Na-Pi2c 
Phosphate transport across the apical membrane is mediated by the three members of the SLC34 family 
(SLC34A1-A3) of solute carriers. Expression of SLC34A1/Na-Pi2a and SLC34A3/Na-Pi2c is 
restricted to the brush border membrane of renal proximal tubules.  In rats and mice, Na-Pi2a has the 
most important role in renal phosphate reabsorption (70-80%), while Na-Pi2c was thought to have the 
most important regulatory role around weanling animals. However, in adult animals, maintained on a 
normal phosphate diet Na-Pi2c mediates only a very small percentage of phosphate reabsorption. 
SLC34A2/Na-Pi2b expression is restricted to the gut.    
Transcription of the Na-Pi2a and 2c is controlled by the FGF23-Klotho axis, but RNA levels do not 
reflect protein activity as the localization of the cotransporters to the brush border membrane, where 
these transporters are active, is highly regulated. Na-Pi2a and 2c are expressed in the brush membrane 
of the renal tubular cells. They are co-transporters that reabsorb phosphate from the urine. The FGF23-
Klotho and PTH induce internalization of the co-receptors and therefore, inhibit phosphate reuptake.  
4.4.6 The parathyroid hormone (PTH) 
Serum PTH concentrations are dependent upon the release of PTH stored in secretory granules within 
the parathyroid gland and by the synthesis of new PTH. Calcium, phosphate and vitamin D metabolites 
play a role in regulating PTH release and synthesis. On the other hand PTH regulates calcium, 
phosphate and vitamin D levels resulting in a loop of positive and negative feetback (339). 
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PTH regulation: 
The PTH pool in the secretory vesicles is controlled by RNA binding proteins that regulate PTH-
mRNA stability by binding to the 3’untranslated region. In addition, vitamin D negatively affects 
transcription of PTH. PTH is synthesized as prepro-peptide containing a 25-amino-acid presequence 
and a 6-amino presequence. Both are cleaved off in the endoplasmic reticulum, and mature full-length 
PTH (1-84aa) is stored in secretory vesicles.  
Calcium homeostasis: 
Calcium binds to the calcium-sensing receptors (CaRs) on the parathyroid chief cells to decrease 
secretion of PTH as released PTH increases Calcium uptake and decreases calcium wasting. In detail, 
PTH inhibits reabsorption of Calcium by the bone and excretion by the kidney by inhibiting the 
FGF23-Klotho axis in the renal tubules. Inhibition of the FGF23-Klotho axis also increases the 
production of vitamin D, which enhances absorption of calcium from the intestine (339). Continuous 
exposure to PTH can result in bone resorption. 
CaR is a G protein-coupled receptor that activates phospholipase C (PLC) and mitogen-activated 
protein kinases (MAPKs) and inhibits andenylat cyclase (AC) (Figure 4-9). This activates calcium-
sensitive proteases in the secretory vesicles of the parathyroids, resulting in cleavage and inactivation 
of PTH.  
 
 
Figure 4-9 Activation of the Calcium-sensing receptor and subsequent downstream effects (Kumar et al. 2011) 
 
The calcium-sensing receptor (CaR) is activated by calcium and in turn inhibits adenylate cyclase (AC) and activates 
phospholipase C (PLC) and mitogen-activated protein kinase (MAPK). 
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Phosphate homeostasis: 
PTH induces internalization of the sodium-phosophate cotransporters Na-Pi2a and Na-Pi2c, resulting in 
renal phosphate wasting and hypophosphatemia (384). PTH binds to the PTH/PTHrP-receptor 
(PTHR1) at the basolateral and apical membrane of the proximal renal tubule.  In the basolateral 
membrane the receptor activates the PKA pathway while in the apical membrane it activates the PKC 
pathway, both leading to ERK activation.  This stimulates internalization of NaPi2a and Na-Pi2c via 
clathrin-coated pits (384). Figure 4-10 
 
Figure 4-10 Downregulation of Na-Pi2a (Forster et al. 2006) 
Schematic representation of the sequence of steps involved in PTH-induced down-regulation of Na-Pi2a in an epithelial 
proximal tubule cell. PDZ: PSD-95, Discs-large and ZO-1, NHERF1: Na/H-exchanger regulatory factors, dibasic KR motif: a motive in the last intracellular loop of the NA-Pi2a protein that is required for PTH sensitivity, light blue spheres: Na-Pi2a, dark blue stars: clathrin. 
 
4.4.7 Players in phosphate homeostasis 
Many different players of the phosphate homeostasis have been mutated or knocked out in mice. All 
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these studies contributed to the picture of the actual complexity of phosphate homeostasis.  
Those mice do not produce any vitamin D. Their phenotype consists of retarded growth, secondary 
hyperparathyroidism, and hypogonadism. 
KO of 1α-hydroxylase (385): 
Analysis of the mice showed that they suffer from hypocalcemia and elevated levels of PTH. In 
addition the levels of 24-hydroxylase were reduced. 
In contrast to humans, in mice Na-Pi2a and Na-Pi2c are essential for phosphate reuptake. Therefore, it 
is necessary to study the double knock out.  
Na-Pi2a/Na-Pi2c double knock out (386): 
These mice show growth retardation, hypophosphatemia, hypercalcemia and hyperphosphaturia. In 
addition, the level of vitamin D is increased and the levels of PTH and FGF23 are decreased. 
The renal tubules express FGFR1, 3 and 4. In order to investigate, which receptor is essential for 
regulation of phosphate levels recombinant FGF23 was injected in a conditional knock out for fgfr1 
and knock out animals for fgfr3 or fgfr4. The resulting measurement of serum phosphate led to the 
conclusion that FGFR1 plays the principal role in phosphate regulation, while FGFR4 plays a minor 
role. Interestingly, fgfr1 conditional knock out animals showed elevated levels of FGF23, probably due 
to a negative feedback loop, but unchanged phosphate levels. This suggests the presence of 
compensatory mechanisms against high serum phosphate levels.  
Conditional Knock out of fgfr1 (372): 
In this study a selective pan-FGFR inhibitor, PD173074, was injected into WT animals. This 
pharmacological inhibition of the FGFRs had similar effects on the Cyp27B1 and Cyp24A1 levels as 
the Klotho mutation or FGF23 knock out. Injection of PD172074 induced upregulation of 1α-
hydroxylase and parathyroid hormone as well as downregulation of 24-hydroxylase, causing 
hyperphosphatemia and hypervitaminosis D.   
Pan inhibition of FGFRs (387): 
In addition, this study shows that FGFR inhibition blocks FGF23 transcription in the bone and that this 
is dominant over vitamin D induced FGF23 transcription. 
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The vitamin D receptor mutant mice are short lived and retarded in growth. In addition, their skin is 
wrinkled, they have alopecia and rickets as well as impaired bone formation. Furthermore, they show 
hypocalcemia and hypophosphatemia.   
Vitamin D receptor mutant (388, 389):  
Mice that have a deletion of the phex gene, that’s located on the X chromosome, are named after their 
most prominent phenotype: hypophosphatemia. It has been confirmed that the phenotype is caused by 
elevated levels of FGF23 (see below). 
Hyp mice (390): 
In addition to hypophosphatemia, the mice also show rickets in the bone, retarded growth, 
hyperphosphaturia, hypocalcemia and kyphosis.  
This mouse model has proven to be well suited for rescue studies (see below) 
Hyp mice that were injected with an antibody against FGF23 recovered from hypophosphatemia. In 
addition, they had elevated levels of Na-Pi2a, 1α-hydroxylase, and 24-hydroxylase compared to 
untreated hyp mice. The level of vitamin D was also elevated compared to the hyp mice, while the level 
of PTH was decreased. There was no change in the calcium levels. This shows that rescue of FGF23 
levels is essential for rescue of vitamin D and PTH levels and of Na-Pi2a localization to the brush 
border membrane. In addition, rescue of FGF23 is important to stabilize serum phosphate levels. In 
contrast, regulation of FGF23 levels is not enough to rescue Calcium levels. 
Anti FGF23 antibodies in hyp mice (391): 
In this study it was shown that the FGF23-Klotho axis, that controls phosphate levels, signals through 
the MEK signaling pathway.  
Inhibition of the MEK signaling pathway in the hyp mice (373): 
Hyp mice that were treated with a MEK inhibitor, PD0325901, recovered in terms of 1α-hydroxylase 
expression, vitamin D levels, phosphate levels, and expression of NaPi2a expression in the brush 
border membrane.  
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Table 4-3 Overview over the changes in the different mouse models 
No diff = no difference; Ab = antibody 
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5 Material and Methods 
5.1 Reagents and antibodies 
FGF2 was from Sigma-Aldrich (St. Louis, MO, USA). The FGFR kinase inhibitor TKI258 [388] was 
provided by Drs. D. Graus-Porta and C. Garcia-Echeverria (Novartis Institutes for Biomedical 
Research, Basel, Switzerland). The compound indicated in the thesis as “FGFR inhibitor” is another 
compound, that more potently the FGFRs. The following antibodies were used: Pser 473 -AKT (9271), 
AKT (9272), Pser 65 -4E-BP1 (9451), Asp175-cleaved caspase 3 (9661), Ptyr 196 -FRS2 (3864), Ptyr 436 -
FRS2 (3861), FGFR1 (3472), Ptyr 202 /tyr 204 -ERK1/2 (9101), ERK1/2 (9102),  GAB1 (3232), Ptyr 180 
/tyr 182 –p38 (9215), p38 (9212), Pser 240 /ser 244 -S6 ribosomal protein (2215) from Cell Signaling 
(Danvers, MA, USA); FRS2 (sc-8318), SHP2/SH-PTP2(c-18) (sc-280) from Santa-cruz Biotechnology 
Inc. (Santa Cruz, CA, USA); actin (MAB1501) from Chemicon (Billerica, MA, USA); GRB2 
(G16720) from Transduction Laboratories (BD Biosciences, Mississauga, ON, CDN); Flag (F7425) 
from Sigma-Aldrich (St. Louis, MO, USA); CD31 (550274) from BD Bioscience (San Jose, CA, 
USA);  HIF1α (NB100-449) Novus Biological; Na-Pi2a rabbit polyclonal antibody was a courtesy of 
Jörg Biber in Zurich (Switzerland); Polyclonal antibodies to a 19 amino acid peptide of human Memo, 
which shows high similarity to the mouse Memo, were produced in rabbits (aa 25-43 human Memo 
NM_015955: NAQLEGWLSQVQSTKRPAR), the same peptide was used for mAB production in 
mice. Monoclonal antibody of Klotho was produced in mice by immunizing them against a synthesized 
amino peptide (DDAKYMYYLKKFIMETLKAIKLDGV), which is a part of the human Klotho 
protein.  
5.2 Cell Culture 
Mouse embryonic fibroblasts (MEFs): 
Immortalized mouse embryonic fibroblasts (MEF) were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% Fetal Calf Serum (GIBCO Invitrogen AG, Basel, 
Switzerland) and Penicillin and Streptomycin (growth medium). 
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MEFs were generated by digestion of the torso and lower part of the head from Memo conditional 
knock- out mice. Digestion was performed by addition of fresh trypsin-EDTA in PBS every 30 
minutes; the samples were incubated on 37°C on an Eppendorf shaker until digestion was complete. 
The cell suspension was decanted in a fresh tube containing FBS. After centrifugation at 1000rpm for 5 
minutes the pellet was resuspended in DMEM containing 10% FBS. Next day, the medium was 
exchanged and thereby most non-fibroblastic cells were removed.  
Immortalization was achieved by growing the MEFs until they entered crisis at about passage 3. Then 
we waited for spontaneous immortalization. 
To obtain inducible Memo knock-out MEFs, the spontaneously immortalized cells were transfected 
with a tamoxifen inducible Cre recombinase. Virus production: Ecophoenix cells were transfected with 
24µg of pMSCV-CreERT2-puror placmid with lipofectamin 2000 (from invitrogen). After 3.5 days of 
growing at 37°C the supernatant was collected, filtrated on 0.45mu filter and 5ug/ml polybrene was 
added. 5ml of this supernatant was used to infect one 10cm dish of MEFs. After 6 hours of incubation 
at 37°C the supernatant was removed and fresh DMEM-10%FBS was added. After 48 hours of 
expression the selection with puromycin was started. 
Knock-out MEFs were generated by incubation of the cells in 0.5 ug/ml 4-hydroxytamoxifen in 
DMEM-10%FBS for 3 days. Control cells were incubated in DMEM-10%FBS with ETOH. 
HEK293-kl and HEK293-βkl: 
HEK293 cells were stably transfected with full length Κlotho (HEK293-kl) [98] or βKlotho (HEK293-
βkl) [290] to achieve FGF23 (HEK293-kl) and FGF19 and 21 (HEK293-βkl) responsive HEK293 cells 
[290]. 
Memo was downregulated with siRNA. HEK293-kl cells were seeded in 6 well plates. Next morning 
siRNA treatment was performed: Mix1: 2.5ul Optimem, 4ul Lipofectamin, Mix2: 2.5ul Optimem, 4ul 
siRNA for Memo or LacZ as control. Mix1 and 2 were combined, mixed and incubated at room 
temperature for 15 minutes before adding to the plate. After 4 to 6 hours fresh DMEM-10%FCS was 
added. 24 hours later the cells were starved before they were stimulated. Lysates were prepared as 
described before (392).  
4T1 mouse mammary carcinoma cells: 
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The mouse mammary tumor cell line 4T1 (obtained from Dr. R. Weinberg, Whitehead Institute for 
Biomedical Research, USA) was grown in DMEM-10%FBS and Penicillin and Streptomycin. 
Short hairpin (sh) RNAs for targeting Memo in 4T1 cells were designed using algorithms available 
from Invitrogen and the corresponding sense and antisense oligonucleotides were obtained from 
Microsynth AG (Switzerland). The two Memo sequences targeted NM_015955 nucleotides 1002 to 
1022 (sh7) and 1213 to 1231 (sh10). The annealed shRNA oligos were cloned into BglII/HindIII 
digested pSUPERretro-Neo-GFP. A double stranded LacZ shRNA oligo was cloned into the same 
vector to use as a control.  
4T1 mammary tumor cells were transfected with the two independent Memo shRNA specific vectors 
(sh10 and sh7) and with the control lacZ vector using lipofectamine (Invitrogen, Carlsbad, CA, USA). 
Resistant cells were selected in 0.5 mg/ml G418 (11811031) from Invitrogen (Carlsbad, CA, USA) and 
individual clones expressing sh10 and sh7 and the control LacZ were selected. 
5.3 Lysates, western blot analyses and immunoprecipitations 
Over-night serum starved cultures (DMEM-0.1%BSA (Sigma)) were stimulated with 50ng/ml FGF2 or 
treated with 500µM CoCl2, 50nM FGFR inhibitor, or 30µM LY294002 for the indicated time. 
Whole cell lysates for western blot analyses were prepared in NP-40 buffer (50mM Hepes (pH 7.4), 
150mM NaCl, 25mM beta-glycerophosphate, 25mM NaF, 5mM EGTA, 1mM EDTA, 15mM PPI and 
1% NP-40) supplemented with leupeptin (10 ug/ml), aprotinin (10 ug/ml), vanadate (2mM), DTT 
(1mM) and PMSF (1mM). The lysates were boiled in sample buffer, separated by SDS-PAGE, blotted 
onto polyvinylidene difluoride membranes (Millipore Corporation) and probed with the specific 
antibodies. Whole cell lysates for co-immunoprecipitations (Co-IP) were prepared in 2 times Co-IP 
buffer (50mM Tris (pH 7.5), 5mM EGTA, 150mM NaCl, 25mM beta-glycerophosphat, 25mM NaF) 
supplemented with 10% Triton X-100, 10% Glycerol, vanadate (2mM), PMSF (1mM), aprotinin (10 
ug/ml), leupeptin (10 ug/ml) and MgCl2 (10mM). The IPs were collected with protein-A or G 
sepharose beads (Sigma) and centrifuged. The pellets were washed three times with Co-IP buffer. 
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Proteins were released by boiling in sample buffer SDS-PAGE and immunoblotting was preformed as 
described for whole cell lysates. 
5.4 Electron Microscopy 
For electron microscopy, pieces of hearts were fixed in Karnovsky’s fixative (3% paraformaldehyde, 
0.5% glutaraldehyde in 10 mM PBS pH 7.4), washed, and post-fixed in 1% OsO4. After dehydration 
with graded series of ethanol, samples were embedded in Epon and sections of 60 to 70 nm thickness 
were cut [389]. Sections were double stained with uranyl acetate and lead acetate [390] and viewed in a 
FEI Morgangi 268D transmission electron microscope. 
5.5 Hypoxia 
Control and Memo KD 4T1 cells were put in hypoxic chambers that were filled with hypoxic gas (1% 
O2, 5% CO2, 94% N2) for 20 minutes. Afterwards, the chambers were disconnected and cells were 
incubated in the chambers filled with the hypoxic gas in the cell incubator for the indicated times. 
Lysates were prepared immediately after opening the chambers. As mimetic for hypoxic conditions 
lysates were prepared from cells that were incubated in 500µM CoCl2 for the indicated times. 
5.6 Proliferation assay 
Proliferation was measured by seeding cells at a density of 8000 per well in a 96 well plate and 
growing to 80% confluency. After addition of 10µM 5bromo-2’-deoxyuridine (BrdU), the cells were 
incubated for 2 hours at 37°C. BrdU incorporation was measured using the BiotrackTM cell 
proliferation ELISA system (GE-healthcare, Little Chalfont, UK). 
5.7 Apoptosis assay 
5.7.1 YoPro 
Cytotoxic effect of CoCl2 treatment, FGFR inhibition, and AKT inhibition was evaluated by YoPro 
assays (Invitrogen, Carlsbad, CA, USA) [391]. Control and KD 4T1 cells were seeded on 96 well 
plates (in quadruplets) and were either treated with CoCl2 or with inhibitors blocking specific signaling 
molecules (a specific FGFR inhibitor, or the commercially available FGFR inhibitor TKI258 or the 
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PI3K-inhibitor LY204002) for the indicated times. The first measurement with the YoPro assay 
measures apoptosis or cytotoxity: 25µl of YoPro-Mix (3ml 5 * YoPro buffer (100mM pH4 Na-citrate, 
134mM NaCl) and 37.5µl 1mM YoPro (Invitrogen, Carlsbad, CA, USA)) is freshly prepared in the 
dark and added to the 96 wells; cells are incubated 10 minutes in the YoPro-Mix before the plate is read 
in a Cytofluor II, filter 485/529nm. The second measurement allows a determination of cell growth and 
total cell number: 25µl of lysis buffer (3ml per plate: 0.18ml 500mM EDTA, 0.18ml 500mM EGTA, 
0.18ml 10% NP-40, 2.46ml 1 * YoPro buffer) is added into the wells, plates are incubated for 30 
minutes in the dark and then read in a Cytoflour II, filter 485/529nm. 
5.7.2 MitoProbeTM DilC1(5) Assay 
DilC1(5) stains cells that have an active mitochondrial potential. Loss of mitochondrial potential 
correlates proportionally with loss of DilC1(5) staining and indicates cellular death. 
The analysis of stress response to CoCl2 and Etoposide was performed by measuring the mitochondrial 
membrane potential via staining with Dilc1(5) (M34151, Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer’s protocol. Cells were treated with CoCl2 or Etoposide for the indicated times, before 
they were collected for FACS analysis: Supernatant and trypsinised cells were combined, centrifuged 
and resuspended in PBS. 5ul of Dilc1(5) was added to 10 6 cells in 1ml PBS. Cells were incubated for 
20 minutes at 37°C, centrifuged and resuspended in 500µl of PBS. A FACScalibur Flow Cytometer 
(Becton Dickinson, Franklin Lakes, NJ, USA) was used for analysis. 
5.8 Migration assay 
Control and Memo KD 4T1 were preincubated for 1 hour in DMEM-10% FCS supplemented with 
DMSO or FGFR inhibitor. Cells were counted and 100’000 cells per well were seeded on collagen 
(11179179001, Roche, IN, USA) coated transwell cell culture chambers (8.0µm plycarbonate 
Membrane, 6.5 mm Insert, 24 well plate, Costar, Corning Incorporated, NY, USA). After the indicated 
time the migrated cells were stained with cristal violet (101408, Merck KGaA, Darmstadt, Germany) 
and counted. 
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5.9 RNA extraction, RT-PCR and real-time PCR 
RNA from growing 4T1 cells was extracted using the Qiashredder and RNeasy Mini Kit coupled with 
RNase-free DNase set (Qiagen, Venlo, The Netherlands Qiagen) following the manufacturer’s 
instructions. RNA from tissues and tumors were obtained from snap frozen tumor pieces, following 
extraction with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
protocol. RNAs were washed using the RNeasy Mini Kit (Qiagen) and treated with RNase-free DNase 
set (Qiagen). cDNA was obtained from 1ug of total RNA, using the Ready-to-go You-Prime First-
Strand Beads kit (GE-healthcare, Little Chalfont, UK) with oligos-dT primers (Promega). Semi-
quantitative PCR was performed as follow: 2ml of 10X Buffer (Roche), 0.2ml of Taq polymerase 
(5U/ml Roche), 0.4ml of 10mM dNTP mix (Roche), 0.1ml of each primer (100mM), 1ml of cDNA, 
filled to a final volume of 20ml with sterile H2O. Thermal cycling reaction using an Icycler device 
(Bio-Rad, Reinach, Switzerland) was: 94°C for 2 min; followed by 25 to 35 cycles of 95°C for 30 sec, 
60°C for 30 sec, 72°C for 45 sec. The amplified products were further extended by additional 
incubation at 72°C for 10 min. PCR products were then loaded on a 1% agarose gel containing 
ethidium bromide. QRT-PCR was performed with ABI prism 7000 (Applied Biosystems, Austin, TX, 
USA) using Absolute QPCR SYBR Green ROX Mix (THERMO Scientific, Waltham, MA, USA) 
following the manufacturer’s guidelines. All quantitations were normalized to GAPDH. GAPDH 
primers for semi-quantitative PCR and real-time PCR are described in Chapter 0.  
Primers used for detection of 
VEGF-A: 5’-ACCCTGGCTTTACTGCTGTACC-3’ 
5’-TGCATTCACATCTGCTGTGCTG-3’ 
TRPV5: 5’- TTGGTGCCTCTCGCTACTTT-3’ 
  5’- AGCGCAGTAGGTCTCCAAAA-3’ 
NCX1: 5’- CGAGACTGTGTCGAACCTGA-3’ 
  5’- TCAGGGACCACGTAAACACA-3’ 
PMCA: 5’- GATCCTCTTGTCGGTGGTGT-3’ 
  5’- CCGTACTTCACTTGGGCAAT-3’ 
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CB28:  5’- GACGGAAGTGGTTACCTGGA-3’ 
  5’- TTCCTCGCAGGACTTCAGTT-3’ 
5.10 Immunohistochemistry 
Kidneys were fixed 24 hours in PBS containing 4% paraformaldehyde then incubated 24 hours in 70% 
ethanol. Fixed tissues were embedded in paraffin. Immunohistochemitry was performed on 4µm thick 
sections using the monoclonal Memo antibody. The staining was carried out with the Discovery XT 
Staining Module (Ventana Medica Systems S.A.). 
5.11 Generation of the mouse strains 
Animal experiments were done according to the Swiss guideline governing animal experimentation and 
approved by the Swiss veterinary authorities. 
5.11.1 Memo cKO and KO mice 
A mouse strain with a loxP-flanked (floxed) Memo gene was generated by targeting the second exon of 
Memo.  PCR synthesis of homology arms and loxP-exon 2 were performed on 15ng/µl gDNA extracted 
from ES cells (129/OLA), 1.5mM MgCl2, 0.2mM dNTP mixture, 0.03 U/µl Red Hot DNA polymerase 
(Abgene, ref. AB-0406/A9), 0.005 U/µl Pwo polymerase (Roche diagnostics, ref. 1 644 947), 
respective primer pair (200nM each) in the following cycling conditions:  
Pre-denaturation step 2 min. at 94°C, 14 cycles [15 s at 94°C – 3 min. at 70°C (-0.5°C per cycle)], 20 
cycles [15 s at 94°C – 3 min. (+ 10 s per cycle) at 63°C], post elongation step 7 min. at 63°C, storage at 
4°C. 
Each PCR product was purified, SfiI digested and ligated in a vector containing a pgk-neomycine 
cassette flanked with 2 loxP sites and 2 Frt sites. Sequencing of the exonic regions, loxP and FRT sites 
was performed to avoid any risk of PCR-induced mutations. 
The targeting construct was linearized by SalI restriction and overhanging ends were filled by the 
Klenow fragment. Purification was carried out by two successive rounds of phenol/chloroform 
extractions followed by an ethanol precipitation and two washes with 70% ethanol. Pure DNA was air 
dried and resuspended in sterile deionized water. Embryoinic cells (ES) were electroporated with the 
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targeting construct and selected for resistance to G418. ES clones that underwent recombination and 
were hence resistant were initially screened for homologous recombination at the Memo locus by PCR 
using 5’ external forward combined with a neo cassette specific reverse primer, as well as with a neo 
cassette forward primer 5’ combined with a 3’ external reverse primer using the Expand-Long-
Template-PCR system (Roche # 11 681 834 001), according to manufacturer’s instructions. Single 
integration was confirmed by Southern blotting using a neo specific radiolabeled probe. Two ES clones 
showed specific homologous recombination at the Memo locus (3 lox allele) and were used for 
aggregation experiments and chimera production. Only one clone (109) gave a chimera with germline 
transmission. Those mice were crossed to a FLP deleter transgenic mouse to remove the Neo cassette 
and generate the Memo cKO mice. By crossing those mice with a Cre deleter transgenic mouse strain 
exon number 2 of Memo was removed and the Memo KO mice were generated. 
5.11.2 Meox2Cre mice 
Meox2Cre mice express the Cre recombinase under the control of the mesenchyme homeobox 2 
promoter starting at day E5. The Cre recombinase is active in the embryo and in extra-embryonic 
mesoderm derivatives, including the chorionic plate and yolk sac mesoderm. All other regions of 
placenta are Cre negative [393].  
5.11.3 Memo cKO Actin Cre mice 
To achieve a mouse strain which can be temporally controlled for memo excision, the Memo cKO 
strain (Memofl/fl) was crossed to a mouse strain harboring the Cre recombinase under a tamoxifen 
inducible actin promoter, the pCX-CreERTM transgenic. Memofl/fl mice were crossed with pCX-
CreERTM transgenics to generate heterozygous offspring for the floxed Memo allele and the Cre. 
Homozygous founders for the floxed Memo allele were generated by mating these heterozygous mice. 
Loss of Memo was induced by intraperitoneal (IP) injections of Tamoxifen (Sigma) in corn oil (Sigma) 
on 4 to 5 consecutive days. The age of the mice at the time of injection varied between 2 to14 weeks. 
Homozygous negative Cre mice were control treated with tamoxifen. Injected mice were controlled by 
weight. 
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5.11.4 Memo cKO rtTA LC-1 Cre mice 
In order to generate a kidney-specific, temporally controlled Memo knock out strain we used a kidney 
specific tet-ON system. The Memo cKO strain (Memofl/fl) was crossed to a mouse strain harboring the 
doxycycline rtTA under the Pax8 promoter (B6.Cg-Tg(Pax8 rtTA2S*M2)1Koes/J) and to a mouse 
strain harboring the LC-1 Cre recombinase under a Ptet bi-1 promoter that is expressed in all cells of the 
mouse. 
B6.Cg-Tg(Pax8 rtTA2S*M2)1Koes/J mouse line: 
Transgenic Pax8-rtTA mice are viable and fertile. These mice express an optimized reverse 
tetracycline-sensitive transactivator (rtTA2S-M2) protein under the control of the murine Pax8 
promoter. The Pax8 promoter directs expression to proximal and distal tubules and the collecting duct 
system of both embryonic and adult kidney. The rtTA2S-M2 variant of rtTA contains five amino acid 
changes in the TetR moiety (S12G, E19G, A56P, D148E, and H179R) and a synthetic optimized 
transactivating domain, resulting in reduced basal activity and enhanced doxycycline sensitivity 
compared to wild-type rtTA. When mated to a second strain carrying a gene of interest under the 
regulatory control of a tetracycline-responsive promoter element (TRE or tetO), expression of the target 
gene in kidney cells is induced with administration of the tetracycline analog, doxycycline (dox). These 
Pax8-rtTA mice provide a Tet-On tool that allows the inducible expression of genes in renal tubular 
epithelial cells.  
Development of this strain: The Pax8-rtTA construct was designed to contain an optimized rtTA variant 
(rtTA2s-M2) cDNA and SV40 polyA sequence replaced at the endogenous ATG translational start site 
of a murine Pax8 sequence. This 6.6 kb transgene was microinjected into the pronucleus of one-cell 
fertilized mouse embryos obtained from superovulated F2 (C57BL/6 * DBA) females, which were then 
implanted into pseudopregnant foster mice. Founder mice were bred to C57BL/6 mice, and the 
resulting transgenic offspring were bred together for many generations. The mice were backcrossed to 
C57BL/6J for at least five generations to generate the congenic strain that was used in this study 
(Jackson Laboratory Stock nr. 007176). The Pax8-rtTA construct integrated approximately five copies 
in a head-to-tail orientation within a mouse L1 line repetitive element (which are located throughout 
the genome). 
LC-1 Cre mice line: 
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This mouse line contains the Cre recombinase and the luciferase gene under the control of a 
bidirectional Ptetbi-1 promoter, that contains the tetracycline responsive promoter element [394, 395]. 
The resulting Memo cKO-rtTA-LC-1 mouse line is a tet-On tool that allows the inducible excision of 
Memo in renal tubular epithelial cells. Simultaneously to the induction of Cre transcription the enzyme 
luciferase is transcribed. Therefore, the activity of Ptetbi-1 transcription can be controlled by luciferin 
injection and transillumintor imaging. 
 
Figure 5-1 The doxycycline inducible kidney specific Memo knock out mouse line 
A) Transgenic Pax8-rtTA mice express the rtTA2S-M2 transactivator protein under the control of the murine Pax8 promoter, 
which directs expression to proximal and distal tubules and the collecting duct system of the kidney. 
B) In the presence of doxycycline rtTA activates the bidirectional tet-promoter. Subsequently the Cre recombinase is 
expressed specifically in the cells that express rtTA. 
C) In the cells that are expressing the PAX8 promoter and therefore, are expressing the Cre recombinase exon number 2 of 
Memo gets excised and no Memo protein is transcribed. 
Female Memofl/fl mice that were not positive for rtTA and Cre recombinase expression at the same time 
were bred with males in order to give rise to offsprings that harbored two floxed Memo alleles and 
were positive for rtTA and Cre recombinase expression at the same time. Pregnant females of such 
breedings were doxycycline induced at E0.5. As doxycycline transgresses the uterus the embryos 
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positive for rtTA and Cre expression where induced for Memo loss. Doxycycline treatment was 
continued until the pups were born and reached the age of about 3 weeks. 
5.12 Microarray of livers and kidneys (performed by the microarray facility 
inhouse) 
5.12.1 Sample preparation 
5.12.1.1 Microarray of livers 
200ng of total RNA per sample were processed. cDNA was made with the WT cDNA Synthesis and 
Amplification kit and labeling was perfomed with the WT Terminal Labeling kit from Affymetrix 
(Affymetrix, Santa Clara, CA) according to the manufacturer’s instructions. 
5.12.1.2 Microarray of kidneys 
100ng of total RNA per sample was amplified with the Ambion WT expression Kit (Ambion) 
according to the manufacturer’s instructions. The resulting cDNA was fragmented and labeled with the 
Affymetrix GeneChip WT Terminal Labeling and Controls Kit according to the manufacturer’s 
instructions. 
5.12.2 The array 
GeneChip Mouse Gene 1.0 ST arrays were hybridized following the “GeneChip Whole Transcript 
(WT) Sense Target Labeling Assay Manual” (Affymetrix, Santa Clara, CA) with a hybridization time 
of 16 hours. The Affymetrix Fluidics protocol FS450_0007 was used for washing. Scanning was 
performed with Affymetrix GCC Scan Control v. 3.0.1 on a GeneChip® Scanner 3000 with autoloader 
(Affymetrix). 
Probesets were summarized and probeset-level values normalized with justRMA() function from R 
(version 2.9.0) / Bioconductor (version 2.5) package affy using the CDF environment MoGene-1_0-st-
v1.r3.cdf (as provided by Bioconductor) and annotation from Netaffx (www.netaffx.com).  
Differentially expressed genes were identified using the empirical Bayes method (F test) implemented 
in the LIMMA package. Adjusted p-values were calculated with the false discovery rate method 
(Wettenhall JM Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray 
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data. Bioinformatics (Oxford, England) 2004).  
Probesets with a p-value of < 0.01, and an absolute log 2 fold-change of more than 2-fold (in linear 
space) were selected. 
5.13 Blood- and Urine analysis 
5.13.1 Measurement of bilirubin, cholesterol, Creatine Kinase, insulin, iron, glucose, potassium, 
triglycerides, total protein   
Blood was collected from males (wt n=5, ko n=5) via orbital sinus bleeding after anesthesia with 
Isofluorane, ForeneR (ABBOTT, ZG, Switzerland). At the time of Memo loss mice were 14 weeks of 
age, the first blood collection was performed 3 weeks later and the second measurement 14 weeks after 
Memo loss. The analysis of the blood parameters was performed by ICS, Strasbourg, France.   
5.13.2 Blood analysis performed in Dallas 
Blood was collected from males (wt n=16, ko n=19) that were induced for loss of Memo at the age of 2 
to 3 weeks. About 8 weeks later these mice were fasted overnight and blood collection was performed 
from the vena cava after the mice have been anaesthetized with a mixture of 1.2ml of narketan 10 
(Vétoquinol), 0.8 ml of Rompun 2% (Bayer), 8 ml of PBS-Ca2+/Mg2+. Analysis was performed on the 
Vitros 250 in Dallas, Tx, USA at the UTSouthwestern University of Medical Center. 
5.13.3 Measurement of phosphate, calcium, sodium, potassium, BUN, creatinine and Albumin 
Blood was measured at the Zentrallabor of the University of Basel and Urine was analysed by the 
hospital in Lausanne (CHUV).  
5.13.3.1 Calculations 
The fractional excretion was calculated as: 
Fractional excretion of x = (Ux*Ucr*100)/(Px*Ucr); U = concentration in urine, P = concentration in 
plasma, Cr = creatinine, if x= calcium, then Px=Pca/2 as only half of the calcium is free in the blood 
Excretion rate was calculated as: 
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Excretion rate of x = Ux/Volume of urine 
5.14 Metabolic cages 
Kidney-specific Memo KO (n=3) and control animals (n=10) were placed in metabolic cages and 
acclimatized for three days during which body weight was measured. Following the three 
acclimatization days three days of measurement followed. We performed three measurements, each 24 
hours. We measured body weight, food- and water intake, amount of feces and urine. At the end of the 
experiment all animals were sacrificed. In addition to the urine we collected blood, kidney, liver, 
thyroid gland, and bone for analysis.  
5.15 Islolation of brush border membrane 
Adapted from Biber et al. 2007 (393).The left kidney of KO and control animals were isolated from the 
animals and each cut into pieces. These pieces were kept on ice and ice cold buffer was added. Buffer: 
300mM D-mannitol, 5mM EGTA, 12mM Tris-base (pH 7.1), freshly added PMSF (0.5mM). The 
samples were homogenized with a Polytron (PT 1600 E) until all big pieces were processed. 1.12ml of 
H2O and MgCl2 up to 12mM were added. Incubation on ice for 15 minutes before the samples were 
centrifuged for 15 minutes at 4500rpm (1500g) at 4°C. The supernatant was decanted into new 
Eppendorf tubes and were centrifuged at 18500rpm (25000g) for 30 minutes. The pellet was re-
suspended in 500µl of the same buffer than before. For complete re-suspension we homogenized with a 
25G needle. The solution was processed 10 times. Concentration was measured by NanoDrop (witec 
AG, 6014 Littau, Switzerland) and sample buffer was added. The samples were boiled, separated by 
SDS-PAGE, blotted onto polyvinylidene difluoride membranes (Millipore Corporation) and probed 
with specific antibodies. 
5.16 ELISA for VEGF, PTH and FGF23 
5.16.1 VEGF ELISA 
Control and KD 4T1 cells were plated at a density of 8000 cells per 96-well and allowed to grow for 24 
hours in DMEM supplemented with 10% FCS. Treatment with CoCl2, FGFR or PI3K inhibitor was for 
24 hours. Control cells were treated with DMSO, the vehicle of FGFR and PI3K inhibitors. 
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Supernatants from 3 wells were pooled and divided into 3 wells for the ELISA. The levels of VEGF-A 
were quantified using the Quantikine ELISA kit (R&D Systems, Minneapolis, USA). The number of 
viable cells was determined using CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega, WI, USA)  
5.16.2 PTH ELISA 
Blood was collected from Memo KO and control animals, centrifuged for 15 minutes, 6000rpm at 4°C. 
Serum was collected and snap frozen. Thawed samples were of used for the ELISAs. 
The concentration of PTH was measured in the serum of 9 Memo null and 6 control mice and of 6 
kidney-specific Memo KO and 12 control animals. We performed the measurement with the ELISA kit 
from Immutopics (60-2305, Immutopic International, San Clemente, CA) according to the 
manufacturers protocol. 
5.16.3 FGF23 ELISA 
Blood was collected from Memo KO and control animals, centrifuged for 15 minutes, 6000rpm at 4°C. 
Serum was collected and snap frozen. Thawed samples were of used for the ELISAs. 
The concentration of FGF23 was measured in the serum of 11 Memo null and 4 control mice as well as 
of 6 kidney-specific Memo KO and 12 control animals. We performed the measurement with the 
ELISA kit from Kainos Laboratories (Kainos Laboratories, Inc, Japan) according to the manufacturers 
protocol. 
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6 Rational of the work 
Memo (Mediator of ErbB2 driven cell motility) was identified in a screen for binding partners of 
ErbB2. ErbB2 has five major phosphorylation sites, two of which (Y1201=YC and Y1227=YD) are 
required for cellular migration and therefore might play an important role in breast cancer metastasis. 
To identify binding partners of these two sites, a screen using YC- and YD-phospho-peptides was 
performed and interacting partners were ascertained by a massspec approach. One of the unannotated 
proteins found to associate with the phospho-YD site was subsequently given the name Memo, due to 
its important function in mediating heregulin-induced migration. It was later revealed that the 
importance of Memo for migration is not confined to mediating signaling downstream of ErbB2, but 
that it also functions downstream of other receptor tyrosine kinases.  
As we were interested in continuing to explore the role of Memo in mouse mammary carcinoma cells, 
we used shRNA-based approaches to focus in on the functions of Memo in migration, cellular 
sensitivity to FGFR inhibition and resistance to stress conditions. 
Another part of this study aimed at shedding light on the role of Memo in normal physiology. 
Conventional Memo knock-out led to embryonic lethality. Therefore, we generated an inducible, full-
body Memo knock-out model (Memo null animals). We found that embryos that lost Memo after E13.5 
survived until birth, but died rapidly thereafter. Studies in pups and young adults showed that Memo 
null animals suffered from severe premature aging symptoms. In addition, these mice showed 
postprandial hypoglycemia and increased sensitivity to insulin.  
Although this is a rare metabolic phenotype for mouse models of premature aging, which mainly arise 
from DNA repair defect or nuclear structural alterations, it has been reported for two, namely the 
Klotho mutant and FGF23 knock-out models.  The Klotho and FGF23 mutant mice illustrated for the 
first time that a defect in the kidney, not directly related to DNA damage, can result in a severe 
systemic phenotype such as premature aging. These two strains were shown to have defects in the 
regulation of physiological levels of phosphate, calcium and vitamin D. Since the characterization of 
these two mouse models, much research has been performed to understand the process of aging and the 
roles that vitamin D and phosphate play. Given that Memo null animals share this rare metabolic 
phenotype, we believed that it could be a novel protein player in the Klotho-FGF23 system.  
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To investigate this we took two approaches:  
1) First, we generated a second mouse model that allowed us to temporally induce Memo loss 
specifically in the kidney, in the same cells that express Klotho, since only cells that express the co-
receptor Klotho are sensitive to FGF23. We subsequently examined the kidney metabolism in both the 
Memo null and kidney-specific Memo KO models; and  
2) Second, we investigated the general role of Memo in in vitro FGFR signaling, specifically looking at 
its function in FGF23-mediated FGFR activation.  
The goal of this thesis was to further understand the process of aging, the effects of which affect our 
quality of life and put a strain on our limited healthcare resource. 
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Abstract 
Memo is encoded by a single-copy gene present in all branches of life and is ubiquitously expressed in 
adult organs and during embryogenesis. To study Memo’s role in physiology, we generated a 
conditional strain, Memofl/fl. These mice were crossed with the pCX-CreERTM strain, in which 
expression of the inducible Cre transgene is driven by the actin promoter. Tamoxifen treatment of 
Memofl/fl / pCX-CreERTM mice resulted in deletion of Memo in all organs. Loss of Memo led to the 
rapid onset of a premature aging phenotype accompanied by alterations in insulin and glucose 
metabolism. Memo null mice share many features of Klotho and FGF23 mutant strains. Therefore, we 
investigated Memo’s role in FGFR signaling in vivo and in vitro. Memo null kidneys have altered 
expression of Cyp27B1, Cyp24A1 and the sodium phosphate (Na-Pi) cotransporter, important 
regulators of vitamin D production and phosphate reabsorption. Using an inducible system to ablate 
Memo in mouse embryonic fibroblasts (MEFs) isolated from Memofl/fl   embryos, we show that FGFR 
signaling activity and duration is lower in knock-out, compared to wild-type MEFs. The results 
obtained both in vivo and in vitro support the hypothesis that Memo is a novel regulator of FGFR 
signaling.    
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Introduction 
Memo was discovered during a screen for proteins essential for ErbB2 induced tumor cell motility 
(Memo; mediator of ErbB2-driven cell motility) (1). We have shown that the 33kDa Memo is 
complexed with heregulin (HRG)-activated ErbB2 and is essential for maintaining directionality during 
HRG-induced migration (2). In addition, we observed that migration induced by epidermal growth 
factor (EGF) or fibroblast growth factor (FGF) also requires Memo (1), suggesting that it might have a 
broad function in signaling downstream of receptor tyrosine kinases.  In this study we present evidence 
that Memo is a novel downstream regulator of the FGFR pathway. 
To study the role of Memo in normal physiology, we generated a mouse strain harboring a conditional 
allele of the Memo gene. In order to control temporal Memo deletion, Memo floxed (Memofl/fl) mice 
were crossed with pCX-CreERTM transgenics which allows Memo deletion following tamoxifen 
treatment. Surprisingly, loss of Memo led to the rapid onset of a premature aging phenotype 
accompanied by alterations in insulin and glucose metabolism. Memo null mice share many features of 
Klotho and FGF23 mutant strains (3-5).  
Unlike the majority of the FGF ligands, the three endocrine ligands, FGF15, FGF21 and FGF23, have 
low affinity for heparin/heparan sulfate proteoglycans (6) and use Klotho family proteins as 
coreceptors. Thus, for binding to their cognate FGFRs, FGF15 and FGF21 require βKlotho (7), while 
FGF23 requires Klotho (8, 9).  Klotho, which encodes a single-pass transmembrane protein of 130 kDa, 
is mainly expressed in renal tubular cells, parathyroid chief cells, and epithelial cells of the choroid 
plexus (5). FGF23 is secreted from bone and signals in the renal tubules and other organs, where its 
coreceptor Klotho is expressed. Upon binding to the FGFR1-Klotho complex in the nephron, FGF23 
controls production of active vitamin D, 1,25-dihydroxyvitamin D3, and phosphate reabsorption.  
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Defects in FGF23 or Klotho expression in mice lead to a severe premature aging phenotype (3-5), 
caused by elevated levels of phosphate (10, 11). Moreover, in FGF23 and Klotho mutant strains, low 
glycemia and increased insulin sensitivity have been observed (12); (13). 
In this study we present data supporting the hypothesis that Memo is a novel downstream regulator of 
the FGFR pathway. The FGFR is constitutively bound to FRS2, an adaptor protein that is 
phosphorylated upon ligand activation of the receptor (14). FRS2 forms complexes with GRB2/SOS as 
well as GAB1, leading to activation of the ERK and PI3K pathways. The enzyme PLCγ is also 
recruited to FGFR where it is activated by phosphorylation. We show that Memo binds to the FGF-
activated complex of FGFR-pFRS2-GRB2/GAB1. Moreover, loss of Memo in mouse embryonic 
fibroblasts (MEFs) has a negative effect on FGFR signaling since strength and duration of FRS2 
phosphorylation is decreased, and strength and duration of PLCγ, AKT, ribosomal protein S6 kinase, 
and ERK activity is reduced. Taken together, our data suggest that similar to Klotho or FGF23 
mutation, deletion of Memo leads to premature aging due to attenuation of FGFR signaling. 
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Material and Methods 
Reagents and antibodies 
FGF2 was from Sigma-Aldrich (St. Louis, MO, USA). The following antibodies were used: Pser 473-
AKT (9271), AKT (9272), Ptyr 196-FRS2 (3864), Ptyr 436-FRS2 (3861), Pthr 202 /tyr 204 -ERK1/2 
(9101), ERK1/2 (9102),  GAB1 (3232), Pser 240 /ser 244-S6 ribosomal protein (2215), all from Cell 
Signaling (Danvers, MA, USA); FRS2 (sc-8318), SHP2/SH-PTP2(c-18) (sc-280), HA-probe (sc-7392 
and sc-805) from Santa-cruz Biotechnology Inc. (Santa Cruz, CA, USA); actin (MAB1501) and 
Ptyr783-PLCγ (07-509) from Millipore (Billerica, MA, USA);  GRB2 (G16720) from Transduction 
Laboratories (BD Biosciences, Mississauga, ON, CDN); Polyclonal antibodies to a 19 amino acid 
Memo peptide were produced in rabbits (aa 25-43 human Memo NAQLEGWLSQVQSTKRPAR) and 
monoclonal antibodies to a 18 amino acid Memo peptide were produced in mice (aa 279-294 human 
Memo RNWQDSSVSYAAGALTVH). Both antisera recognize human and mouse Memo. 
Cell Culture and generation of conditional Memo KO MEFs 
Mouse embryonic fibroblasts (MEFs) were generated by standard procedures from Memofl/fl embryos 
and were spontaneously immortalized by passaging in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% Fetal Calf Serum (GIBCO Invitrogen AG, Basel, Switzerland) and Penicillin 
and Streptomycin (growth medium).   To obtain inducible Memo knock-out MEFs, cultures were 
infected with a pMSCV-CreERT2-puror retrovirus expressing a tamoxifen inducible Cre recombinase. 
Virus was produced as follows: Ecophoenix cells were transfected with pMSCV-CreERT2-puror 
plasmid together with lipofectamin 2000 (Invitrogen). After 3.5 days at 37°C the supernatant was 
collected, filtered through 0.45 mu filters and 5 ug/ml polybrene was added; 5 ml was used to infect 
one 10 cm dish of MEFs. After 6 hours of incubation at 37°C the supernatant was removed and fresh 
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DMEM-10% FBS was added. After 48 hours, selection with puromycin ((P7255) Sigma-Aldrich (St. 
Louis, MO, USA)) -containing medium was started. Knock-out of Memo was achieved by incubation 
of the MEFs in 0.5 µg/ml 4-hydroxytamoxifen ((T5648) Sigma) in DMEM-10% FBS for 3 days. 
Control cells were incubated in DMEM-10% FBS plus ETOH. 
67NR mammary tumor cells (15) were engineered to express Myc-tagged FGFR1. Transfection was 
performed with 8 µg of pMIRB control vector or Myc-FGFR-pMIRB in 800 µl of Optimem using 16 
µl of lipofectamine. One day after transfection, selection was started by addition of 1 mg/ml G418 
(11811031 from Invitrogen, Carlsbad, CA, USA) to the medium.  
Lysates, western blot analyses and immunoprecipitations 
Over-night serum-starved MEF cultures (DMEM-0.1% BSA (Sigma)) were stimulated with 50 ng/ml 
FGF2 for the indicated time. Whole cell lysates for western blot analyses were prepared in NP-40 
buffer (50mM Hepes (pH 7.4), 150mM NaCl, 25mM beta-glycerophosphate, 25mM NaF, 5mM EGTA, 
1mM EDTA, 15mM PPI and 1% NP-40) supplemented with leupeptin (10 ug/ml), aprotinin (10 ug/ml), 
vanadate (2mM), DTT (1mM) and PMSF (1mM). The lysates were boiled in sample buffer, separated 
by SDS-PAGE, blotted onto polyvinylidene difluoride membranes (Millipore Corporation) and probed 
with the specific antibodies. Whole cell lysates for co-immunoprecipitations (Co-IP) were prepared in 2 
times concentrated Co-IP buffer (50mM Tris (pH 7.5), 5mM EGTA, 150mM NaCl, 25mM beta-
glycerophosphat, 25mM NaF) supplemented with 10% Triton X-100, 10% Glycerol, vanadate (2mM), 
PMSF (1mM), aprotinin (10 ug/ml), leupeptin (10 ug/ml) and MgCl2 (10mM). The IPs were collected 
with protein-A or G sepharose beads (Sigma) and centrifuged. The pellets were washed three times 
with 10% Triton X-100 in PBS. Proteins were released by boiling in sample buffer SDS-PAGE and 
immunoblotting was preformed as described for whole cell lysates. 
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Generation of the conditional Memo KO and the pCX-CreERTM / Memofl/fl mouse strains 
Animal experiments were done according to the Swiss guidelines governing animal experimentation 
and approved by the Swiss veterinary authorities. Conditional Memo knock-out (Memofl/fl) mice were 
generated by gene targeting. Briefly, a targeting vector containing a 5’ homology arm, two loxP 
recombination sites flanking exon 2, an FRT-flanked Pgk-Neomycin resistance cassette, and a 3’ 
homology arm was constructed. The targeting vector was introduced in Sv129/Ola embryonic stem 
(ES) cells by electroporation. ES clones that had undergone homologous recombination were 
confirmed by PCR and Southern blot analysis; positive ES clones were used for aggregation, chimera 
production, and were analyzed for germline transmission. The positive mice were crossed with a FLP 
deleter transgenic mouse, to remove the neomycin-resistance cassette. These mice referred to as 
Memofl/fl mice were crossed with pCX-CreERTM transgenics (16), in which expression of the 
tamoxifen-inducible Cre is driven by the ubiquitous actin promoter, in order to generate heterozygous 
pCX-CreERTM /Memofl/+ offspring that were mated to generate pCX-CreERTM / Memofl/fl mice. 
Constitutive Memo loss was induced by intraperitoneal (IP) injection of 0.5 – 1 mg of Tamoxifen 
(Sigma) in corn oil (Sigma) over 4 or 5 consecutive days. The age of the mice at the time of injection 
varied between 2 to 14 weeks. As controls, Memofl/fl matched littermates that were negative for the Cre 
recombinase transgene were treated with tamoxifen. The health status of the tamoxifen- injected mice 
was evaluated by weighing.   
Analysis of the Memo null mice 
Glucose- and Insulin Tolerance Tests: 14 week-old pCX-CreERTM / Memofl/fl males were treated with 
tamoxifen to induce ubiquitous Memo loss. Glucose- (GTTs) (control n=5; KO n=5) and Insulin 
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tolerance tests (ITTs) (control n=2; KO n=3) were performed 6 weeks and 21 weeks, respectively, after 
tamoxifen injection. For GTTs, glucose (2 g/kg of body weight) (D-(+)-glucose anhydrous; Fluka) was 
given orally via gauge needle; for ITTs, insulin (1 U/kg) (human recombinant insulin; Sigma) was 
administered by intraperitoneal injection. Blood samples were collected at the indicated times from tail 
veins, and glucose levels were determined using a Glucometer (Free Style mini form ABBOTT). 
Measurements of blood insulin levels: Memo null and control mice were fasted over-night. Blood was 
collected and serum was prepared. Measurements for insulin were performed at ICS in Strasbourg, 
France. 
RNA extraction, qPCR and isolation of specific nephron segments 
Pieces of kidney or liver were snap frozen and RNA extraction was performed with TRIzol reagent 
(Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s protocol. RNA was washed using 
the RNeasy Mini Kit (Qiagen) and treated with RNase-free DNase (Qiagen). cDNA was obtained from 
1 µg of total RNA using the Ready-to-go You-Prime First-Strand Beads kit (GE-healthcare, Little 
Chalfont, UK) with oligos-dT primers (Promega). Fold-changes are expressed as expression values of 
Memo null mice divided by expression values of control littermates. Standard deviation was calculated 
by using the following formula: 
STDFold-change = ((STDMemo-null/Fold changeMemo-null)^2 + (STDControl/Fold changeControl)^2)^0.5 * Fold change  
Isolation of nephron segments was performed as follows. After anesthesia (sodium pentobarbital, 5 
mg/100 g mouse body weight) the left kidney was perfused with microdissection medium containing 
0.24% collagenase (Type A, Boehringer Mannheim). The microdissection medium was prepared from 
Hanks sterile solution containing 1 g/liter glucose supplemented with 1mM lactic acid, 1mM 
glutamine, 1mM sodium pyruvate, 0.5mM MgCl2, 1mM CH3COONa, 0.1% protease-free serum 
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albumin, 20mM Hepes and was adjusted to pH 7.4. Thin pyramids were cut from the kidney and 
incubated 25 min at 30°C (60 min at 37°C for the inner medulla) in 0.15% collagenase solution and 
then thoroughly rinsed in microdissection solution. Glomeruli and different nephron segments were 
microdissected at 4°C according to anatomical and morphological criteria (17). Dissected tubules were 
analysed by western blot analysis for Memo levels. Alternatively, RNA was extracted and analysed by 
qPCR. 
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Results 
Memo ablation leads to premature aging. 
Memo is a 33 kDa protein that is expressed in all organs from adult mice (Figure 1A and 1B). To gain 
insight into the physiological role of Memo, a conditional strain with exon two of the Memo gene 
flanked by loxP sites (Memofl/fl) was generated. In order to temporally control the onset of Cre 
recombinase activity, a strain harboring the pCX-CreERTM transgene was used (16). The transgene is 
under the control of the ubiquitously expressed CAGGS promoter consisting of the CMV early 
enhancer and the chicken beta-actin promoter. Cre activity is induced by tamoxifen, which results in 
Memo deletion in all organs; these animals will be referred to as Memo null mice. Memofl/fl mice that 
are negative for the Cre recombinase were control-treated with tamoxifen and are referred to as control 
mice. Tamoxifen treatment had no detectable effect on the these mice.  
To test for Cre functionality, 12 week old male mice were treated on 5 consecutive days with 
tamoxifen; eight weeks later lysates were prepared from various organs and a western analysis was 
performed for Memo. There was a strong decrease in Memo levels in each of the examined organs. In 
the liver, duodenum and kidney there is little or no detectable Memo; while in the testis and spleen 
there is still some protein detectable (Figure 1C).  
Next, Memo loss was induced at different ages between 2 and 14 weeks and the phenotypic 
consequences on the mice were monitored. Remarkably, we observed that the Memo null animals 
exhibited a small stature and showed multiple signs of premature aging (Figure 2A), including hair 
graying, alopecia, kyphosis (Figure 2A), hypogonadism, weight loss (data not shown), loss of the 
subcutaneous adipose layer (Figure 2B top), and loss of spermatozoa in the epididymis (Figure 2B 
bottom). The earlier Memo loss was induced by tamoxifen injection the more rapid the onset of these 
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phenotypes and the shorter the time of survival (Figure 2C).  In summary, Memo loss has a dramatic 
effect on the overall physiology of the mice. 
 
Memo null mice have altered insulin and glucose sensitivity 
Prompted by the observation that many mouse models of premature aging show altered insulin 
sensitivity (18-20), we measured blood glucose and insulin levels in Memo null mice. The mice had 
normal fasting blood glucose levels, but showed a tendency to lower blood insulin levels than control 
littermates (Supplemental Figure 1), suggesting that Memo loss increased insulin sensitivity. Next, we 
performed glucose (GTT) and insulin (ITT) tolerance tests and observed that in the Memo null mice 
there was an increased capacity for glucose disposal (Figure 2D top) and an increased hypoglycemic 
response to exogenous insulin (Figure 2D bottom), which is consistent with increased insulin 
sensitivity in these animals. In Figure 2D one representative experiment of the three that were 
performed is shown. 
 
Investigation of Memo expression and key proteins of the FGF23-Klotho axis in the kidney 
Based on the observation that aging-like phenotypes associated with increased insulin sensitivity were 
also observed in Klotho and FGF23 mutant strains, we hypothesized that Memo might function as a 
regulator of the FGF23-Klotho signaling pathway in the kidney. First, we examined Memo RNA and 
protein levels in different nephron segments that were separated by microdissection.  Quantitative PCR 
(qPCR) carried out on RNA from dissected nephrons showed that Memo is highly expressed in the 
thick ascending limb (TAL) and to a lesser extent in other nephron segments including the connecting 
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tubule (CNT) and distal convoluted tubules (DCT) (Figure 3A), the location of Klotho expression (21).  
The western analysis showed that Memo protein is present in all the segments, except for the cortical 
collecting duct (CCD) and the Glomerulus (Glom) (Figure 3B). Thus, Memo is widely expressed 
throughout the nephron and overlaps with Klotho. The inducible system is efficient since Memo was 
not detected in kidney lysates prepared from tamoxifen treated Memofl/fl /pCX-CreERTM mice (Figure 
3C). Finally, we examined whether Memo loss had an impact on FGFR1 or Klotho levels in kidneys by 
performing qPCR; there were no significant differences in control compared to Memo null mice for 
FGFR1 levels, while some litters showed a slight downregulation for Klotho (Supplementary Table 1).  
In the next set of experiments, we determined whether loss of Memo perturbed expression of genes 
known to be regulated by FGF23-Klotho signaling. For this, we examined 1α-hydroxylase, which is 
encoded by Cyp27B1, and synthesizes the active form of vitamin D (1,25-dihydroxyvitamin D3) from 
its inactive precursor (22); as well as 24-hydroxylase, which is encoded by Cyp24A1, and catabolises 
active vitamin D and 25-dihydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 (23).  FGF23-Klotho 
signaling inhibits transcription of Cyp27B1, and upregulates transcription of Cyp24A1.  Klotho mutant 
mice show increased levels of Cyp27B1 and Cyp24A1 RNA (24). We also examined the type-IIa and -
IIc sodium-phosphate cotransporters (Na-Pi2a/Na-Pi2c), which mediate phosphate reabsorption in the 
kidney and are also controlled by FGF23. Klotho mutant mice have lower levels of Na-Pi mRNA (25). 
QPCR was carried out on RNA isolated from kidneys collected from four litters of control and Memo 
null mice and the levels of Cyp27B1, Cyp24A1 and the Na-Pi2a/2c transcripts were investigated.  Na-
Pi2a/2c levels are downregulated 1.5 to 3.7 times in Memo null mice in the four litters (Table 1), a 
phenotype that is comparable to that described in Klotho mutant mice. Moreover Memo null mice all 
showed abnormal expression of Cyp27B1 and Cyp24A1, however, individual litters showed either up 
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(1.5 to 9.3) or down-regulation (1.6 to 2.4) of these transcripts (Table 1).   
In summary, the results suggest that Memo deficiency affects activity of the FGF23-Klotho-FGFR1 
pathway in the kidney. Since the phenotype observed in Memo null mice shares many similarities with 
Klotho and FGF23 mutant mice, in particular postprandial low glycemia and increased insulin 
sensitivity, we consider it likely that aberrant FGFR signaling in Memo null kidneys contributes to the 
observed premature aging syndrome.    
 
Memo regulates FGFR signaling 
Based on our previous publication showing that Memo is required for optimal FGFR-mediated 
migration in T47D breast cancer cells (1) and the results presented above, we propose that Memo is a 
novel regulator of FGFR signaling. In order to examine the role of Memo in FGF-induced signaling 
more closely, we developed a model of immortalized mouse embryonic fibroblasts (MEFs) from 
Memofl/fl embryos. These were infected with a retrovirus harboring an inducible Cre recombinase 
(pMSCV-CreERT2), allowing us to tightly regulate Memo deletion. Following 3 days of 4-
hydroxytamoxifen treatment there was essentially no Memo protein detectable in lysates from these 
cells compared to matched control Memofl/fl MEFs that were treated with ethanol (referred to as Memo 
KO MEFs and WT MEFs, respectively) (Supplemental Figure 2A). 
QPCR was used to determine FGFR expression in the MEFs, revealing that FGFR2 and FGFR4 are 
more highly expressed than FGFR1 and FGFR3 and that the Memo KO MEFs have similar levels 
(Supplemental Figure 3). To measure total FGFR activity, phosphorylation of FRS2, the adaptor protein 
that links the receptors to intracellular signaling pathways, was used as a read-out. FRS2 is 
constitutively associated with FGFRs and becomes heavily phosphorylated on Tyr and Thr residues 
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following ligand binding to the receptor (14). WT and Memo KO MEFs were stimulated with FGF2, 
which activates all FGFRs, for various times, lysates were prepared and a western analysis was carried 
out using site-specific phospho-FRS2 antibodies recognizing Tyr436 and Tyr196 residues. Both 
residues were rapidly phosphorylated following FGF2 treatment. However, the overall level of 
phosphorylation on both Tyr residues was significantly reduced and the duration of phosphorylation on 
both sites was shorter in Memo KO MEFs compared to WT MEFs (Figure 4A upper and lower panels). 
FRS2 protein levels are equivalent in WT and Memo KO MEFs (Figure 4A and Supplemental Figure 
2A). These results suggest that Memo is needed for optimal stimulation of FGFR signaling.  
The activity of the downstream PLCγ, ERK and PI3K/AKT/S6K pathways was also measured using 
phospho-specific antibodies. In comparison to the WT MEFs, there was a consistent decrease in pERK 
1/2 levels in Memo KO MEFs (Figure 4B).  ERK phosphorylates FRS2 on multiple Thr residues (26), 
which is reflected in a mobility shift in the protein. The upward-shift in FRS2 mobility is not as 
pronounced in Memo KO MEFs compared to WT MEFs, which is particularly evident in the lower 
panel of Figure 4A, providing additional evidence for impaired ERK activation in the Memo KO 
MEFs. The levels of PLCγ phosphorylation on Tyr783, AKT phosphorylation on Ser473 and ribosomal 
S6 phosphorylation on Ser240/244 were also lower in Memo KO MEFs compared to WT cells (Figure 
4C). Taken together, the results suggest that in the absence of Memo, FGFR signaling is dampened as 
evidenced by decreased phosphorylation on FRS2 and decreased activation of PLCγ, ERK and 
PI3K/AKT signaling. 
 
Memo associates with FGFR-activated signaling proteins 
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Memo loss does not lead to a complete block in FGFR signaling, but lowers the overall level of 
activation and downstream signaling. To provide mechanistic insight into these results, we first asked 
whether Memo is associated with FGFR-activated complexes. Since the MEFs express the 4 FGFRs, 
but at low levels, we used 67NR mammary cancer cells, which were engineered to overexpress a Myc-
tagged FGFR1 to probe for FGFR-Memo complexes. FGFR was detected in Memo IPs from lysates of 
67NR Myc-FGFR1 transfected cells; no receptor was complexed with Memo in IPs from 67NR control 
lysates (Figure 5A). The Memo-FGFR complex is constitutive since the level of receptor was the same 
in IPs from lysates of unstimulated and FGF-stimulated cultures (Figure 5A). Since 67NR tumor cells 
show constitutive activation of FGFRs and addition of FGF has minimal effects on downstream 
signaling (27), to examine the effects of FGF on signaling complexes, the remaining experiments were 
carried out with the MEFs.  
Memo was detected in IPs of FRS2 made with lysates of WT MEFs, both from control and FGF 
stimulated cultures (Figure 5B), suggesting that it is constitutively complexed with the adaptor protein. 
No Memo was detected in FRS2 IPs made with lysates from Memo KO MEFs (Figure 5B) or in IPs 
made with a non-specific antibody (Supplemental Figure 2B). Moreover, in lysates from WT MEFs, 
Memo was detected in GAB1 IPs and in GRB2 IPs, and there was an increase in Memo in IPs from 
lysates of FGF-treated cultures (Figure 5C upper and lower panels, resp). Taken together the results 
suggest that Memo constitutively associates with FGFR and FRS2 and can be found in complexes with 
other FRS2 associated proteins after ligand addition.  
Finally, we examined whether Memo influences ligand-activated FGFR-complex formation. FRS2 IPs 
from lysates of control and FGF-stimulated WT and Memo KO MEFs were probed for complexed 
SHP2, GAB1 and GRB2 (Figure 5E).  In lysates from FGF-treated WT MEFs, there was a strong 
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increase in the level of FRS2-complexed SHP2 and GRB2; GAB1 was detected in complexes from 
unstimulated cells and was moderately increased after FGF treatment (Figure 5D). Importantly, FRS2 
IPs from lysates of FGF-treated Memo KO MEFs, had slightly less complexed SHP2 and GRB2; 
GAB1 levels were not altered (Figure 5D).  As shown in Figure 4A, the levels of FRS2 P-Tyr436 and 
P-Tyr196, sites that recruit SHP2 and GRB2, respectively were significantly reduced in Memo KO 
MEFs compared to WT MEFs.  Thus, the decreased FRS2 binding of SHP2 and GRB2 likely reflects 
the alterations in FRS2 Ptyr levels in the Memo KO MEFs (Figure 4A). Taken together, the results 
show that Memo is constitutively associated with FRS2 and upon ligand stimulation shows increased 
association with the FRS2-recruited SHP2 and GRB2 (Figure 5E).  
Discussion 
Memo has an established role in ErbB2 receptor induced motility, controlling microtubules and 
adhesion site formation, as well as cell directionality (1, 2, 28). To gain insight into the physiological 
role of Memo, we generated tamoxifen inducible Memofl/fl / pCX-CreERTM mice. Surprisingly, Memo 
deletion led to a premature aging phenotype and to alterations in insulin and glucose metabolism. We 
show that Memo binds to the complex of FGFR-FRS2-GRB2/GAB1 and regulates the strength and 
duration of FGFR signaling. Based on the in vivo characteristics of the Memo null animals, and the 
data generated using cellular models, our results suggest that Memo deletion causes premature aging 
due to a role for Memo in maintaining physiological FGFR signaling in the kidney. We propose that 
Memo is a novel regulator of FGFR signaling.  
There are multiple mouse models of premature aging. However, after determining that Memo null mice 
were postprandial hypoglycemic and showed increased insulin sensitivity, we focused on the kidney 
since FGFR signaling has an essential role in regulation of vitamin D and phosphate homeostasis in this 
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organ. FGF23 and Klotho mutant mice show characteristic alterations in this pathway.  Klotho mutants 
have elevated levels of Cyp27B1 and Cyp24A1 (24). Memo null mice also show abnormal expression 
profiles of Cyp27B1 and Cyp24A1, however, there was not a consistent up- or down-regulation. In the 
normal kidney, the vitamin D/ Vitamin D receptor (VDR) complex feeds-back to control Cyp27B1 and 
Cyp24A1 expression (29). In Klotho mutant kidneys VDR is down-regulated, which has been proposed 
to contribute to alterations in feedback loop control and altered expression of these enzymes (24). In 
contrast to Klotho mutants, there was no reduction in VDR levels in the kidneys of Memo null mice 
(data not shown), which could explain why Klotho mutants show consistent up-regulation of Cyp27B1 
and Cyp24A1 and Memo null mice show inconsistent alterations.  
FGF23 also regulates the Na-Pi2a and Na-Pi2c cotransporters that mediate phosphate reabsorption. We 
found that the RNA levels of both were downregulated in Memo null kidneys, a phenotype that has also 
been observed in Klotho mutant mice (25). Since it has been shown that alterations in serum phosphate 
levels lead to increased Glucose-6-Phosphatase (G6Pase) RNA and activity in the liver (30), we 
examined RNA from Memo null livers for the level of the catalytic subunit of this enzyme (G6Pc1). 
Phosphoenolpyruvat-Carboxykinase (PEPCK), another regulator of glucose homeostasis was also 
examined in liver RNA.  Both G6Pc1 and PEPCK levels were increased in Memo null livers compared 
to control, 1.5 to 3.6 times and 2 to 2.9 times, respectively (Table 2). In summary the specific metabolic 
phenotype of the Memo null mice, postprandial hypoglycemia and increased insulin sensitivity, that 
they share with the Klotho and FGF23 mutant animals is a strong indicator that these three proteins are 
in the same pathway.  
We used in vitro cellular models to gain insight into Memo’s role in regulation of FGFR signaling. 
Upon FGFR activation the constitutively bound adaptor protein FRS2 is phosphorylated and forms 
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complexes with SHP2, GRB2/SOS as well as GAB1, leading to activation of ERK and PI3K pathways 
(Figure 5E). In the 67NR mammary cells we found association of Memo with Myc-tagged FGFR and 
in the MEFs, Memo was detected in complexes with FRS2 and other associated signaling partners. 
Indeed, our results suggest that Memo, like FRS2, is constitutively associated with FGFR. Whether this 
association is via a direct interaction with FRS2, remains to be explored. Although FGF-induced 
complexes form in the Memo KO MEFs, ligand-induced activation of the ERK and the 
PI3K/AKT/S6K pathways is dampened in both strength and in duration. Moreover, FRS2 and PLCγ, 
the latter recruited directly to the active FGFR, both showed decreased Tyr-P levels. Lower FRS2 Tyr-P 
might in turn contribute to the decreased signaling activity of the ERK and the AKT/S6K pathways 
observed in the Memo KO MEFs.  
A number of proteins modulate FGFR signaling including CBL, Sprouty and SEF. While screening for 
their expression, we found that SEF is more highly expressed in Memo null kidneys and in Memo KO 
MEFs compared to controls (Table 2). SEF is a transmembrane protein that has been shown to inhibit 
FGFR and FRS2 phosphorylation, as well as ERK activation (31). Elevated levels of SEF might 
contribute to lower FGFR signaling activity in Memo’s absence, something that will be explored in the 
future. FGFR localization to specific compartments of the membrane has been shown to affect 
signaling (32). Following ErbB receptor activation Memo associates with the RhoA-GTP/ mDia 
complex to control actin dynamics (28). Thus, it is possible that Memo is required to localize FGFRs to 
specific compartments of the membrane to ensure proper signaling.  
Since Cre recombinase expression is under the control of an actin promoter, Memo is lost in many 
organs following tamoxifen addition to the Memofl/fl/pCX-CreERTM mice. Thus, there might be 
multiple physiological effects contributing to the premature aging phenotype, something that we have 
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not addressed in this study. However, it is worth mentioning that phenotypes reflecting alterations in 
other FGFRs were not observed in the Memo null mice. FGFR1 and FGFR2 mutant embryos die 
between E7.5-9.5 and E4.5-5.5, respectively (33-35). Memo null embryos die starting at E13.5 (R.M. 
unpublished), suggesting that Memo does not have an early role downstream of these receptors. FGFR3 
is not essential for embryogenesis, but in its absence adult mice show bone malformation (36, 37), a 
phenotype that was not observed in the Memo null mice. FGF15 signals via FGFR4/βklotho in the liver 
(7). FGFR4 and βklotho null strains both show elevated bile acid levels due to upregulation of Cyp7A1 
RNA (38, 39). There was no change in Cyp7A1 expression in Memo null livers (not shown). Thus, it is 
possible that Memo has a specific role in the kidney or that Memo loss in this organ has such a 
dramatic effect that other phenotypes do not have time to develop. This will be examined in the future 
once mice with a conditional kidney specific Memo mutation are available. In conclusion, Memo null 
mice share many features of Klotho and FGF23 mutant strains; the results we present support the 
hypothesis that Memo is a novel regulator of FGFR signaling.  
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Figure 1 Memo expression in mouse organs 
(A) Western blot analysis of Memo levels in lysates from the indicated organs of a control mouse.   
(B) Quantificaiton of Memo levels in in the western analysis of panel A, normalized to tubulin levels 
(ImageJ).  
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(C) 12 week old Memofl/fl mice that were pCX-CreERTM positive (+) or negative (-) were injected with 
tamoxifen and sacrificed 8 weeks later.  The indicated organs were analyzed by Western for their level 
of Memo protein. 
 
 
Figure 2 Premature aging and metabolic phenotype of the Memo null mice 
(A) Memo null mice. The mice were tamoxifen-injected at 2 (upper) and 6 (lower) weeks of age with 
tamoxifen and pictures were taken 6 and 18 weeks later, respectively.  
(B) Hematoxylin and Eosin (H&E) paraffin sections of skin (top) and epididymis (bottom). Memo null 
mice show loss of subcutaneous fat (arrowhead).  The epididymis of the control littermates contain 
spermatozoa (arrows) that are missing in the Memo null animal. 
(C) Mice at the indicated ages (x-axis: 2, 3, 4, 6, or 14 weeks) were injected with tamoxifen and 
monitored for signs of premature aging (n-number in each group). The experiment was terminated and 
the animals sacrificed according to the severity of the phenotype; the number of weeks of survival after 
tamoxifen injection is indicated on the y-axis. 
(D) Glucose Tolerance Tests (top) and Insulin Tolerance Tests (bottom) were performed with male mice 
that were treated with tamoxifen at 14 weeks of age. Mice were fasted overnight and sucrose was 
administered orally with a gauge needle for the GTTs; insulin was intraperitoneally injected for the 
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ITTs. Blood glucose levels were measured at the indicated times. See also Figure S1 
 
 
 
Figure 3 Expression of Memo in the kidney 
The kidney of a WT mouse was microdissected and RNA and protein were isolated from different 
segments of the nephron. (A) Memo RNA levels were determined by qPCR and normalized to GAPDH 
levels. (B) A western analysis for Memo protein was performed (upper panel) and quantified with 
ImageJ normalizing to actin levels (lower panel). Lysates from MEFs served as a positive control. 
PCT=Proximal Convoluted Tubule; PST= Proximal Straight Tubule; TAL=Thick Ascending Limb of 
Henle's loop; DCT/CNT=Distal Convoluted Tubule/Connecting Tubule; CCD=Cortical Collecting 
Duct; GLM=Glomerulus. 
C) Lysates from Memo null mice or control littermates were prepared 4 weeks after tamoxifen injection 
and a western analysis for Memo was performed.   
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Figure 4 Analysis of FGFR signaling in WT and Memo KO MEFs  
Cell lysates prepared from serum-starved control and Memo KO MEFs that were treated for the 
indicated times with FGF2 were analyzed by western for the indicated proteins and P-proteins. (A) 
FRS2; upper panel pFRS2 (Tyr436); lower panel pFRS2 (Tyr196); * non-specific band that is not 
visible on the lower panel due to different running times. (B) ERK 1/2 and pERK1/2.  (C) 
pPLCγ (Tyr783); pAKT (Ser473) and AKT; pS6 (Ser240/244) and Memo. The results are 
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representative of at least three experiments. See also Figure S2 and S3 
 
 
 
 
 
Figure 5 Identification of Memo containing complexes 
(A) Cell extracts were made from of 67NR cells, expressing Myc-tagged FGFR1 or a control vector 
treated for 6 minutes with FGF2 (+) or not treated (-), then subjected to immunoprecipitation with a 
Memo antiserum. A western analysis was performed with Myc serum to detect complexed Myc-tagged 
FGFR1 and, as a control, Memo. A western performed with whole cell extracts (WCE) is shown in the 
left panel. s= short exposure, l= long exposure.  
(B-D) Cell lysates were prepared from WT and Memo KO MEFs treated for 6 minutes with FGF2 (+) 
or not treated (-). (B) Lysates were subjected to immunoprecipitation with an FRS2 antiserum and 
probed for complexed Memo, and probed with FRS2, as a control. (C) Lysates were subjected to 
immunoprecipitation with a GAB1 (upper panel) or a GRB2 antiserum (lower panel) and probed for 
complexed Memo, and probed with GAB1 or GRB2 as controls. (D) Lysates were to 
immunoprecipitation with an FRS2 antiserum and probed for SHP2, GAB1 and GRB2, and probed 
with FRS2, as a control. 
(E) Scheme of FGF-induced signaling. Upon ligand binding, FGFR and the FRS2 adaptor protein are 
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phosphorylated on multiple Tyr residues. PLCγ1 is recruited to the active FGFR. SHP2 and GRB2 are 
recruited to FRS2 P-Tyr436 and P-Tyr196 residues, respectively, which promotes activation of the ERK 
and AKT signaling pathways. Memo was found constitutively associated with FRS2 (Panel B).  See 
also Figure S2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
100 
 
 
 
 
  
Results 
101 
 
 
Results 
102 
 
 
 
Results 
103 
 
 
Results 
104 
 
 
Results 
105 
 
7.2 Analysis of Memo in development 
7.2.1 Analysis of Memo conventional knock-out animals (Memo KO) (R. Masson and P. Kaeser) 
The main work of this analysis was done by Régis Masson. He did the planning of the experiment and 
he had the main responsibility. I helped in plugging the animals and isolating the embryos, taking 
pictures and genotyping them.  
A Memo conventional knockout mouse strain was generated to investigate the function of Memo 
throughout development. Heterozygous knockout animals were viable and fertile, however, following 
interbreeding no homozygous Memo knockout animals were born. Thus, Memo knockout is embryonic 
lethal, demonstrating that Memo has an essential but undefined function in mouse embryonic 
development.  
To gain insight into the stage and possible etiology of embryonic lethality, the genotype of embryos 
derived from heterozygous intercrossing was investigated at various days post coitum. Viable KO 
embryos on a mixed background were found until E13.5 but showed abdominal bleeding from E11.5. 
In addition, blood vessels of the yolk sac and placenta were less perfused with blood in the KO animals 
(unpublished data of Régis Masson and Patrick Kaeser) (Figure 7-1). While more recent data shows 
that at least some Memo KO embryos on a C57Bl/6 background are viable up to day E17.5 
(unpublished data of Shunya Kondo), experiments detailed in my thesis were performed with mice on a 
mixed background. 
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Figure 7-1 Control and Memo KO embryos at E11.5 
The gross phenotype of resultant embryos from heterozygous Memo KO interbreeding was investigated. Homozygous 
embryo in the yolk sac (upper) and the separated placenta (lower) are depicted, WT (left) and Memo KO (right). Note 
poorly perfused yolk sac and placental vasculature and pale appearance of KO embryo. 
 
7.2.2 Analysis of Memo conditional knock-out (Memo cKO) mice crossed to Meox2Cre 
transgene mice (J. Zmajkovic) 
This work was performed by Jakub Zmajkovic under my supervision throughout the study. I taught him 
how to handle, breed, label and genotype mice. We developed the breeding strategy together and I 
worked with him throughout his work with mice. 
The observed differences in gross vascular appearance in the Memo KO placenta, suggested a role for 
Memo in placental function. To investigate if this was the origin of the defect in blood supply to the 
embryo, we tested if expression of Memo in the placenta would rescue the embryonic lethality of 
Memo KO embryos.  Memo conditional knockout animals (Memo cKO) were crossed to Meox2Cre 
mice, which express Cre recombinase under the control of the mesenchyme homeobox 2 promoter. The 
promoter activates Cre recombinase specifically in the embryo and in extra-embryonic mesoderm 
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derivatives, including the chorionic plate and yolk sac mesoderm, starting at day E5.0 (394), all other 
regions of the placenta are Cre recombinase negative. Thus in Memo cKO Meox2Cre animals Memo is 
expressed in the placenta of the embryos, while the embryo does not express the protein.  Genotyping 
the offspring of Memo cKO Meox2Cre interbreeding showed that no Memo cKO Cre positive animals 
were born, indicating that expression of Memo in the placenta does not rescue the embryonic lethality 
caused by loss of Memo (unpublished data of Jakub Zmajkovic). Further analysis is needed to 
investigate if these embryos survive longer than the Memo KO embryos. 
7.2.3 Analysis of the Memo conditional knock-out (Memo cKO) strain crossed to the pCX-
CreERTM transgene mice  
Those experiments were done initially together with Régis Masson, but in my second year, I performed 
and planned all experiments myself. 
Next, we asked in which stage of embryonic development Memo function is essential, we designed a 
mouse model in which deletion of Memo could be temporally controlled. For these experiments the 
Memo conditional knock-out strain was crossed to a mouse strain harboring the pCX-CreERTM 
transgene (395). This transgene is under the control of the ubiquitously expressed CAGGS promoter, 
consisting of the CMV early enhancer and the chicken beta-actin promoter. Cre recombinase activity is 
induced in all cells following tamoxifen injections. To investigate if Memo expression up to E13.5 
rescued the observed embryonic lethality, Cre negative Memo cKO females were crossed to Cre 
positive Memo cKO males and resultant pregnant mice injected with tamoxifen for three consecutive 
days from E13.5. In treated mice, tamoxifen freely crossed the placenta resulting in loss of Memo in 
Cre positive embryos. When compared to non-injected mice, tamoxifen treatment resulted in a 
prolonged gestation of two days. Genotyping of newborn pups revealed that Memofl/fl (Memo cKO) 
and Memo null animals were born at the predicted mendelian rate. Nevertheless, the animals that were 
knock-out for Memo were pale at the time of birth and survived up to one month after birth. The cause 
of death is thus far unknown and awaits further investigation.    
7.3 Characterisation of the Memo cKO actin Cre ERTM Mice 
The tamoxifen inducible Memo knock-out strain allowed us to induce the deletion of Memo at any 
given developmental stage. To evaluate the consequence of Memo knock-out in later developmental 
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stages, Memo cKO Cre ERTM mice at various postnatal ages were treated with tamoxifen for 4 to 5 
consecutive days, resulting in knock-out of Memo in all organs (Memo null mice). To control for 
potential non-specific effects of tamoxifen in these studies, Memo cKO mice that did not express the 
Cre recombinase (control animals) were treated with tamoxifen. No effect of tamoxifen was observed 
in these mice. In contrast, following Memo deletion mice developed a severe premature aging 
phenotype, including well-known aging signs (see chapter 0) and an unusual metabolic phenotype. The 
time of appearance of the first signs of aging correlated with the age of mice at the time of Memo loss 
(see also chapter 7.1). 
 
Figure 7-2 Hindlimb reflex and organ weight of Memo null and control animals 
 
(A) Pictures of control and Memo null animals held by the tail. On the left the control animal shows a normal hindlimb 
reflex. On the right the Memo null animal shows an unusual hindlimb reflex. The mice shown on the left and right are 
littermates. 
(B) Organ weights (relative to bodyweight) of one control and two Memo null male animals are depicted. Strong reduction 
of WAT, seminal glands and testis can be found in the Memo null animals. In contrast, Memo null animals show increased 
weight of lungs and brains compared to control animals. This is one representative result of many. 
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The first signs of premature aging were defects in the hindlimb reflex (Figure 7-2A) and graying of the 
hair. Later in the course of the study, Memo null mice lost their hair and exhibited severe weight loss 
and progressively suffered from stiff joints, kyphosis and showed problems with their eyes (see chapter 
0). Post mortem weight analysis of different organs demonstrated smaller gonads and severe reduction 
of the white adipose tissue (WAT) in the Memo null animals compared to control animals, while the 
lungs and brains were heavier in the Memo null mice (Figure 7-2B). Histological analysis revealed that 
the skin showed a loss of subcutaneous fat and the epidydimis contained no spermatozoa (see Chapter 
0), both phenotypes characteristic of aging.  
It is known that mouse models that show reduced size of the gonads often display an associated defect 
in the function of mitochondria (personal communication with A. Trifunovic). Therefore, we 
investigated the mitochondrial shape, which is predictive for mitochondrial function. We isolated the 
hearts, an organ with high number of mitochondria, of control and Memo null animals and studied 
mitochondrial shape by electron microscopy. Organs were fixed, sectioned and investigated with a 
transmission electron microscopy. Figure 7-3 shows that there is no difference in size or shape of 
mitochondria in control and Memo null mice.  
 
Figure 7-3 Pictures of mitochondria in the heart of control and Memo null mice 
Representative pictures of mitochondria (from the heart) of control (left) and Memo null (right) mice. Scale bar, 500 nm. 
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Since we concentrated in the further experiments on the kidney we performed a Memo staining of the 
kidney in control and Memo null mice to ensure that there that Memo null mice are knock out for 
Memo in the kidney. Figure 7-4 (upper panels) shows that Memo is expressed in the kidney. 
Furthermore, it shows that Memo is more highly expressed in the cortex as compared to the medulla. In 
the right upper panel we observed that Memo is not highly expressed in the glomeruli as compared to 
the rest of the cortex. Some cells show a pronounced nuclear staining while other show a more uniform 
staining of the nucleus and cytoplasm. The lower panel of Figure 7-4 shows a good knock out of Memo 
in the kidney.   
 
Figure 7-4 Memo staining of the Kidney 
Staining of formalin fixed and paraffin embedded kidney sections of control (upper panels) and Memo null (lower panels) 
animals. Scale barleft panels 50µM, scale bareright panels 10µM 
 
To get an overview over the defects in the Memo null mice we performed microarray on livers and 
kidneys of Memo null and control cells. For the liver microarray 3 control and 3 Memo null animals 
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were included, for the kidney array 4 control and 3 Memo null animals. Organs were collected from the 
mice, snap frozen and RNA was isolated. Table 7-1 and Table 7-2 show list of genes that are up- or 
downregulated in the livers or kidneys, respectively, of Memo null mice as compared to control 
animals. Listed are genes that are changed at least two fold and have a p-value of at least 0.01.   
Table 7-1 List of Genes that are up- or downregulated in the livers of Memo null animals as compared to control 
animals 
Minimum of two fold change and p-value of 0.01. logFC = logarhythmic  fold change; AveExpr = average expression 
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Table 7-2 List of Genes that are up- or downregulated in the kidneys of Memo null animals as compared to control 
animals 
Minimum of two fold change and p-value of 0.01. logFC = logarhythmic  fold change; AveExpr = average expression 
 
It was not in the scope of this study to follow up on these microarrays and to validate any genes. 
However, we hope that this data will be useful to us and potentially to others in the future.  
Chapter 7.1 demonstrated that the transcriptional levels of enzymes of the FGF23-Klotho axis are 
affected on loss of Memo. For the Klotho mutant mice it has been shown that not only these enzymes, 
but also the level of the vitamin D receptor (VDR) were affected (299). Therefore, we investigated the 
levels of VDR in Memo null mice. Kidneys and livers were collected and snap frozen from Memo null 
mice and matched control littermates. RNA was prepared and analyzed by quantitative PCR for the 
level of VDR. Figure 7-5 shows that the level of the VDR is not significantly affected by the postnatal 
loss of Memo.  
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Figure 7-5 RNA levels of vitamin D receptor (VDR) 
The values are normalized to GAPDH 
 
To gain further insight into the observed phenotype, blood analysis was performed on Memo null and 
control male mice that were induced for Memo deletion at the age of 14 weeks. Blood analysis was 
performed 3 and 14 weeks following tamoxifen treatment weeks (Table 7-3). To investigate the general 
health of the mice and the function of major organs, we measured total protein level in the serum. In 
Memo null animals total protein levels were lower, an indication of possible liver or kidney disease. In 
case of liver or renal insufficiency elevated levels of bilirubin (liver disease) or potassium (kidney 
disease) would be expected, however the levels of bilirubin and potassium were slightly reduced in 
Memo null animals. The levels of creatine kinase were also tested, as an indicator of skeletal- and 
cardio-muscle damage. Memo null mice show decreased levels of creatine kinase, therefore no 
indication for muscle damage was observed. Increased iron levels were found, which could be 
indicative of blood haemolysis, however if this were the case a high bilirubin level would also be 
expected. As the Memo null mice show low bilirubin levels haemolysis can be excluded. To complete 
the blood analysis glucose, insulin, cholesterol, and triglyceride levels were tested. Levels for glucose 
and insulin were decreased and levels of cholesterol and triglycerides were increased in Memo null 
animals when compared to control animals. Interestingly, glucose levels were increased shortly after 
Memo loss (3 weeks) and subsequently (14 weeks after Memo loss) decreased, while the cholesterol 
levels were the inverse of this (Table 7-3). 
Table 7-3 Overall blood analysis of Memo null and control animals 
Blood analysis of Glucose, Potassium, Cholesterol, Triglycerides, Iron, Bilirubin, total protein and Creatine Kinase was 
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performed with mice that were induced for Memo loss at the age of 14 weeks. The first measurement of blood parameters 
was performed 3 weeks after Memo loss and the second 14 weeks thereafter. Creatine Kinase was measured only once, 3 
weeks after Memo loss. (ncontrol=4, nMemo null=3) 
 
We also performed blood analysis to specifically investigate renal function, comparable to how it has 
been done in the Klotho and FGF23 mutant mice. Blood was collected from Memo null and control 
animals. This experiment was first done in Dallas, Tx with mice that were induced for Memo loss at 
about 2.5 weeks of age and blood was collected 8 weeks later. There were 16 WT and 19 Memo null 
animals analyzed (Table 7-4). Another experiment was performed in Switzerland: loss of Memo was 
induced at the age of 11 days and blood was collected 20 days later. One WT animal and 5 Memo null 
animals were analyzed. These samples were measured by the University Hospital in Basel (Table 7-5).  
Table 7-4 Blood analysis of Memo null and control animals performed in Dallas (Memo loss at about 2.5 weeks, 
sampling 8 weeks later 
These measurements were performed in Dallas, TX. Therefore, the parameters were measured in mg/dl. The conversion of 
mg/dl to mmol/l is: mmol/l=(mg/dl)/~3 
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Table 7-5 Blood analysis of Memo null and control animals (Memo loss at 11 days, sampling 20 days later) 
 
 
In the Dallas analysis a 1.46+/-0.43 (p-value 0.003) fold increase in blood urea nitrogen (BUN) levels 
was observed in Memo null animals. BUN is an indicator for renal function and upregulated levels of 
BUN indicate renal insufficiency. In addition, we also found slight but significant upregulation of 
Calcium, with a fold increase of 1.11+/-0.1 (p-value 0.003).  There was no detectable difference in the 
serum phosphate levels. In the study performed in Switzerland we measured not only BUN, but also 
Creatinine, another indicator for renal function. In those mice we observed no change in the levels of 
both indicators 20 days after induction of Memo loss. Consistent with the Dallas data there was an 
increase in calcium levels in the KO animals, with a comparable fold increase of 1.16+/-0.1, while 
phosphate levels were not altered.   
In conclusion, blood analysis shows that Memo null mice suffer from renal insufficiency and from a 
slight hypercalcemia. Surprisingly, we did not find elevated serum phosphate levels. This is in contrast 
to the findings in Klotho and FGF23 mutant animals.  
In addition to the serum phosphate levels, we investigated the expression of the sodium phosphate 
cotransporters in the brush border membrane of the kidney. Na-Pi2a and Na-Pi2c are cotransporters 
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required to reabsorb phosphate from the urine. We isolated the brush border membrane, in which Na-
Pi2a is localized, and performed western blot analysis of Na-Pi2a expression (Figure 7-6). We found 
lower expression of the N-terminal fragment of Na-Pi2a (band at approximately 40kDa in panel A, 
qualified in B). This indicates that in the absence of Memo enzymatic cleavage of Na-Pi2a is reduced. 
In one out of 5 KO mice the expression of the full length Na-Pi2a is elevated (Figure 7-6). This is 
likely related to animal variability and currently we have not considered this in our analysis.  
 
Figure 7-6 Level of Na-Pi2a in the renal brush border membrane of WT and Memo null mice 
A) Brush border membrane vesicles were isolated from kidneys of WT and Memo null animals and western analysis was 
performed. The blot was probed with anti Na-Pi2a and actin antibodies. The band at 80-100 kDa in the Na-Pi2a blot 
represents full length Na-Pi2a and the band at 40 kDa represents the N-terminal fragment of Na-Pi2a. Inset: Whole kidney 
lysates were prepared from the same WT and Memo null animals and western analysis performed. The blot was probed with 
anti Memo and anti actin antibodies. B) Quantification of the western blot shown in (A). In blue is the upper (80-100 kDa) 
and in brown the lower (40 kDa) band of Na-Pi2a, both normalized to actin levels. 
 
 
In the future, mice will be housed in metabolic cages, to further investigate the renal phenotype. Using 
these cages we can collect urine samples over a period of 24 hours, allowing us to calculate creatinine 
excretion rates in order to estimate the volume of serum that is processed by the kidney per minute. 
This will give us a more detailed picture of kidney function in Memo null and control animals. 
7.4 Characterization of the inducible kidney-specific Memo knock-out mouse line 
Based on the hypothesis that the premature aging phenotype is caused by loss of Memo in the kidney 
and subsequent dampening of the FGF23-Klotho axis, we generated an inducible, kidney specific, 
Memo knock-out mouse line.  
We crossed the Memo floxed (Memofl/fl) mice with two mouse lines: one expressing the tetracycline-
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sensitive transactivator rtTA, under the control of the Pax8 promoter (the B6.Cg-Tg(Pax8 
rtTA2S*M2)1Koes/J mouse line) (396); and one harboring Cre recombinase under the control of a 
ubiquitous promoter containing a tetracycline-responsive promoter element (the LC-1 Cre mouse line) 
(397). Pax8 is only expressed in renal tubular epithelial cells, the same cells that express Klotho. Thus, 
upon doxycycline treatment the mice specifically lose Memo expression in these cells. Memo floxed 
animals not simultaneously expressing both the rtTA and the Cre recombinase were used as controls; 
administration of doxycycline had no detectable effect on these mice. 
Pups were exposed to doxycycline starting at E0.5. Only those pups positive for rtTA and Cre 
recombinase expression lost Memo expression in the kidney upon this treatment. Figure 7-7 shows 
whole kidney lysates from kidney-specific knock-out (KO) and control (WT) animals. Knock-out 
animals show no expression of Memo in the kidney.  
 
Figure 7-7 Western analysis of whole kidney lysates from kidney-specific knock-out and control animals 
  
All doxycycline treated animals were weighed regularly. Although the Memo knock-out animals had 
lower body weights as compared to the control animals (Figure 7-8), they did not display any  overt 
premature aging symptoms. 
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Figure 7-8 Body weight curve of male animals 
 
To investigate if the observed lower body weight was due to renal insufficiency, we made use of 
metabolic cages. Ten control and three knock-out mice were included in this study. All animals were 
given a three day acclimatization period in the metabolic cages, prior to the onset of sample collections. 
Measurements were performed over three consecutive days (24 hours each). We measured body 
weight, food and water intake and fecal and urinary output (Table 7-6). In general, the animals 
appeared to be in good health over the course of the experimental period, as indicated by the relatively 
static body weight measurements (WT: +0.25+/-0.35; KO: -0.16+/-0.45). Nevertheless, a tendency of 
the KO animals to lose some weight can be seen. In addition, the food intake of the KO animals was 
slightly less when compared to that of the control animals (KO/WT=0.84+/-0.1, p-value 0.03). 
However, as this difference is not significant, we do not believe that food intake alone could be 
responsible for the body weight differences observed. Furthermore, we measured slightly higher water 
intake (KO/WT=1.42+/-0.6) and larger urinary volumes (KO/WT=1.97+/-1.12) from the KO animals. 
Although the difference in water intake is not statistically significant (p-value 0.14), the larger urinary 
volume is (p-value 0.01). Therefore, KO animals have a higher urinary output as compared to the 
control animals. 
Table 7-6 Investigation of the metabolism of kidney-specific KO and control animals in metabolic cages 
Fold change = value (KO) / value (WT) 
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At the end of the experiment all animals were sacrificed and the blood, urine and kidneys were 
collected for analysis. Blood anaylsis was performed by the University hospital in Basel and urine 
analysis by the University hospital in Lausanne (CHUV). Blood analysis showed upregulation of BUN 
(1.6+/-0.6, p-value 0.004) and creatinine (1.8+/-0.8; p-value 0.07) in the KO animals (Table 7-7). In 
addition we examined the creatinine excretion rate, which gives an indication of proper kidney 
functioning as it represents how much serum is processed by the kidney per minute. KO mice showed a 
reduced clearance of creatinine (0.55+/-0.2; p-value 0.01).  
Table 7-7 Blood analysis of kidney-specific Memo knock-out and control animals 
Blood was collected and analyzed for the different parameters. Fold change = value (KO) / value (WT) 
 
Furthermore, we investigated phosphate and calcium levels in the serum and urine. In contrast to the 
Klotho and FGF23 mutant mice, but consistent with the Memo null mice, the kidney-specific Memo 
knock-out mice did not show altered phosphate levels (1.07+/-0.8) (Table 7-7). The slight increase in 
calcium levels in the kidney-specific Memo KO animals as compared to controls (1.11+/-0.05, p-value 
0.007) is also in agreement with the results obtained with the Memo null mice. The levels of sodium 
(Na) and albumin remained unchanged (1+/-0.03 and 1+/-0.07).  
In summary, these data show that knock-out of Memo in the kidney is enough to induce severe kidney 
insufficiency. We did not find elevated serum phosphate levels. This is surprising since this is believed 
to be the main cause for the aging phenotype in Klotho and FGF23 mutant animals. In line with the 
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data from the Memo null animals, we found slight hypercalcemia in the kidney-specific Memo KO 
animals.  
In addition to the serum levels of phosphate we also investigated the localization of Na-Pi2a in the 
brush border membrane (Figure 7-9). Comparable with the results obtained from the Memo null 
animals, we observed a decrease in the expression of the N-terminal fragment of Na-Pi2a (represented 
by the band around 40kDa) in two out of three kidney-specific Memo KO animals. This suggests that 
deletion of Memo in the kidney prevents enzymatic cleavage of Na-Pi2a. 
 
Figure 7-9 Level of Na-Pi2a in the renal brush border membrane of WT and kidney-specific KO mice 
A) Brush border membrane vesicles were isolated from kidneys of WT and KO animals and western analysis performed. 
The blot was probed with anti Na-Pi2a and actin antibodies. The band at 80kDa in the Na-Pi2a blot represents full length 
Na-Pi2a, while the bands between 25 and 40kDa represent N-terminal fragments of Na-Pi2a. Inset: Whole kidney lysates 
were prepared from the same WT and KO animals and western analysis performed. The blot was probed with anti Memo 
and anti actin antibodies. B) Quantification of the western blot shown in (A). The values are normalized to actin levels. 
 
Despite the lack of change in the serum phosphate levels, these data further suggested that a defect in 
phosphate reabsorption exists. We then analyzed the urine and blood samples collected from the 
animals that were housed in the metabolic cages and calculated the fractional excretion and excretion 
rates. Figure 7-10 shows that neither the fractional excretion (1.5+/-1, p-value 0.24) nor the excretion 
rate (0.91+/-0.28, p-value 0.63) of phosphate are different between KO and control animals. We do see 
slight differences in the fractional excretion rates of sodium (1.86+/-1.05, p-value 0.02) and potassium 
(1.45+/-0.58, p-value 0.04) which are approaching  significance, but more importantly, we observe a 
highly significant increase in both the fractional excretion and excretion rate of Calcium (7.37+/-6.16, 
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p-value 0.001 and 4+/-2.9 p-value 0.001, respectively). This indicates that the kidney-specific Memo 
KO mice are hypercalciuric. 
 
Figure 7-10 Fractional excretion and Excretion rate 
A) Fractional excretion in percentage. B) Excretion rate in µmol/24h 
Fractional excretion of x = (Ux*Ucr*100)/(Px*Ucr); U = concentration in urine, P = concentration in plasma, Cr = 
creatinine, if x= calcium, then Px=Pca/2 as only half of the calcium is free in the blood. 
Excretion rate of x = Ux/Volume of urine 
7.5 Characterization of the defect in calcium homeostasis in Memo null and 
kidney-specific Memo KO animals  
To further investigate calcium homeostasis we evaluated the mRNA levels of important calcium 
regulators in the kidney. QPCR was carried out on RNA isolated from kidneys. We investigated the 
levels of ‘plasma membrane resident transient receptor potential vanilloid 5’ (TRPV5), sodium calcium 
exchanger (NCX1), plasma membrane Ca2+ ATPase (PMCA) and calbindin (CB28) transcripts. QPCR 
analysis revealed that none of those targets are significantly altered in Memo null mice (Table 7-8). Thus 
far, we investigated only three KO animals and 10 control animals. By increasing the number of animals the 
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upregulation for TRPV5, NCX1 and CB28 might become significant, while TMCA is definitely not 
different in Memo null mice as compared to control animals. 
Table 7-8 mRNA levels of TRPV5, NCX1, PMCA and CB28 in Memo null and control mice  
Fold change = expression of KO / expression of control 
 
Analysis of RNA isolated from kidney-specific Memo KO animals revealed higher expression of 
TRPV5, NCX1 and CB28 (Table 7-9). NCX1 (1.96+/-0.97, p-value 0.02) and CB28 (2.24+/-1.07, p-
value 0.006) are approximately two fold increased while TRPV5 is three fold increased (3.42+/-2.02, p-
value 0.003). This indicates that alterations in expression of calcium regulators in the kidney induce the 
observed hypercalciuria in kidney-specific Memo KO animals.  
Table 7-9 mRNA levels TRPV5, NCX1, PMCA and CB28 in kidney-specific Memo KO and control cells 
Fold change = expression of KO / expression of control 
 
It has been reported that Klotho and FGF23 mutant mice have hypercalcemia and show ectopic 
calcification in the lungs (bronchi) and heart (255). Therefore, we investigated whether calcification of 
soft tissues was present in the Memo null mice. We treated paraffin sections of heart isolated from 
Memo null mice with von Kossa stain for calcium, and found restricted calcium deposition in the heart 
of Memo null mice (Figure 7-11). Although promising, this initial finding requires further 
investigation. 
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Figure 7-11 Von Kossa staining on the heart of Memo null mice 
Von Kossa staining has been performed on sections of the heart of Memo null mice. These are representative pictures of two 
different knock out males. Positive von Kossa staining is indicated by arrows. Scale bar 100 µm. 
Taking all the data into consideration, our results suggest that deletion of Memo, from the whole body 
or from the kidney alone, induces renal insufficiency and a defect in the cleavage of Na-Pi2a in the 
brush border membrane. Despite this, KO animals from both models exhibit normal serum phosphate 
levels. Surprisingly, we found slight but significant hypercalcemia and robust hypercalciuria in the 
kidney-specific KO animals as compared to the control animals. Supporting these data is the fact that 
we found upregulated levels of important calcium regulating proteins in the kidney of kidney-specific 
Memo KO animals. 
Thus far, we didn’t detect a major changed that occurred only in Memo null animals and not in kidney-
specific Memo KO mice and therefore, could be a possible inducer of the premature aging phenotype 
that we observe exclusively in Memo null mice. Next, we investigated the serum level of parathyroid 
hormone (PTH) and FGF23. We performed ELISA with serum collected from Memo KO mice and 
control animals. 
PTH ELISA: 
We measured serum of 9 Memo null and 6 control mice as well as of 6 kidney-specific Memo KO and 
12 control animals. This revealed a significant downregulation of PTH in Memo null mice (0.09+/-2.2, 
p-value 0.01) (Table 7-10 on the left). We detected a tendency but no significant decrease of PTH in 
kidney-specific Memo KO animals (0.13+/-0.35, p-value 0.29) as compared to control animals (Table 
7-10 on the right).  
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Table 7-10 Levels of PTH in Memo null (left) and kidney-specific Memo KO animals (right) compared to control 
mice 
Fold change = Level(KO)/Level(control) 
 
 
FGF23 ELISA: 
We measured serum of 11 Memo null and 4 control mice as well as of 6 kidney-specific Memo KO and 
12 control animals. There was no difference in Memo null (5.95+/-12.6, p-value 0.35) or in kidney-
specific Memo KO animals (2.71+/-6.6, p-value 0.18) as compared to control animals (Table 7-11 left 
respectively right).  
Table 7-11 Levels of FGF23 in Memo null (left) and kidney-specific Memo KO animals (right) compared to control 
mice 
Fold change = Level(KO)/Level(control) 
 
This data shows the first difference between the two Memo KO models; only Memo null animals show 
a significant decrease in PTH levels.  
7.6 Memo is a novel downstream effector of the FGFR pathway 
Our in vivo data indicated that Memo could have a function in the kidney downstream of the FGF23-
Klotho pathway. We were interested if there was also evidence for a role of Memo downstream of 
FGFR signaling in vitro. Thus, we investigated the role of Memo downstream of general FGF signaling 
in mouse embryonic fibroblasts (MEFs) and in the 67NR mouse mammary carcinoma cells (chapter 
7.1). We were also interested in the role of Memo downstream of FGFR signaling stimulated by 
endocrine FGFs. Klotho expression is spatially restricted and expression is required for cells to be 
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responsive to FGF23. Therefore, we investigated signaling stimulated by either FGF23 or FGF19 and 
21 in HEK293 cells, which were stably transfected with flag-Klotho (HEK293-kl) and flag-βKlotho 
(HEK293-βkl) respectively. 
7.6.1 Signaling in the HEK293-kl cells  
Work of chapter 5.4.1 to 5.4.4 was performed in the laboratory of Dr. Makoto Kuro-o at the University 
of Southwestern Medical School, Dallas, Texas. 
Memo was down regulated by siRNA in HEK293-kl cells that were starved overnight and stimulated 
with FGF23. Control transfection was performed with a scrambled siRNA. Lysates were prepared from 
cells that were stimulated with FGF23 for the indicated times and analyzed by western. As a readout for 
the FGF23-Klotho-FGFR1 pathway activity, phosphorylation levels of ERK1/2 and FRS2 were 
analyzed. As a control for transfection efficiency, levels of flag-Klotho were analysed with an anti Flag-
antibody.  Flag-Klotho expression was high and equal in control and Memo down regulated cells. As 
HEK293 cells expressed low levels of the FRS2 protein, the detection of its phosphorylation was 
challenging, nonetheless the signal detected with the anti-phospho FRS2 antibody suggested that there 
is less active FRS2 in Memo down regulated HEK293-kl cells stimulated with FGF23 compared to 
control transfected cells (Figure 7-12A). Because of the poor quality of the FRS2 western blots we 
concentrated on the activation levels of ERK, which is downstream of FRS2. Western blot analyzes 
showed that ERK is activated earlier in the Memo down regulated HEK293-kl cells compared to 
control cells. 
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Figure 7-12 FGFR pathway stimulation by FGF23, FGF19 and FGF21 
 
Cell lysates were prepared from HEK293 cells that were stably transfected with flagged-Klotho (A) or flagged-βKlotho (B 
and C), down regulated for Memo (control siRNA treatment with scrambled siRNA), starved over night and stimulated with 
FGF23 (A), FGF19 (B) or FGF21 (C). The lysates were analysed by western and probed for Flag protein as Klotho/βKlotho 
transfection control, Memo as siRNA down regulation control and FRS2 (only in A) and ERK as readout for FGFR pathway 
activity. 
 
7.6.2 Signaling in the HEK293-βkl cells  
Next we investigated the signaling downstream of the other two endocrine FGFs. For those 
experiments we used HEK293 cells that were stably transfected with flagged-βKlotho and therefore 
responsive to FGF19 and FGF21 (HEK293-βkl). Memo was down regulated by siRNA before the cells 
were starved overnight and stimulated with FGF19 or FGF21. Control transfection was performed with 
a scrambled siRNA. Lysates were prepared from cells that had been stimulated with FGF19 or FGF21 
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for the indicated times and analyzed by western. As a readout for activity of the FGF19 or 21 
stimulated βKlotho-FGFR1-pathway the phosphorylation level of ERK1/2 was analyzed. As a control 
for transfection efficiency the membranes were blotted with an anti-Flag antibody. Flag expression was 
high and equal in control and Memo down regulated cells. Comparable to FGF23 stimulated cells there 
was earlier activation of ERK in the Memo down regulated cells stimulated with FGF19 (Figure 
7-12B). In contrast, when the cells were stimulated with FGF21 there was no difference in ERK 
activation between control and down regulated cells (Figure 7-12C).  
Collectively, these data suggest that Memo plays a role downstream of FGF23 and FGF19 signaling. 
7.6.3 Investigation of complex formation of Memo, Klotho and FGFR1  
As there were changes in signaling downstream of FGF23 and FGF19 upon Memo down regulation we 
investigated if Memo co-precipitates with Klotho and/or FGFR1 in HEK293-kl cells. HEK293-kl cells 
were down regulated for Memo by siRNA or control transfected with a scrambled siRNA, cells were 
starved overnight and subsequently stimulated with FGF23. Lysates were prepared and subjected to 
immunoprecipitation (IP) with FGFR1 and probed for Memo and Klotho (Figure 7-13A), whole cell 
extract (WCE) is displayed as input-control of the IPs. Klotho could be detected in the precipitates of 
FGFR1 in control and Memo down regulated cells, irrespective of stimulation with FGF23. In contrast, 
detection of Memo in the FGFR1 precipitates was not possible. Next, we investigated lysates that were 
subjected to IP with Klotho and probed with an anti-Memo and anti-FRS2 antibody. While it was 
possible to detect FRS2 in the precipitates of Klotho, we were unable to detect Memo (Figure 7-13B). 
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Figure 7-13 IP of FGFR1 and Klotho in HEK293-kl cells 
 
HEK293-kl cells were treated with siMemo or siScrambled, starved over night and stimulated with FGF23. Whole cell 
extract (WCE) or immunoprecipitations of FGFR1 (A) or Klotho (B) were run on a SDS page and immunoblotted. The 
protein levels of Klotho, FGFR1 and FRS2 were analysed. ERK and Memo protein levels were analysed as loading- and 
down regulation-controls respectively. 
 
In summary, these data suggest that FGFR1 and Klotho co-precipitate irrespective of Memo expression 
and FGF23 stimulation. So far it was not possible to show that Memo co-precipitates with FGFR1 or 
Klotho in these cells. 
7.6.4 Inhibitory effect of secreted Klotho  
It has been published that Klotho has an inhibitory effect on insulin and IGF-1 signaling in cancer cells 
(347, 350). We were interested if Klotho also has an inhibitory effect on insulin/IGF-1 signaling in 
mouse embryonic fibroblasts (MEFs) and if so, whether this effect is dependent on Memo expression. 
Firstly, we investigated if the MEFs were responsive to insulin and IGF-1. MEFs were isolated from 
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Memo cKO embryos and immortalized. Under cell culture conditions Memo expression was lost 
spontaneously from MEFs. As a control we used unrelated WT MEFs. Memo WT and KO cells were 
starved over night and stimulated with insulin or IGF-1 for the indicated times. Lysates were prepared 
and analyzed by western blot analysis. Activation of AKT and ERK downstream of both ligands 
showed that the MEFs are responsive to insulin and IGF-1 irrespective of Memo expression (Figure 
7-14). Due to the fact that there was a difference in the level of total protein content of ERK and AKT 
between WT and KO cells, quantification by ImageJ was performed. When normalized to total protein 
levels, the phosphorylation levels show that there is a difference in ERK and AKT activation in WT and 
KO MEFs stimulated by insulin and IGF-1 (Figure 7-14B). Insulin stimulation induced earlier 
activation of ERK and AKT in Memo KO cells (activation after 1 minute of stimulation) compared to 
WT cells (activation after 5 minutes) (lanes 8 and 14). The same was true for IGF-1stimulation. IGF-1 
induced earlier activation of ERK and AKT in the Memo KO cells (activation after 5 minutes) 
compared to WT cells (activation after 10 minutes) (lanes 4 and 11). The earlier activation of ERK is 
consistent with the findings in the HEK293-kl cells stimulated with FGF23. In contrast, the earlier 
activation of AKT is only seen in the MEFs upon insulin and IGF-1 stimulation. 
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Figure 7-14 Stimulation of WT and KO MEFs with insulin and IGF-1 
 
(A) Cell lysates prepared from WT and Memo KO MEFs starved over night and stimulated with insulin and IGF-1 for the 
indicated times were analysed by western for AKT and ERK as well as their phospho-proteins. 
(B) Quantification of the blot shown in (A). The phosphorylation levels of the proteins were normalized to the total protein 
levels. Depicted is the level of phosphorylation of ERK (top) and AKT (bottom).   
 
 
To test a possible inhibitory effect of soluble Klotho on insulin and IGF-1 signaling, lysates were 
prepared from cells starved over night, inhibited with soluble Klotho and stimulated with insulin or 
IGF-1. For this experiment we also performed quantification of the western analysis by ImageJ as the 
total amount of protein was not the same in WT and KO cells. We show that Klotho is able to inhibit 
ERK signaling but not AKT signaling in IGF-1 stimulated WT cells (Figure 7-15, lane 5). This finding 
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is not in accordance with prior publications and the current concept of how Klotho would inhibit the 
pathway. Inhibition of IGF-1 induced ERK activation in KO cells cannot be judged from this western 
analysis, as we could not detect ERK activation upon IGF-1 stimulation. Nevertheless, there is 
inhibition of AKT signaling by soluble Klotho in the KO cells (lane 10). Insulin induced signaling 
could not be inhibited by Klotho in this experiment. 
 
Figure 7-15 Inhibitory effect of Klotho on the insulin and IGF-1 pathway in the MEFs 
 
(A) Cell lysates prepared from WT and Memo KO MEFs starved over night, treated with soluble Klotho and stimulated 
with insulin and IGF-1 for the indicated times were analysed by western for AKT and ERK and their phospho-proteins. 
(B) Quantification of the blot shown in (A). The phospho levels of the proteins were normalized to the total levels. Depicted 
is the level of phosphorylation of ERK (top) and AKT (bottom).   
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These results show that the MEFs are responsive to insulin and IGF-1 and that Memo plays a role in 
their downstream signaling, as shown by earlier activation of the downstream proteins ERK and AKT. 
Pre-incubation of the cells in soluble Klotho prior to stimulation with IGF-1 and insulin showed that 
Klotho was able to inhibit IGF-1 signaling in WT and KO cells, but not insulin signaling. 
 
7.7 Memo downstream of FGFR signaling in mouse mammary carcinoma cells  
When I joined the lab Régis Masson and Susan Jacobs were working with the 4T1 cell line. Susan 
down regulated Memo in the 4T1 cells by shRNA. This was supervised by Régis Masson. I did not 
contribute to the generation of the KD cells. I was given the cells by Régis when I started in the group. 
The aim was that I perform in vitro experiments supporting their in vivo studies. I worked with the 4T1 
cells until the MEFs that I was generating at that time were ready for experiments.  
It has been shown that Memo is important for migration downstream of both heregulin and FGF2 (6). 
Therefore, we studied Memo and its role in FGFR signaling in cancer cells. We used 4T1 mouse 
mammary carcinoma cells previously described by Aslakson and Miller (398). 4T1 cells have 
constitutively active FGFR signaling due to autocrine production of the ligands (399). 
For the following experiments Memo was stably down regulated by shRNA hairpins in the 4T1 cells 
(S. Jacob). Memo down regulation was achieved with two different shRNAs against Memo, sh10 and 
sh7. As control, the non-transfected parental cell line and control transfected cells with shRNA against 
LacZ were used. These experiments were performed with single clones. For the respective level of 
Memo in the different clones, please refer to Figure 7-16. 
 
Figure 7-16 Down regulation of Memo in 4T1 cells by shRNA hairpin against Memo (S. Jacob and I. 
Samarzija) 
 
Cell lysates prepared from 4T1 parental cells, 4T1 cells treated with two different shRNA against Memo, (shRNA 10 and 7), 
or shRNA against LacZ (as control) were analysed by western for the level of Memo and tubulin.  
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7.7.1 Effect of Memo down regulation on FRS2 phosphorylation in 4T1 cells (F. Maurer) 
This experiment was performed by a technician in our lab, Francisca Maurer. She got cells that I 
cultured and performed the IP and western analysis by herself.  
Control and Memo knock-down (KD) 4T1 cells were tested for FRS2 activation. Due to the autocrine 
FGF loop the cells could not be further stimulated by addition of FGF ligands. Therefore, lysates of 
growing cells were subjected to immunoprecipitation with FRS2 and total phospho-tyrosine was 
analysed by western (F. Maurer). Whole cell extract (WCE) is shown as input control.  The blot 
incubated with the pTyr antibody shows that FRS2 was less phosphorylated in the KD cells compared 
to control cells (Figure 7-17). This data indicates that Memo plays also a role in the FGFR pathway of 
mouse mammary carcinoma cells.  
 
Figure 7-17 Phosphorylation status of FRS2 in 4T1 control and Memo down regulated cells (F. Maurer) 
Lysates of growing control and Memo KD 4T1 cells were immunoprecipitated by FRS2 and analysed by western. Whole 
cell extract (WCE) and IP of FRS2 were probed with anti-pTyr and anti-FRS2 antibodies. 
 
7.7.2 Apoptosis, proliferation and migration in control and Memo down regulated (KD) cells 
Hypothesizing that Memo plays a role in cancer we performed assays to investigate apoptosis, 
proliferation and migration in control and Memo KD 4T1 cells. 
7.7.2.1 Apoptosis 
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• YoPro assay of 4T1 cells upon stress induction 
Control and Memo KD cells were seeded in 96 well plates and treated with a selective FGFR inhibitor, 
a PI3K inhibitor LY294002 and CoCl2, an oxidative stress inducer. As control the cells were treated 
with DMSO, the vehicle control for the FGFR1 and PI3K inhibitor. After 32 or 48 hours of treatment 
the amount of apoptotic cells was assessed by YoPro assay (Figure 7-18A). After 32 or 48 hours almost 
no basal apoptosis (1-2%) was detectable. FGFR inhibition induced apoptosis in control cells (17% 
after 32 hours and 24% after 48 hours respectively) but not in the KD cells (3%). Blocking of the PI3K 
pathway with the LY inhibitor in addition to FGFR inhibition induced even higher apoptosis rates. But 
the difference between control (59% and 63%) and KD cells (12%) remained about the same. In 
contrast, treatment with CoCl2 induced more apoptosis in the KD cells (34% and 59%) compared to 
control cells (6% and 12%). The experiment was repeated with a different FGFR inhibitor, TKI258, 
and another control clone as well as an additional Memo KD clone. The results of the first and second 
experiments were comparable. After 48 hours of treatment with the FGFR inhibitor 26% of the control 
cells died compared to 2% and 3% of the Memo KD cells. 
This suggests that Memo KD cells are more sensitive to oxidative stress, but more resistant to FGFR 
inhibition. 
 
Results 
137 
 
 
Figure 7-18 Apoptosis of 4T1 
(A) 4T1 cells were treated with CoCl2, a FGFR inhibitor or a combination of the FGFR inhibitor and LY294002, a PI3K 
inhibitor. Cells were treated with the vehicle DMSO of the inhibitors as control. Apoptosis was measured after 32 (left) or 
48 hours (right) by YoPro assay. 
(B) Cell lysates of 4T1 cells were prepared from cells treated with 500µM CoCl2,500µM CoCl2 in combination with 50nM 
of a FGFR inhibitor, or 50nM FGFR inhibitor alone (control of the experiment was untreated cells or treatment with 
DMSO, the vehicle of the FGFR inhibitor). The lysates were analysed by western and probed for cleaved caspase 3. 
 
• Western analysis for cleaved caspase 3 upon stress induction in 4T1 cells 
In addition, we performed western blot analysis on lysates of control and KD 4T1 cells that were 
treated with CoCl2, an FGFR inhibitor or a combination of the two. Treatment with DMSO, the vehicle 
of the inhibitor, and untreated cells served as controls. To assess the level of apoptosis we used cleaved 
caspase 3 as readout. There was a clear signal for cleaved Caspase 3 after 12 hours in the KD cells 
treated with CoCl2 while the control cells show only a moderate signal (Figure 7-18B). Surprisingly, 
the combination treatment of CoCl2 and FGFR inhibitor caused only a moderate level of cleaved 
caspase 3 in both control and KD cells. The results of the YoPro assay concerning sensitivity to the 
FGFR inhibitor was confirmed by western analysis of the cleaved caspase 3. There is a moderate level 
of cleaved caspase 3 in the control cells upon FGFR inhibitor treatment, but no signal in the KD cells 
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indicating that the Memo KD cells are more resistant to FGFR inhibition when not challenged with 
oxidative stress (Figure 7-18B).  
• Sensitivity to CoCl2 of Memo KO MEFs 
Furthermore, we tested sensitivity to CoCl2 in the MEFs that were either WT or Memo KO. In this case 
we stressed WT and KO MEFs by addition of CoCl2 and stained with Dilc1(5) to measure the 
mitochondrial membrane potential by FACS. Dilc1(5) stains cells with intact mitochondrial membrane 
potential. Upon cell death the mitochondrial potential is lost. Staining with Dilc1(5) is lost 
proportionally to the loss of mitochondrial membrane potential. Figure 7-19A shows that after 24 hours 
15% of the Memo KO cells compared to 3% of the WT cells lost Dilc1(5) staining. Those data are in 
line with the results from the YoPro assay that show that Memo KD cells are more sensitive to CoCl2 
• Investigation of Memo’s effect downstream of DNA damage 
To investigate if cells that have no Memo are generally more sensitive to stress, we induced DNA 
damage by treatment with etoposide. Cells were stained with Dilc1(5) and analysed by FACS. After 48 
hours of etoposide treatment 33% of the Memo KO cells were apoptotic and only 13% of the WT cells 
(Figure 7-19B). 
 
Figure 7-19 Apoptosis of WT and KO MEFs upon Etoposide treatment 
 
(A) MEFs were treated with 500µM CoCl2 for 24 hours, stained with Dilc1(5) and sorted by FACS. Positive staining with 
Dilc1(5) indicates loss of the membrane potential and therefore apoptosis. Orange = membrane potential of Memo KO 
MEFs, Blue = membrane potential of WT MEFs. M1 is the gate for apoptotic cells, M2 is the gate for living cells. 
M1orange=15%, M1blue=3%. 
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 (B) MEFs were treated with etoposide for 48 hours, stained with Dilc1(5) and FACS sorted. Positive staining with Dilc1(5) 
indicates loss of the membrane potential and therefore apoptosis. Orange = membrane potential of Memo KO MEFs, Green 
= membrane potential of WT MEFs. 
These data indicate that Memo KO MEFs are more sensitive to DNA damage and oxidative stress and 
that loss of Memo renders the cells in general more sensitive to stress.  
 
7.7.2.2 Proliferation 
Next, proliferation was investigated by quantifying BrdU incorporation. Cells were seeded in 96-well 
plates and at 80% confluency exposed to BrdU for two hours. There was no difference between the 
proliferation rates of control and KD clones as measured by BrDU incorporation (Figure 7-20). 
 
Figure 7-20 Proliferation assay with 4T1 cells 
Control (LacZ1 and 2) and Memo KD (10.7, 10.a, and 10.2) cells were treated with BrdU for 2 hours. Incorporation of 
BrdU was evaluated and plotted. Incorporation into LacZ1 cells was set at 100%. 
7.7.2.3 Migration 
As mentioned above our group has reported that Memo down regulation in human cancer cells caused a 
FGF2-stimulated migration defect (6). Hence, we investigated migration in 4T1 control and Memo KD 
cells by boyden chamber assays. 
Equal numbers of control and KD cells were seeded on top of the membrane. Migrated cells were 
counted after 6 or 12 hours. During migration the cells were either treated with a selective FGFR 
inhibitor or DMSO as vehicle control (Figure 7-21). The basal migration was lower in the KD clones 
(1200 and 3500 migrated cells respectively) than control cells (8000 cells) after 6 hours of migration. 
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Nevertheless, after 12 hours the KD cells caught up (17 000 and 16 000 cells compared to 18 000 
control cells).  
 
Figure 7-21 Boyden Chamber Migration assay with 4T1 cells 
 
4T1 control and Memo KD cells were seeded in Boyden Chambers and treated with a FGFR inhibitor or DMSO as control. 
Migration was stopped after 6 hours (A) or 12 hours (B) and the cells were counted. 
 
In addition, this experiment showed that blocking FGFR signaling with a FGFR inhibitor was more 
efficient in control cells (70% of inhibition) than in the KD clones (40% respectively 35% of 
inhibition). 
These data suggest that Memo inhibits FGF2 stimulated migration initially (during the first 6 hours of 
migration), but that Memo KD cells are able to catch up after 12 hours of migration. Furthermore, these 
data support the hypothesis that Memo KD clones are more resistant to FGFR signaling inhibition.  
7.7.3 Memo and oxidative stress 
As discussed above (section 7.7.2.1) Memo KD 4T1 clones and Memo KO MEFs are more sensitive to 
oxidative stress induced by CoCl2. 
CoCl2 induces apoptosis via two different pathways: 1) It blocks the electron chain reaction in the 
mitochondrial membrane or 2) it activates the ASK-p38 pathway (400).  
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Therefore, we investigated if there is a difference in the shape and size of mitochondria in the KO 
compared to WT MEFs, as this can be a read-out for functionality of mitochondria. We stained WT and 
KO MEFs that were isolated from different animals with mitotracker that stains the mitochondria. 
Figure 7-22 shows that there is no obvious difference between the mitochondria of the WT and KO 
cells.  
 
Figure 7-22 Staining of mitochondria in MEFs after CoCl2 treatment 
WT (left) and KO (right) MEFs were treated with 500µM CoCl2 and stained with mitotracker to visualize the mitochondria. 
Thus, we investigated p38 signaling downstream of CoCl2 treatment in 4T1 cells. Lysates were 
prepared from control and KD cells that were treated with CoCl2 for the indicated time. Memo KD cells 
show a stronger induction of p38 after 8 hours of CoCl2 treatment (Figure 7-23A), which indicates that 
they are more stressed. The Memo KD clone 10.a has the highest level of Memo and also shows the 
least amount of p38 induction (see insert Figure 7-23A).  
In addition, the KD cells show inactivation of S6 ribosomal protein at all time-points investigated 
(Figure 7-23B). In parallel, we find dephosphorylation of 4E-BP1 upon CoCl2 treatment (Figure 
7-23C). This suggests an implication of Memo in the TOR-HIF1α crosstalk that has been earlier 
described (401). 
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Figure 7-23 Cell Signaling downstream of CoCl2 
Cell lysates were prepared from control and Memo KD 4T1 cells that were treated with 500µM CoCl2 for the indicated 
times. Protein levels of Memo are shown in the insert of (A). The lysates were analysed by western blot and probed for p38 
(A), pS6 (B) and 4E-PB1 (C). Tubulin was used as loading control. 
 
CoCl2 is not only an oxidative stress inducer, but also a hypoxia-mimicking agent. Therefore, we 
wanted to exclude that the effects we observed downstream of CoCl2 are due to its hypoxia mimicking 
properties. Initially we investigated if the cells show a defect in stabilizing the Hypoxia Induced Factor 
1α (HIF1α) (Figure 7-24). In addition, we investigated if the cells show a difference in signaling 
downstream of real hypoxic conditions. Cell lysates were prepared of control and Memo KD 4T1 cells 
that were either treated with CoCl2 or exposed to floating hypoxic gas (1% O2, 5% CO2, 94% N2) for 
20 minutes and then incubated in this gas for the indicated time. Figure 7-24 shows that HIF1α is 
stabilized upon CoCl2 and to a lesser extent also by hypoxic conditions in control cells. In the KD cells 
HIF1α is stabilized upon CoCl2 treatment, although to a lesser extent then in the control cells. 4T1 cells 
show basal stabilization of HIF1α in normal growing conditions, a feature common to many cancer 
cells. The same applies for HIF1α stabilization upon hypoxic conditions. This indicates that 
stabilization may be slightly affected in 4T1 cells down regulated for Memo. Nevertheless, the 
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inactivation of S6 is unique to CoCl2 treatment. Thus, this effect seems to correlate with oxidative 
stress. 
 
Figure 7-24 CoCl2 and hypoxia treatment of 4T1 cells 
Cell lysates were prepared of control and Memo KD 4T1 cells that were incubated in 500µM CoCl2 or hypoxic gas for the 
indicated times and analyzed by western. The membrane was blotted for HIF1α, pS6 and tubulin. 
 
7.7.4 Memo and VEGF secretion 
Another line of investigation in the lab followed the question of the role of Memo in cancer. Therefore, 
colleagues in the lab (R. Masson, S. Jacub, I. Samarzija) investigated the effect of down regulation of 
Memo in an FGF driven cancer model. They injected control and Memo down regulated (KD) cells in 
the mammary fat pad and measured primary tumor growth. They found that primary tumor growth was 
initially slower in the tumors formed by KD cells but caught up after 20 days.  In addition, they found 
by histological analyses of the tumors that tumors grown from Memo KD cells are more slowly 
vascularised, but that vascularisation caught up after several days. 
The vascular endothelial growth factor (VEGF) is an essential factor for the in growth of blood vessels 
into the tumor (402). Endothelial cells of the surrounding blood vessels need to be stimulated by VEGF 
to grow into the tumor area. VEGF can be secreted by the tumor cells themselves or by cells of the 
tumor stroma. Interestingly, the FGFR pathway has already been described to induce VEGF release 
(207). Therefore, we investigated if Memo KD reduced the secretion levels of VEGF-A. 
We tested VEGF secretion by performing an ELISA assay on the control and Memo KD clones. Equal 
numbers of cells were seeded on 96-well plates and the supernatant of triplicates pooled to perform the 
ELISA assay. The basal level of VEGV-A secretion is higher in the control cells compared to the Memo 
KD cells (Figure 7-25A). The level of secreted VEGF-A was increased upon addition of CoCl2 in 
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control and KD cells, although the amount of the increase seemed to correlate with the basal secretion 
level. Addition of PI3K inhibitor (LY294002) or FGFR inhibitor reduced the secretion level 
significantly in control and KD cells. Nevertheless, in control cells the FGFR inhibitor was slightly 
more efficient than LY294002, while in the KD cells the efficiency of the two inhibitors was 
equivalent. 
This data shows that Memo KD induces lower basal VEGF and CoCl2 stimulated release and 
additionally supports the preceding data demonstrating that Memo KD cells are less sensitive to FGFR 
inhibition.  
 
Figure 7-25 VEGF secretion and expression in 4T1 cells 
 
(A) ELISA assay for VEGF-A with control and Memo KD cells. Cells were plated and treated with DMSO, CoCl2, 
LY294002 or FGFR inhibitor for 48 hours. The pooled supernatant of triplicates was used to perform the ELISA assay. 
(B) RNA was collected of control and Memo KD cells and the level of VEGF-1 and GAPDH were evaluated by semi-
quantitative PCR  
 
Furthermore, we investigated if translation of the VEGF is affected. A semi-quantitative PCR for 
VEGF-A on the cDNA of control and KD Memo clones was performed. There was no difference in the 
RNA level of VEGF-A in Memo KD clones compared to control clones (Figure 7-25B). 
These data suggest that the Memo KD clones translate equal levels of VEGF-A, but secrete or release 
less into the medium compared to control clones. Overall, this data supports the hypothesis that Memo 
KD clones show a delay in primary tumor outgrowth, due to slower vascularisation of the tumor, 
caused by the reduced levels of secreted VEGF-A. 
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8 Outlook and Discussion 
The goal of this thesis was to further understand the mechanisms of aging, a fundamental process that 
is becoming more critical to study as average age of our population increases.   
Knock out of Memo in mice is embryonic lethal at E13.5, demonstrating that Memo is an essential 
protein. Memo knockout embryos at E11.5 show abdominal bleeding and low perfusion of the blood 
vessels. Nevertheless, the etiology of death is still unclear and needs further investigation. Here we 
show that conditional knock-out mice induced for loss of Memo in the whole body after E13.5 are 
viable, but have severe defects that lead to rapid death after birth. Memo null animals developed 
premature aging symptoms including weight loss, graying hair and hair loss, stiff joints, kyphosis, loss 
of subcutaneous fat and white adipose tissue, nonfunctional and hypotrophic gonads as well as a defect 
in the hindlimb reflex. In addition, Memo null mice displayed a severe metabolic phenotype, including 
postprandial hypoglycemia and higher sensitivity to insulin. This is an unusual phenotype for 
premature aging models and similar metabolic phenotypes have only ever been reported for two other 
mouse models, namely the FGF23 and Klotho mutant strains.    
Data provided by this study suggest that Memo null mice suffer from renal insufficiency and have a 
defect in the renal FGF23-Klotho axis that regulates the levels of vitamin D production, phosphate 
reabsorption and calcium uptake. We show that regulators of the FGF23-Klotho axis are affected upon 
Memo loss. The current study includes data suggesting that expression of vitamin D metabolizing 
enzymes and expression of Na-Pi cotransporters, important for phosphate reabsorption, are deregulated. 
Furthermore, we show evidence that cleavage of Na-Pi2a is inhibited in the Memo KO animals, 
although we do not find differences in serum phosphate levels. Blood analysis showed possible renal 
insufficiency and a slight hypercalcemia in Memo null animals. Staining of the hearts of Memo null 
animals with von Kossa, a stain for calcium deposits, supports the findings of the blood analysis. We 
found small regions of calcifications of soft tissue in hearts of Memo null mice.   
In addition to the full body conditional knock-out, we also generated an inducible, kidney-specific 
Memo knock-out strain. These mice do not suffer from premature aging, but they show a decrease in 
body weight compared to control animals and renal insufficiency. In line with the data from Memo null 
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mice, we show that kidney-specific Memo KO animals have a defect in the FGF23-Klotho axis and in 
the cleavage of Na-Pi2a. In addition, we provide data showing that they have less efficient creatinine 
clearance. Nevertheless, these animals also have normal serum phosphate levels. Interestingly, our 
investigations into the renal functioning of these animals, using metabolic cages, revealed that the 
kidney-specific KO animals are hypercalciuric.  
In vitro we investigated metabolic FGF signaling in HEK293 cells that were stably transfected with 
Klotho or βKlotho (HEK293-kl and HEK293-βkl) and that were transiently downregulated for Memo.  
We could show that activation of ERK takes place more rapidly in Memo downregulated cells 
stimulated with FGF23 and FGF19 as compared to control cells. In addition, we showed that FGF23 
stimulation of HEK293-kl cells induces less FRS2 phosphorylation in Memo knock-down cells 
compared to control cells. Limited by the expression levels of the protein, we could not show activation 
of AKT. 
This study also provides data suggesting that Memo is generally downstream of the FGFR pathway and 
that Memo binds to the FGFR-signalosome. These experiments were performed in mouse embryonic 
fibroblasts that were stimulated with FGF2. Knock-out of Memo in these cells dampens FGFR 
signaling with respect to intensity and duration. We provide evidence that Memo co-
immunoprecipitates with all the members of the FGFR-signalosome. In addition, we show that Memo 
is downstream of the FGFR pathway in 4T1 cells, a mouse mammary carcinoma cell line that has an 
autocrine FGF loop. We demonstrate that stable downregulation of Memo by shRNA results in lower 
activation of FRS2. 
Another line of investigation showed that Memo KD 4T1 cells are less sensitive to FGFR inhibition, as 
assessed by apoptosis and migration assays, and more sensitive to CoCl2 treatment. Treatment with 
CoCl2 induced stronger phosphorylation of p38 in the Memo KD cells indicating higher stress levels. 
Furthermore, inactivation of S6 ribosomal protein as well as dephosphorylation of 4E-BP1 could be 
detected in Memo KD cells treated with CoCl2. 
8.1 The premature aging defect 
Memo null mice showed a severe premature aging phenotype. In addition to the well known premature 
aging symptoms they also showed a particular metabolic phenotype: postprandial hypoglycemia and 
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increased sensitivity to insulin. Although atypical for premature aging models, they shared this 
particular metabolic phenotype with two other aging models: the Klotho- and FGF23-mutant mice. 
Thus, we investigated if there are other similarities between the Memo and the Klotho/FGF23 mutant 
models.  To accomplish this, we analyzed two different mouse models; knock-out of Memo in the 
whole body (Memo null mice) and kidney-specific knockout of Memo. 
8.1.1 Analysis of the FGF23-Klotho axis 
The current study provides data supporting the hypothesis that loss of Memo in the kidney deregulates 
the renal FGF23-Klotho axis. Such a deregulation has been shown for the FGF23 and Klotho mutant 
mice. Memo null and kidney-specific Memo KO mice (collectively referred to as Memo mice) show 
similar changes to the FGF23/Klotho mutant mice with respect to the Klotho-FGF23 axis. We provide 
evidence that the levels of Cyp27B1, the vitamin D converting enzyme, and Cyp24A1, the vitamin D 
catabolizing enzyme, are deregulated in Memo mice. These deregulations did not yet reach statistical 
significance. We believe that this is due to high variations of transcription-levels depending on the age 
of the mice. So far, we were not able to investigate a sufficient number of animals at the same age. 
Therefore, to date, we don’t know if these are significant changes. 
However, the observed expression levels of Cyp27B1 and Cyp24A1 are deregulated as compared to 
control animals. In contrast, Klotho mutant mice show a consistent upregulation of Cyp27B1 and 
Cyp24A1 [303]. A possible explanation for this discrepancy may be revealed by the fact that Klotho 
mutant animals show a downregulation of vitamin D receptor (VDR) levels. The vitamin D receptor 
forms a negative feedback loop by downregulating the expression of 1α-hydroxylase. Conversely, no 
downregulation of VDR expression was observed in the Memo null animals. Inactivation of the 
feedback loop probably results in the consistent upregulation of the Cyp27B1 and Cyp24A1observed in 
the Klotho mutant mice, whereas in Memo null animals the intact feedback loop would modulate 
expression of these enzymes to varying degrees. Alternatively, as Memo mice are expected to be 
normal with respect to Klotho levels, the function of the soluble form of Klotho should be maintained 
in Memo mice. This is important to consider with regard to the phenotype as it has been published that 
the soluble form of Klotho has essential functions in regulation of serum phosphate and FGF23 levels 
(301). It was beyond the scope of this study to investigate the function of soluble Klotho in Memo 
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mice.   
One limitation of this study is that due to the limited number of animals available, the level of the Cyps 
and Na-Pis could in some cases only be analyzed for one control animal. Nevertheless, when more 
control animals were included, which are not littermates but treated simultaneously and had the same 
age at the time of treatment (matched breeding), the outcome of the experiments was the same. 
We show here that the expression level of the sodium-phosphate cotransporters IIa and IIc (Na-Pi2a/2c) 
are downregulated in the kidneys of Memo null mice. This is in line with data reporting that the mRNA 
levels of these transporters are downregulated in Klotho mutant mice [305]. In addition, it has been 
shown that in the Klotho mutant strain the content of Na-Pi2a in the brush border membrane is 
increased (301). We show here that cleavage of Na-Pi2a in the brush border membrane, which leads to 
receptor internalization and degradation (403), is blocked in Memo mice, however, we do not see an 
accumulation of the full length receptor in the brush border membrane of Memo mice.  
Another regulator of Na-Pi2 expression in the brush border membrane is the parathyroid hormone 
(PTH), which is secreted by the parathyroid gland. PTH is the principal regulator of calcium 
homeostasis and also inhibits phosphate reabsorption by regulation of 1α-hydroxylase levels. Although, 
we observed lower PTH levels in Memo null animals there is no difference in NaPi2a expression in the 
brush border membrane. This could indicate that in this situation the effect of PTH is overruled.   
8.1.2 Blood- and urine analysis 
Different blood analyses of Memo mice compared to control animals have been performed. We provide 
data showing that both Memo null and kidney-specific Memo KO animals suffer from renal 
insufficiency. We investigated the levels of two different indicators for renal insufficiency, BUN (in 
both models) and creatinine (in the kidney-specific KO animals only). Both indictors were deregulated 
in the Memo mice.  Interestingly, we observed upregulated BUN levels in Memo null animals that were 
induced for Memo loss at the age of 2.5 weeks and for which blood sampling was performed 8 weeks 
later, but observed no differences in Memo null animals induced for Memo loss at 11 days of age and 
for which blood sampling was performed 20 days later. It is possible that 20 days is not enough time for 
these specific changes to be detected, however, both Memo null animal groups showed premature 
aging symptoms, suggesting that other changes do occur at this time point. 
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In contrast to the published data that suggests that elevated phosphate levels are the cause of premature 
aging symptoms in Klotho and FGF23 mutant animals (250, 257), both Memo models displayed 
normal serum phosphate levels.  In addition, we tested phosphate excretion of the kidney-specific 
Memo KO mice and found that to also be normal. These results are surprising, as Memo null mice 
present with a specific and severe premature aging phenotype which in the literature has been attributed 
to increased serum phosphate levels. 
In addition to phosphate, we also investigated calcium levels. Deregulation of calcium metabolism has 
been described for the Klotho and FGF23 mutant mice, although it has never been considered to be 
causative for premature aging. Blood and urine analyses revealed a slight hypercalcemia in both animal 
models and a robust hypercalciuria in kidney-specific Memo KO animals (analysis of the status of the 
Memo null animals is ongoing). It is interesting that the major defect that we observe is an abnormal 
calcium metabolism, something which has not previously been linked to premature aging as causing 
factor. To date we have not observed any differences in the metabolism between the Memo null and the 
kidney-specific Memo KO mice. 
To elucidate the cause of aging in Memo null mice it was important to find specific differences between 
Memo null and kidney-specific Memo KO animals. To date it is unclear if the premature aging 
symptoms of the Memo null animals arise simply by the accumulation of the multiple defects expected 
from Memo knock-out in the whole body, or if there is a specific difference in the metabolism 
controlled by the FGF23-Klotho axis. To investigate the possibility of such a specific difference further, 
we investigated the levels of PTH and FGF23 in the serum of Memo and control animals. Only the 
Memo null mice showed a significant decrease in PTH levels. Even though the kidney-specific animals 
have a tendency for reduced PTH levels, the difference is not significant.  Therefore, this reduced PTH 
levels specifically in the Memo null animals could be the trigger of the premature aging symptoms 
observed in the Memo null animals.  
Furthermore, PTH is known to be one of the major regulators of calcium homeostasis. In addition, PTH 
inhibits vitamin D, directly and indirectly via 1α-hydroxylase (339). To date, we don’t know the level 
of vitamin D in the Memo mice. This will be measured in the future and could further elucidate the role 
of Memo in aging. 
As mentioned above, PTH is an important calcium regulator. PTH is secreted by the parathyroid gland 
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upon a drop of serum calcium concentration. Therefore, low levels of PTH in Memo null mice that 
show slight hypercalcemia are in line with the published regulation of PTH secretion upon serum 
calcium levels. We found further evidence for deregulated calcium homeostasis beyond the function of 
PTH. Our data suggest increased expression of TRPV5, NCX1 and CB28 in kidneys of kidney-specific 
Memo KO mice. All three proteins are implicated in the active reabsorption of calcium from the urine 
into the blood stream. Upregulation of these proteins could be a rescue attempt of the organism against 
the observed hypercalciuria in kidney-specific Memo KO mice.  
For Klotho and FGF23 mutant mice defects in calcium homeostasis have been shown (92, 255). Klotho 
has been shown to be regulator of calcium homeostasis in an FGF23 independent manner. It stabilizes 
TRPV5 in the kidney membrane by cleaving off sugar residues of the transporter (341, 404) and Na+K+ 
ATPase by binding to the ATPase in the membrane of the parathyroid gland in order to induce PTH 
secretion upon low serum calcium levels (342).   In addition, soft tissue calcification has been found in 
the heart, lungs and kidneys of Klotho and FGF23 mutant mice (92, 255) as a consequence of 
hypercalcemia. Supported by our findings of only slight hypercalcemia in the serum, we have observed 
only a very restricted area of the heart to be calcified in Memo null animals and have no evidence of 
calcification in the lungs. High calcium levels can also cause bone malformation however, other than 
the kyphosis described earlier, we did not find any obvious bone malformations. This should be 
investigated more deeply however, for instance with the use of x-ray technologies.   
In the general blood analysis we also measured the levels of glucose and insulin. Both were found to be 
downregulated. In addition, by performing Glucose- and Insulin Tolerance Tests we observed 
postprandial hypoglycemia and higher insulin sensitivity in Memo null animals. Due to the higher 
insulin sensitivity we expected to find lower circulating insulin levels in the Memo null animals. This 
was confirmed by the first blood anaylsis performed.  Surprisingly, we found altered glucose levels in 
the blood analysis performed by the “Institut Clinique de la Souris (ICS)” (Table 7-3) but we did not 
detect any difference in glucose levels of the starved animals during the Glucose- and Insulin Tolerance 
Test (Glucometer (Free Style mini form ABBOTT)) (Chapter 7.1). This might be due to the different 
sensitivities of the two methods.  
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8.2 FGFR signaling 
We have evidence that Memo loss results in a shorter and less intense activation of proteins 
downstream of the FGFR pathway in mouse embryonic fibroblasts. In addition, we showed supporting 
data that Memo binds to the FGFR-FRS2-GRB2/GAB1 complex, the FGFR-signalosome. In order to 
elucidate to which component of the signalosome Memo directly binds, Memo pull-downs with 
purified proteins should be performed. To date the mechanism by which Memo affects FGFR signaling 
is unknown. There are a few possibilities: 1) We published earlier that purified Memo binds to actin 
filaments in vitro [8] therefore, we hypothesize that Memo may affect the localization of the FGF 
receptor. Due to the fact that signaling and signalosome formation is possible in the absence of Memo, 
a role for Memo in localizing the receptor to the cell membrane can be excluded. Nevertheless, Memo 
may have a role in localizing the FGFR within the cell membrane. It has been published that 
localization of FGFR into lipid rafts affects signaling by directing it more towards AKT signaling 
[402]. To examine this, tagged versions of the receptor should be expressed and colocalisation of the 
receptor and lipid rafts should be studied. 2) Another hypothesis is that loss of Memo interferes with 
FRS2-binding partners, thus inhibiting recycling of the receptor, which has been shown to be essential 
for persistent FGFR signaling [124]. This could be tested by staining for Rab11, an important protein 
for receptor recycling. 3) My own results and those of other members of the group, show that Memo is 
localized in the cytoplasm and in the nucleus. In addition, I and others in the lab have shown that 
Memo localizes to the nucleus upon mild stress induction, such as starvation. Therefore, Memo could 
be acting as a shuttling protein to bring receptors to the nucleus. It has been shown previously that a 
nuclear FGFR subpopulation exists (405), although thus far the function of these receptors in the 
nucleus has not been elucidated. In general, it would be interesting to investigate under which 
conditions different pools of Memo are delocalized. 4) An additional hypothesis is that the complex of 
receptor and adaptor proteins forms in the absence of Memo, but the receptor fails to become fully 
activated. Data has been presented that illustrates that the different phosphorylation sites on the FGF 
receptor are activated in a kinetic and ordered manner [403]. Thus, it is possible that the receptor only 
gets partially phosphorylated and not fully activated in Memo KO cells. A masspectrometry approach 
could shed light on this particular theory. 5) Finally, another possibility to investigate is the potential 
upregulation of known negative regulators of FGFR signaling, such as sprouty and SEF (similar 
expression to fgf genes), upon loss of Memo. 
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Our group published earlier that Memo binds only the phosphorylated form of ErbB2 [5, 6]. Data from 
this study shows that Memo binds to FGFR irrespective of stimulation. This is not necessarily 
contradictory to what we published earlier. FRS2, for instance, has also been found to bind the 
phosphorylated and non-phosphorylated forms of FGFR, but only the phosphorylated form of Ret 
[102]. Therefore, it has been established that the binding properties of adapter proteins can vary 
between different receptors.     
Another major interest of this study was cell signaling downstream of FGF23 stimulation. As Klotho 
expression is spatially restricted, HEK293 cells were engineered to stably express Klotho or βKlotho in 
order to make these cells responsive to FGF23 and FGF19/FGF21 respectively. In addition, Memo was 
downregulated in these transfected cells using a siRNA-mediated approach. Consistent with the data 
obtained from the FGF2 stimulation of MEFs, we found less intense phosphorylation of FRS2 
downstream of FGF23 stimulation in Memo knock down (KD) cells. Furthermore, we detected a more 
rapid activation of ERK downstream of FGF23 and FGF19 in Memo KD cells as compared to control 
cells. This is initially counterintuitive, as ERK is downstream of FRS2. However, a negative feedback 
loop from ERK to FRS2 exists (406) and thus one possible explanation for the more rapid activation of 
ERK observed in Memo KD cells could be the disruption of this negative regulatory mechanism. 
Another explanation could be the emergence of a compensatory mechanism to activate ERK in these 
cells. 
It is surprising that we found differences between Memo KD and control cells downstream of FGF23 
and 19 and but not downstream of FGF21. The mechanism of activation in endocrine signaling is 
believed to be the same for all three ligands. One could expect that Memo may only influence signaling 
downstream of αKlotho and not βKlotho, but here we found that Memo is downstream of both Klotho 
family members. This could reflect organ-dependent differences in βKlotho signaling as FGF19 
activates signaling in the liver while FGF21 does so in adipose tissue. This difference has not been 
investigated any further in this study.  
We also investigated FGFR1 complex formation with Klotho upon stimulation of HEK293 cells with 
FGF23. Our data shows that FGFR1 and Klotho are found in a complex irrespective of stimulation with 
FGF23, a point that has been debated in the literature. This study shows that FGFR1 and Klotho can be 
found in a complex in unstimulated cells. 
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Finally, we investigated the role of Memo downstream of insulin and IGF-1 stimulation in MEFs. It has 
been shown that the soluble form of Klotho inhibits insulin and IGF-1 signaling in breast cancer cells 
(350). We tested if treatment of MEFs with Klotho inhibits Insulin and IGF-1 signaling in a comparable 
way. First, we showed that MEFs were responsive to insulin and IGF-1. In addition, our data gives 
evidence that Memo KO MEFs activate ERK and AKT faster as compared to control cells. These 
results confirm our data downstream of FGF23 signaling in the HEK293-kl cells which also showed an 
earlier induction of ERK phosphorylation. Nevertheless, these results are in contrast to data in the 
MEFs that were stimulated with FGF2. In this case we observed delayed activation of ERK 
downstream of FGF2. These opposing results could be due to cell specificity.  It would be interesting to 
investigate the duration of phosphorylation in HEK293 cells and MEFs downstream of IGF-1 
signaling. Together this data suggests that Memo has different functions downstream of individual 
receptors and in different cell types. It has already been shown for FRS2 that it has different functions 
downstream of specific receptors. It has an activating function downstream of FGFRs, but an inhibiting 
function downstream of the insulin-, EGF-, and PDGF receptors [110]. We next tested if treatment of 
MEFs with exogenous Klotho prior to stimulation with insulin or IGF-1 results in an inhibitory effect 
of Klotho and if so, if loss of Memo affects this function. We found that pretreatment with soluble 
Klotho had an inhibitory effect on IGF-1 but not on insulin signaling. To date we don’t have an 
explanation for the diverse effect of Klotho on insulin and IGF-1 signaling. Nevertheless, we could not 
detect any differences in the Memo KO compared to WT cells. It would be interesting to knock down 
Memo in the published breast cancer cell lines and test the inhibitory function of Klotho in those cells.  
8.3 The role of Memo in FGFR signaling dependent apoptosis and migration  
We show here that downregulation of Memo dampens FGFR signaling in 4T1 cells. In addition, there 
is evidence that Memo KD 4T1 cells are more resistant to FGFR inhibition. We provide data indicating 
that FGFR inhibition induces less apoptosis and blocks migration to a lesser extent in Memo KD cells 
when compared to control cells. We hypothesize that the Memo KD cells have adapted to promote 
survival, despite their reduced FGFR activity. This could be tested by transiently downregulating 
Memo and investigating if the resistance to FGFR inhibition persists. 
In addition, we show that inhibition of PI3K in combination with FGFR inhibition has a synergistic 
effect on apoptosis in Memo KD and control cells. More importantly, our data suggests that control 
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cells are more affected by concurrent pathway inhibition than the Memo KD cells. Given this, it is not 
surprising that we find that AKT activation is strongly delayed downstream of FGFR stimulation in 
Memo KO and KD cells. To test if this is due to adaption of the cells to low FGFR signaling, Memo 
WT and KO cells could be transfected with constitutively active AKT (myristoylated AKT) to see if 
this rescues the phenotype. 
Our group has previously published that upon downregulation of Memo, human carcinoma cells 
display a defect in migration downstream of FGF stimulation [6]. We also see a difference in the basal 
migration of Memo KD 4T1 mouse mammary carcinoma cells, which have autocine FGF signaling, 6 
hours after plating. However, when we look at the number of cells that have migrated after 12 hours, 
we see that the Memo KD cells catch up to the control cells. It is possible therefore, that the initial 
migration defect could actually be a reflection of changes that occur in cell adhesion properties upon 
Memo loss, rather than be the result of a true migration defect. It has recently been shown that loss of 
Memo results in defective localization of lamellipodial markers and in a reduced number of short-lived 
adhesion sites (8). Further investigations need to be performed to answer this question. 
In addition, we observed that upon FGFR inhibition Memo KD cells not only migrate to the same 
extent as the control cells, but performed even better, when we look 12 hours after plating. This 
supports the hypothesis that Memo KD cells are adapted to survive with low FGFR signaling. To 
further investigate the migration phenotype, scratch assays and migration towards a gradient in Dunn 
chamber assays could be performed [8].   
8.4 The role of Memo in VEGF secretion 
By ELISA we show that Memo KD cells secrete or release less VEGF into the medium. VEGF 
secretion is essential for vascularization in vivo and it is well established that impaired FGFR signaling 
has an effect on vascularization (407). Some studies show that FGFR signaling upregulates VEGF 
expression, while others show that FGFR signaling mediates the  upregulation of metalloproteinases 
needed for VEGF release from the cellular matrix [209].The current study indicates that there are no 
differences in VEGF mRNA levels between control and Memo KD cells, which implies a post-
translational defect, although this was tested by semi-quantitative PCR and not by qPCR. Our group 
published earlier that FGFR signaling is essential for matrix metalloproteinase (mmp) expression, 
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especially mmp-9, in 4T1 cells [398]. Therefore, we hypothesize that impaired FGFR signaling due to 
loss of Memo causes reduced expression of metalloproteinases, leading to impaired VEGF release. This 
hypothesis could be tested by transfection of a constitutively active AKT (myristoylated AKT) 
construct or by addition of mmp-9 conditioned medium to control and Memo KD cells. 
8.5 The role of Memo in oxidative stress 
This study provides evidence that Memo KD and KO cells are more sensitive to oxidative stress. CoCl2 
is a hypoxia mimicking agent and an oxidative stress inducer (Figure 8-1b). We provide evidence that 
the observed effects of CoCl2 are not due to its hypoxic mimicking properties as there is HIF1α 
activation in control and Memo KD cells. 
Nevertheless, we observed that Memo KD and KO cells apoptose more strongly upon CoCl2 treatment 
as compared to control cells. In addition, we found that there is stronger activation of p38 in the Memo 
KD and KO cells. Therefore, we hypothesize that the increase of apoptosis is due to increased MAPK 
signaling. Oxidative stress is known to induce phosphorylation and potential kinase activation within 
four of the five main MAPK pathways [405-407]. Which one of the MAPK pathways is activated is 
largely dependent upon the origin of the cells and the level of oxidative stress applied. FGFR signaling 
has been shown to be important for survival of stressed cells by activating the AKT pathway. We have 
already shown in this study that Memo downregulation results in delayed AKT activation. This delayed 
activation of AKT could be a reason for the higher sensitivity of Memo KD cells upon stress induction.  
 
Figure 8-1 Effects of CoCl2 
Outlook and Discussion 
156 
 
a) CoCl2 is a known hypoxia mimicking agent as it inhibits the prolylhydroylase. 
b) CoCl2 induces apoptosis by inhibiting the respiratory chain and inducing oxygen reactive species (ROS) or by activating 
ASK-p38 signaling (c). 
8.6 The role of Memo in TOR-HIF1α crosstalk 
In addition to looking at apoptosis, we also investigated cell signaling downstream of CoCl2. Our data 
reveals that under strong hypoxic conditions (treatment of cells with 500µM CoCl2) the ribosomal 
protein S6 and 4E-BP1, both downstream targets of TOR, are hypophosphorylated. This suggests that 
Memo plays a role in the crosstalk between TOR and HIF1α. It has been shown that TOR 
translationally attenuates HIF1α (401). On the other hand, a negative feedback loop exists which shuts 
down TOR signaling under hypoxic conditions to ensure conservation of energy. In addition, it has 
been shown that constant transcriptional activity is required for S6 hypophosphorylation and that 
HIF1α itself is involved in this transcription (401). Furthermore, it has also been shown that some 
translational activity has to take place under hypoxia. The mRNAs encoding these proteins are believed 
to have 5’ terminal oligopyrimidine tract (TOP) sequences in their 5’ untranslated regions, enabling 
Cap-independent translation. There is an ongoing discussion in the literature about the involvement of 
ribosomal protein S6 in the translation of mRNAs that harbor such 5’ TOP sequences (408-410). Our 
data predicts that Memo plays a role in these crosstalks. To date it is not clear by which mechanism 
Memo would accomplish this. The observation that S6 and 4E-BP1 are hypophosphorylated in the 
Memo KD but not in the control cells further complicates the interpretation of these data as it is not 
clear what advantage the control cells would gain by inhibiting this hypophosphorylation. Nevertheless, 
these data suggest that Memo plays a role in this inhibition. 
It has also been published that Klotho mutant mice show higher activity of p38 MAPK due to 
activation of the ASK1 complex [352]. They hypothesized that this is an indication for higher stress 
levels induced by higher levels of oxidative stress in those mice, caused by hyperphosphatemia. We 
didn’t test the phosphorylation status of p38 in Memo mice yet, but higher basal level of oxidative 
stress in Memo KD cells could be another explanation for the higher sensitivity of those cells to 
(additional) stress upon CoCl2. In addition, the observed higher phosphorylation status of p38 is 
another link between Memo and Klotho. 
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8.7 Conclusion  
We have found that Memo null mice develop a severe premature aging phenotype, accompanied by an 
atypical metabolic phenotype which is shared by the Klotho and FGF23 mutant strains. We therefore 
investigated the similarities between our models and the Klotho and FGF23 mutant mice and conclude 
that as with these models: 1) Memo is downstream of FGFR signaling and specifically downstream of 
FGF23 signaling in vitro; 2) the FGF23-Klotho axis in the kidney is affected upon Memo deletion; 3) 
deletion of Memo either in the whole body or specifically in the kidney results in renal insufficiency as 
determined by blood and urine analyses; 4) Memo mice suffer from hypercalcemia and hypercalciuria; 
5) there is an upregulation of TRPV5, NCX1 and CB28 in kidneys of the kidney-specific Memo KO 
mice; and finally, 6) Memo null mice exhibit lower PTH levels.   
Despite of the many similarities found between our models and the Klotho and FGF23 mutant stains, 
we did not see the expected elevation in serum phosphate levels and there was no difference in the 
phosphate excretion. This is intriguing, as elevated serum phosphate levels have been shown to be the 
cause for this premature aging phenotype in the Klotho and FGF23 mutant animals (250, 257). To date 
we still do not have a definitive cause for the premature aging phenotype in Memo null animals. Our 
data suggest that the lower PTH levels in Memo null mice may promote the aging phenotype as it is 
thus far the only metabolic difference that we observe between the two Memo KO models. 
Alternatively, vitamin D levels are known to induce premature aging symptoms when elevated (411) 
and we have yet to measure the serum levels in our Memo KO mice. 
With these two mouse models we have the ideal tools at hand to investigate these differences in the 
future. Thus far, the question remains if those differences are nonspecific and simply due to the 
cumulative effect of Memo loss in multiple organs or if there is a specific twist in the FGF23-Klotho 
axis, e.g. due to Memo knock out in the parathyroid gland, that finally leads to the destructive 
phenotype of premature aging.  
This study furthers our understanding of some of the mechanisms and key players in the processes of 
aging.  As the average age of our population is constantly increasing due to better hygienic conditions, 
advances in disease treatment and prevention, as well as other factors, the symptoms of aging are 
Outlook and Discussion 
158 
 
becoming most influential on our quality of life. Deciphering the manner in which we age at a 
molecular level will hopefully lead to new developments for treatments of age related diseases, 
providing us all with better quality of life in our later years.   
References 
159 
 
9 References 
1. Plachov, D., Chowdhury, K., Walther, C., Simon, D., Guenet, J.L., and Gruss, P. 1990. Pax8, a 
murine paired box gene expressed in the developing excretory system and thyroid gland. 
Development 110:643-651. 
2. Olayioye, M.A., Neve, R.M., Lane, H.A., and Hynes, N.E. 2000. The ErbB signaling network: 
receptor heterodimerization in development and cancer. EMBO J 19:3159-3167. 
3. Heldin, C.H. 1996. Protein tyrosine kinase receptors. Cancer Surv 27:7-24. 
4. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. 1987. 
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu 
oncogene. Science 235:177-182. 
5. Qiu, C., Lienhard, S., Hynes, N.E., Badache, A., and Leahy, D.J. 2008. Memo is homologous to 
nonheme iron dioxygenases and binds an ErbB2-derived phosphopeptide in its vestigial active 
site. J Biol Chem 283:2734-2740. 
6. Marone, R., Hess, D., Dankort, D., Muller, W.J., Hynes, N.E., and Badache, A. 2004. Memo 
mediates ErbB2-driven cell motility. Nat Cell Biol 6:515-522. 
7. Feracci, M., Pimentel, C., Bornet, O., Roche, P., Salaun, D., Badache, A., and Guerlesquin, F. 
2011. MEMO associated with an ErbB2 receptor phosphopeptide reveals a new 
phosphotyrosine motif. FEBS Lett 585:2688-2692. 
8. Zaoui, K., Honore, S., Isnardon, D., Braguer, D., and Badache, A. 2008. Memo-RhoA-mDia1 
signaling controls microtubules, the actin network, and adhesion site formation in migrating 
cells. J Cell Biol 183:401-408. 
9. Meira, M., Masson, R., Stagljar, I., Lienhard, S., Maurer, F., Boulay, A., and Hynes, N.E. 2009. 
Memo is a cofilin-interacting protein that influences PLCgamma1 and cofilin activities, and is 
essential for maintaining directionality during ErbB2-induced tumor-cell migration. J Cell Sci 
122:787-797. 
10. Martin, G.R. 1998. The roles of FGFs in the early development of vertebrate limbs. Genes Dev 
12:1571-1586. 
11. Kato, S., and Sekine, K. 1999. FGF-FGFR signaling in vertebrate organogenesis. Cell Mol Biol 
(Noisy-le-grand) 45:631-638. 
12. Powers, C.J., McLeskey, S.W., and Wellstein, A. 2000. Fibroblast growth factors, their receptors 
and signaling. Endocr Relat Cancer 7:165-197. 
13. Dillon, C., Spencer-Dene, B., and Dickson, C. 2004. A crucial role for fibroblast growth factor 
signaling in embryonic mammary gland development. J Mammary Gland Biol Neoplasia 9:207-
215. 
14. Mailleux, A.A., Spencer-Dene, B., Dillon, C., Ndiaye, D., Savona-Baron, C., Itoh, N., Kato, S., 
Dickson, C., Thiery, J.P., and Bellusci, S. 2002. Role of FGF10/FGFR2b signaling during 
mammary gland development in the mouse embryo. Development 129:53-60. 
15. Lu, P., Ewald, A.J., Martin, G.R., and Werb, Z. 2008. Genetic mosaic analysis reveals FGF 
receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev 
Biol 321:77-87. 
16. Parsa, S., Ramasamy, S.K., De Langhe, S., Gupte, V.V., Haigh, J.J., Medina, D., and Bellusci, S. 
2008. Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling. 
Dev Biol 317:121-131. 
References 
160 
 
17. Yu, C., Wang, F., Kan, M., Jin, C., Jones, R.B., Weinstein, M., Deng, C.X., and McKeehan, 
W.L. 2000. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane 
tyrosine kinase receptor FGFR4. J Biol Chem 275:15482-15489. 
18. Holt, J.A., Luo, G., Billin, A.N., Bisi, J., McNeill, Y.Y., Kozarsky, K.F., Donahee, M., Wang, 
D.Y., Mansfield, T.A., Kliewer, S.A., et al. 2003. Definition of a novel growth factor-dependent 
signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17:1581-1591. 
19. White, K.E., Jonsson, K.B., Carn, G., Hampson, G., Spector, T.D., Mannstadt, M., Lorenz-
Depiereux, B., Miyauchi, A., Yang, I.M., Ljunggren, O., et al. 2001. The autosomal dominant 
hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that 
cause phosphate wasting. J Clin Endocrinol Metab 86:497-500. 
20. White, K.E., Carn, G., Lorenz-Depiereux, B., Benet-Pages, A., Strom, T.M., and Econs, M.J. 
2001. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. 
Kidney Int 60:2079-2086. 
21. Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., 
Fukumoto, S., and Yamashita, T. 2001. Cloning and characterization of FGF23 as a causative 
factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98:6500-6505. 
22. Yamashita, T., Konishi, M., Miyake, A., Inui, K., and Itoh, N. 2002. Fibroblast growth factor 
(FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein 
kinase pathway. J Biol Chem 277:28265-28270. 
23. Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., 
Tomizuka, K., and Yamashita, T. 2004. Targeted ablation of Fgf23 demonstrates an essential 
physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-
568. 
24. Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, 
K., Fukumoto, S., and Yamashita, T. 2004. FGF-23 is a potent regulator of vitamin D 
metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435. 
25. Murakami, M., and Simons, M. 2008. Fibroblast growth factor regulation of neovascularization. 
Curr Opin Hematol 15:215-220. 
26. Miraoui, H., and Marie, P.J. 2010. Fibroblast growth factor receptor signaling crosstalk in 
skeletogenesis. Sci Signal 3:re9. 
27. Dode, C., Levilliers, J., Dupont, J.M., De Paepe, A., Le Du, N., Soussi-Yanicostas, N., Coimbra, 
R.S., Delmaghani, S., Compain-Nouaille, S., Baverel, F., et al. 2003. Loss-of-function 
mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 33:463-465. 
28. DiMeglio, L.A., and Econs, M.J. 2001. Hypophosphatemic rickets. Rev Endocr Metab Disord 
2:165-173. 
29. Econs, M.J. 1999. New insights into the pathogenesis of inherited phosphate wasting disorders. 
Bone 25:131-135. 
30. Dickson, C., Spencer-Dene, B., Dillon, C., and Fantl, V. 2000. Tyrosine kinase signalling in 
breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res 2:191-196. 
31. Moroni, E., Dell'Era, P., Rusnati, M., and Presta, M. 2002. Fibroblast growth factors and their 
receptors in hematopoiesis and hematological tumors. J Hematother Stem Cell Res 11:19-32. 
32. Cronauer, M.V., Schulz, W.A., Seifert, H.H., Ackermann, R., and Burchardt, M. 2003. 
Fibroblast growth factors and their receptors in urological cancers: basic research and clinical 
implications. Eur Urol 43:309-319. 
33. Hunter, T. 2000. Signaling--2000 and beyond. Cell 100:113-127. 
References 
161 
 
34. Schlessinger, J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103:211-225. 
35. Schlessinger, J., Plotnikov, A.N., Ibrahimi, O.A., Eliseenkova, A.V., Yeh, B.K., Yayon, A., 
Linhardt, R.J., and Mohammadi, M. 2000. Crystal structure of a ternary FGF-FGFR-heparin 
complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6:743-750. 
36. Ong, S.H., Guy, G.R., Hadari, Y.R., Laks, S., Gotoh, N., Schlessinger, J., and Lax, I. 2000. 
FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on 
fibroblast growth factor and nerve growth factor receptors. Mol Cell Biol 20:979-989. 
37. Dhalluin, C., Yan, K.S., Plotnikova, O., Lee, K.W., Zeng, L., Kuti, M., Mujtaba, S., Goldfarb, 
M.P., and Zhou, M.M. 2000. Structural basis of SNT PTB domain interactions with distinct 
neurotrophic receptors. Mol Cell 6:921-929. 
38. Mohammadi, M., Dikic, I., Sorokin, A., Burgess, W.H., Jaye, M., and Schlessinger, J. 1996. 
Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and 
elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 
16:977-989. 
39. Mohammadi, M., Honegger, A.M., Rotin, D., Fischer, R., Bellot, F., Li, W., Dionne, C.A., Jaye, 
M., Rubinstein, M., and Schlessinger, J. 1991. A tyrosine-phosphorylated carboxy-terminal 
peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of 
phospholipase C-gamma 1. Mol Cell Biol 11:5068-5078. 
40. Deng, C.X., Wynshaw-Boris, A., Shen, M.M., Daugherty, C., Ornitz, D.M., and Leder, P. 1994. 
Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes 
Dev 8:3045-3057. 
41. Yamaguchi, T.P., Harpal, K., Henkemeyer, M., and Rossant, J. 1994. fgfr-1 is required for 
embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev 8:3032-
3044. 
42. Arman, E., Haffner-Krausz, R., Chen, Y., Heath, J.K., and Lonai, P. 1998. Targeted disruption of 
fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation 
mammalian development. Proc Natl Acad Sci U S A 95:5082-5087. 
43. Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G., and Ornitz, D.M. 1996. Skeletal 
overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 12:390-
397. 
44. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., and Leder, P. 1996. Fibroblast growth factor 
receptor 3 is a negative regulator of bone growth. Cell 84:911-921. 
45. Weinstein, M., Xu, X., Ohyama, K., and Deng, C.X. 1998. FGFR-3 and FGFR-4 function 
cooperatively to direct alveogenesis in the murine lung. Development 125:3615-3623. 
46. Yu, K., Herr, A.B., Waksman, G., and Ornitz, D.M. 2000. Loss of fibroblast growth factor 
receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci U S A 97:14536-
14541. 
47. Ornitz, D.M., and Itoh, N. 2001. Fibroblast growth factors. Genome Biol 2:REVIEWS3005. 
48. Mohammadi, M., Olsen, S.K., and Ibrahimi, O.A. 2005. Structural basis for fibroblast growth 
factor receptor activation. Cytokine Growth Factor Rev 16:107-137. 
49. Goetz, R., Beenken, A., Ibrahimi, O.A., Kalinina, J., Olsen, S.K., Eliseenkova, A.V., Xu, C., 
Neubert, T.A., Zhang, F., Linhardt, R.J., et al. 2007. Molecular insights into the klotho-
dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol 
Cell Biol 27:3417-3428. 
50. Cuevas, P., Carceller, F., Ortega, S., Zazo, M., Nieto, I., and Gimenez-Gallego, G. 1991. 
References 
162 
 
Hypotensive activity of fibroblast growth factor. Science 254:1208-1210. 
51. Cuevas, P., Garcia-Calvo, M., Carceller, F., Reimers, D., Zazo, M., Cuevas, B., Munoz-Willery, 
I., Martinez-Coso, V., Lamas, S., and Gimenez-Gallego, G. 1996. Correction of hypertension by 
normalization of endothelial levels of fibroblast growth factor and nitric oxide synthase in 
spontaneously hypertensive rats. Proc Natl Acad Sci U S A 93:11996-12001. 
52. Ware, J.A., and Simons, M. 1997. Angiogenesis in ischemic heart disease. Nat Med 3:158-164. 
53. Yanagisawa-Miwa, A., Uchida, Y., Nakamura, F., Tomaru, T., Kido, H., Kamijo, T., Sugimoto, 
T., Kaji, K., Utsuyama, M., Kurashima, C., et al. 1992. Salvage of infarcted myocardium by 
angiogenic action of basic fibroblast growth factor. Science 257:1401-1403. 
54. Scholz, D., Cai, W.J., and Schaper, W. 2001. Arteriogenesis, a new concept of vascular 
adaptation in occlusive disease. Angiogenesis 4:247-257. 
55. Khurana, R., and Simons, M. 2003. Insights from angiogenesis trials using fibroblast growth 
factor for advanced arteriosclerotic disease. Trends Cardiovasc Med 13:116-122. 
56. Sugi, Y., Ito, N., Szebenyi, G., Myers, K., Fallon, J.F., Mikawa, T., and Markwald, R.R. 2003. 
Fibroblast growth factor (FGF)-4 can induce proliferation of cardiac cushion mesenchymal cells 
during early valve leaflet formation. Dev Biol 258:252-263. 
57. Sun, X., Mariani, F.V., and Martin, G.R. 2002. Functions of FGF signalling from the apical 
ectodermal ridge in limb development. Nature 418:501-508. 
58. Feldman, B., Poueymirou, W., Papaioannou, V.E., DeChiara, T.M., and Goldfarb, M. 1995. 
Requirement of FGF-4 for postimplantation mouse development. Science 267:246-249. 
59. Hebert, J.M., Rosenquist, T., Gotz, J., and Martin, G.R. 1994. FGF5 as a regulator of the hair 
growth cycle: evidence from targeted and spontaneous mutations. Cell 78:1017-1025. 
60. Armand, A.S., Laziz, I., and Chanoine, C. 2006. FGF6 in myogenesis. Biochim Biophys Acta 
1763:773-778. 
61. Werner, S., Peters, K.G., Longaker, M.T., Fuller-Pace, F., Banda, M.J., and Williams, L.T. 1992. 
Large induction of keratinocyte growth factor expression in the dermis during wound healing. 
Proc Natl Acad Sci U S A 89:6896-6900. 
62. Baskin, L.S., Sutherland, R.S., Thomson, A.A., Nguyen, H.T., Morgan, D.M., Hayward, S.W., 
Hom, Y.K., DiSandro, M., and Cunha, G.R. 1997. Growth factors in bladder wound healing. J 
Urol 157:2388-2395. 
63. Ichimura, T., Finch, P.W., Zhang, G., Kan, M., and Stevens, J.L. 1996. Induction of FGF-7 after 
kidney damage: a possible paracrine mechanism for tubule repair. Am J Physiol 271:F967-976. 
64. Tekin, M., Hismi, B.O., Fitoz, S., Ozdag, H., Cengiz, F.B., Sirmaci, A., Aslan, I., Inceoglu, B., 
Yuksel-Konuk, E.B., Yilmaz, S.T., et al. 2007. Homozygous mutations in fibroblast growth 
factor 3 are associated with a new form of syndromic deafness characterized by inner ear 
agenesis, microtia, and microdontia. Am J Hum Genet 80:338-344. 
65. Min, H., Danilenko, D.M., Scully, S.A., Bolon, B., Ring, B.D., Tarpley, J.E., DeRose, M., and 
Simonet, W.S. 1998. Fgf-10 is required for both limb and lung development and exhibits 
striking functional similarity to Drosophila branchless. Genes Dev 12:3156-3161. 
66. Umemori, H., Linhoff, M.W., Ornitz, D.M., and Sanes, J.R. 2004. FGF22 and its close relatives 
are presynaptic organizing molecules in the mammalian brain. Cell 118:257-270. 
67. Liu, X.H., Aigner, A., Wellstein, A., and Ray, P.E. 2001. Up-regulation of a fibroblast growth 
factor binding protein in children with renal diseases. Kidney Int 59:1717-1728. 
68. O'Leary, D.D., Chou, S.J., and Sahara, S. 2007. Area patterning of the mammalian cortex. 
Neuron 56:252-269. 
References 
163 
 
69. Meyers, E.N., Lewandoski, M., and Martin, G.R. 1998. An Fgf8 mutant allelic series generated 
by Cre- and Flp-mediated recombination. Nat Genet 18:136-141. 
70. Xu, J., Liu, Z., and Ornitz, D.M. 2000. Temporal and spatial gradients of Fgf8 and Fgf17 
regulate proliferation and differentiation of midline cerebellar structures. Development 
127:1833-1843. 
71. Liu, Z., Xu, J., Colvin, J.S., and Ornitz, D.M. 2002. Coordination of chondrogenesis and 
osteogenesis by fibroblast growth factor 18. Genes Dev 16:859-869. 
72. Ohbayashi, N., Shibayama, M., Kurotaki, Y., Imanishi, M., Fujimori, T., Itoh, N., and Takada, S. 
2002. FGF18 is required for normal cell proliferation and differentiation during osteogenesis 
and chondrogenesis. Genes Dev 16:870-879. 
73. Colvin, J.S., Green, R.P., Schmahl, J., Capel, B., and Ornitz, D.M. 2001. Male-to-female sex 
reversal in mice lacking fibroblast growth factor 9. Cell 104:875-889. 
74. Colvin, J.S., White, A.C., Pratt, S.J., and Ornitz, D.M. 2001. Lung hypoplasia and neonatal 
death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme. 
Development 128:2095-2106. 
75. Lu, S.Y., Sheikh, F., Sheppard, P.C., Fresnoza, A., Duckworth, M.L., Detillieux, K.A., and 
Cattini, P.A. 2008. FGF-16 is required for embryonic heart development. Biochem Biophys Res 
Commun 373:270-274. 
76. Grose, R., and Dickson, C. 2005. Fibroblast growth factor signaling in tumorigenesis. Cytokine 
Growth Factor Rev 16:179-186. 
77. Aigner, A., Butscheid, M., Kunkel, P., Krause, E., Lamszus, K., Wellstein, A., and Czubayko, F. 
2001. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine 
stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 
92:510-517. 
78. Bottcher, R.T., Pollet, N., Delius, H., and Niehrs, C. 2004. The transmembrane protein XFLRT3 
forms a complex with FGF receptors and promotes FGF signalling. Nat Cell Biol 6:38-44. 
79. Casu, B. 1985. Structure and biological activity of heparin. Adv Carbohydr Chem Biochem 
43:51-134. 
80. Plotnikov, A.N., Schlessinger, J., Hubbard, S.R., and Mohammadi, M. 1999. Structural basis for 
FGF receptor dimerization and activation. Cell 98:641-650. 
81. Kjellen, L., and Lindahl, U. 1991. Proteoglycans: structures and interactions. Annu Rev 
Biochem 60:443-475. 
82. Rapraeger, A.C. 1993. The coordinated regulation of heparan sulfate, syndecans and cell 
behavior. Curr Opin Cell Biol 5:844-853. 
83. Gospodarowicz, D., and Cheng, J. 1986. Heparin protects basic and acidic FGF from 
inactivation. J Cell Physiol 128:475-484. 
84. Saksela, O., Moscatelli, D., Sommer, A., and Rifkin, D.B. 1988. Endothelial cell-derived 
heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. 
J Cell Biol 107:743-751. 
85. Vlodavsky, I., Folkman, J., Sullivan, R., Fridman, R., Ishai-Michaeli, R., Sasse, J., and 
Klagsbrun, M. 1987. Endothelial cell-derived basic fibroblast growth factor: synthesis and 
deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A 84:2292-2296. 
86. Baird, A., and Ling, N. 1987. Fibroblast growth factors are present in the extracellular matrix 
produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the 
neovascular response. Biochem Biophys Res Commun 142:428-435. 
References 
164 
 
87. Folkman, J., Klagsbrun, M., Sasse, J., Wadzinski, M., Ingber, D., and Vlodavsky, I. 1988. A 
heparin-binding angiogenic protein--basic fibroblast growth factor--is stored within basement 
membrane. Am J Pathol 130:393-400. 
88. Bashkin, P., Doctrow, S., Klagsbrun, M., Svahn, C.M., Folkman, J., and Vlodavsky, I. 1989. 
Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by 
heparitinase and heparin-like molecules. Biochemistry 28:1737-1743. 
89. Flaumenhaft, R., Moscatelli, D., Saksela, O., and Rifkin, D.B. 1989. Role of extracellular 
matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for 
long-term stimulation of plasminogen activator production and DNA synthesis. J Cell Physiol 
140:75-81. 
90. Schlessinger, J., Lax, I., and Lemmon, M. 1995. Regulation of growth factor activation by 
proteoglycans: what is the role of the low affinity receptors? Cell 83:357-360. 
91. Jacobs, A.L., Julian, J., Sahin, A.A., and Carson, D.D. 1997. Heparin/heparan sulfate interacting 
protein expression and functions in human breast cancer cells and normal breast epithelia. 
Cancer Res 57:5148-5154. 
92. Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., 
Kurabayashi, M., Kaname, T., Kume, E., et al. 1997. Mutation of the mouse klotho gene leads 
to a syndrome resembling ageing. Nature 390:45-51. 
93. Ito, S., Kinoshita, S., Shiraishi, N., Nakagawa, S., Sekine, S., Fujimori, T., and Nabeshima, Y.I. 
2000. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel 
Klotho family protein. Mech Dev 98:115-119. 
94. Davies, G., and Henrissat, B. 1995. Structures and mechanisms of glycosyl hydrolases. 
Structure 3:853-859. 
95. Wang, Q., Trimbur, D., Graham, R., Warren, R.A., and Withers, S.G. 1995. Identification of the 
acid/base catalyst in Agrobacterium faecalis beta-glucosidase by kinetic analysis of mutants. 
Biochemistry 34:14554-14562. 
96. Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K.P., Baum, M.G., 
Schiavi, S., Hu, M.C., Moe, O.W., et al. 2006. Regulation of fibroblast growth factor-23 
signaling by klotho. J Biol Chem 281:6120-6123. 
97. Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., 
Fukumoto, S., and Yamashita, T. 2006. Klotho converts canonical FGF receptor into a specific 
receptor for FGF23. Nature 444:770-774. 
98. Gotoh, N., Laks, S., Nakashima, M., Lax, I., and Schlessinger, J. 2004. FRS2 family docking 
proteins with overlapping roles in activation of MAP kinase have distinct spatial-temporal 
patterns of expression of their transcripts. FEBS Lett 564:14-18. 
99. Kodama, Y., Asai, N., Kawai, K., Jijiwa, M., Murakumo, Y., Ichihara, M., and Takahashi, M. 
2005. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 
96:143-148. 
100. Kurokawa, K., Iwashita, T., Murakami, H., Hayashi, H., Kawai, K., and Takahashi, M. 2001. 
Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal 
transduction. Oncogene 20:1929-1938. 
101. Melillo, R.M., Santoro, M., Ong, S.H., Billaud, M., Fusco, A., Hadari, Y.R., Schlessinger, J., 
and Lax, I. 2001. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic 
forms with the mitogen-activated protein kinase signaling cascade. Mol Cell Biol 21:4177-4187. 
102. Degoutin, J., Vigny, M., and Gouzi, J.Y. 2007. ALK activation induces Shc and FRS2 
References 
165 
 
recruitment: Signaling and phenotypic outcomes in PC12 cells differentiation. FEBS Lett 
581:727-734. 
103. Kouhara, H., Hadari, Y.R., Spivak-Kroizman, T., Schilling, J., Bar-Sagi, D., Lax, I., and 
Schlessinger, J. 1997. A lipid-anchored Grb2-binding protein that links FGF-receptor activation 
to the Ras/MAPK signaling pathway. Cell 89:693-702. 
104. Hadari, Y.R., Kouhara, H., Lax, I., and Schlessinger, J. 1998. Binding of Shp2 tyrosine 
phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. 
Mol Cell Biol 18:3966-3973. 
105. Eswarakumar, V.P., Lax, I., and Schlessinger, J. 2005. Cellular signaling by fibroblast growth 
factor receptors. Cytokine Growth Factor Rev 16:139-149. 
106. Altomare, D.A., and Testa, J.R. 2005. Perturbations of the AKT signaling pathway in human 
cancer. Oncogene 24:7455-7464. 
107. Lax, I., Wong, A., Lamothe, B., Lee, A., Frost, A., Hawes, J., and Schlessinger, J. 2002. The 
docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for 
signaling by FGF receptors. Mol Cell 10:709-719. 
108. Gotoh, N. 2008. Regulation of growth factor signaling by FRS2 family docking/scaffold 
adaptor proteins. Cancer Sci 99:1319-1325. 
109. Klint, P., and Claesson-Welsh, L. 1999. Signal transduction by fibroblast growth factor 
receptors. Front Biosci 4:D165-177. 
110. Falasca, M., Logan, S.K., Lehto, V.P., Baccante, G., Lemmon, M.A., and Schlessinger, J. 1998. 
Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane 
targeting. EMBO J 17:414-422. 
111. Hart, K.C., Robertson, S.C., Kanemitsu, M.Y., Meyer, A.N., Tynan, J.A., and Donoghue, D.J. 
2000. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. 
Oncogene 19:3309-3320. 
112. Kang, S., Elf, S., Dong, S., Hitosugi, T., Lythgoe, K., Guo, A., Ruan, H., Lonial, S., Khoury, 
H.J., Williams, I.R., et al. 2009. Fibroblast growth factor receptor 3 associates with and tyrosine 
phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic 
transformation. Mol Cell Biol 29:2105-2117. 
113. Thien, C.B., and Langdon, W.Y. 2001. Cbl: many adaptations to regulate protein tyrosine 
kinases. Nat Rev Mol Cell Biol 2:294-307. 
114. Wong, A., Lamothe, B., Lee, A., Schlessinger, J., and Lax, I. 2002. FRS2 alpha attenuates FGF 
receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl Acad Sci 
U S A 99:6684-6689. 
115. Zhao, Y., and Zhang, Z.Y. 2001. The mechanism of dephosphorylation of extracellular signal-
regulated kinase 2 by mitogen-activated protein kinase phosphatase 3. J Biol Chem 276:32382-
32391. 
116. Casci, T., Vinos, J., and Freeman, M. 1999. Sprouty, an intracellular inhibitor of Ras signaling. 
Cell 96:655-665. 
117. Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y., and Krasnow, M.A. 1998. sprouty encodes 
a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. 
Cell 92:253-263. 
118. Furthauer, M., Lin, W., Ang, S.L., Thisse, B., and Thisse, C. 2002. Sef is a feedback-induced 
antagonist of Ras/MAPK-mediated FGF signalling. Nat Cell Biol 4:170-174. 
119. Tsang, M., Friesel, R., Kudoh, T., and Dawid, I.B. 2002. Identification of Sef, a novel 
References 
166 
 
modulator of FGF signalling. Nat Cell Biol 4:165-169. 
120. Thisse, B., and Thisse, C. 2005. Functions and regulations of fibroblast growth factor signaling 
during embryonic development. Dev Biol 287:390-402. 
121. Tsang, M., and Dawid, I.B. 2004. Promotion and attenuation of FGF signaling through the Ras-
MAPK pathway. Sci STKE 2004:pe17. 
122. Francavilla, C., Cattaneo, P., Berezin, V., Bock, E., Ami, D., de Marco, A., Christofori, G., and 
Cavallaro, U. 2009. The binding of NCAM to FGFR1 induces a specific cellular response 
mediated by receptor trafficking. J Cell Biol 187:1101-1116. 
123. Chin, K., DeVries, S., Fridlyand, J., Spellman, P.T., Roydasgupta, R., Kuo, W.L., Lapuk, A., 
Neve, R.M., Qian, Z., Ryder, T., et al. 2006. Genomic and transcriptional aberrations linked to 
breast cancer pathophysiologies. Cancer Cell 10:529-541. 
124. Toyokawa, T., Yashiro, M., and Hirakawa, K. 2009. Co-expression of keratinocyte growth 
factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol Rep 21:875-
880. 
125. Behrens, C., Lin, H.Y., Lee, J.J., Raso, M.G., Hong, W.K., Wistuba, II, and Lotan, R. 2008. 
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor 
receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 14:6014-6022. 
126. Kwabi-Addo, B., Ozen, M., and Ittmann, M. 2004. The role of fibroblast growth factors and 
their receptors in prostate cancer. Endocr Relat Cancer 11:709-724. 
127. Chang, H., Stewart, A.K., Qi, X.Y., Li, Z.H., Yi, Q.L., and Trudel, S. 2005. 
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple 
myeloma. Blood 106:353-355. 
128. Allerstorfer, S., Sonvilla, G., Fischer, H., Spiegl-Kreinecker, S., Gauglhofer, C., Setinek, U., 
Czech, T., Marosi, C., Buchroithner, J., Pichler, J., et al. 2008. FGF5 as an oncogenic factor in 
human glioblastoma multiforme: autocrine and paracrine activities. Oncogene 27:4180-4190. 
129. Freier, K., Schwaenen, C., Sticht, C., Flechtenmacher, C., Muhling, J., Hofele, C., Radlwimmer, 
B., Lichter, P., and Joos, S. 2007. Recurrent FGFR1 amplification and high FGFR1 protein 
expression in oral squamous cell carcinoma (OSCC). Oral Oncol 43:60-66. 
130. Baird, K., Davis, S., Antonescu, C.R., Harper, U.L., Walker, R.L., Chen, Y., Glatfelter, A.A., 
Duray, P.H., and Meltzer, P.S. 2005. Gene expression profiling of human sarcomas: insights into 
sarcoma biology. Cancer Res 65:9226-9235. 
131. Nord, H., Segersten, U., Sandgren, J., Wester, K., Busch, C., Menzel, U., Komorowski, J., 
Dumanski, J.P., Malmstrom, P.U., and Diaz de Stahl, T. 2010. Focal amplifications are 
associated with high grade and recurrences in stage Ta bladder carcinoma. Int J Cancer 
126:1390-1402. 
132. Courjal, F., Cuny, M., Simony-Lafontaine, J., Louason, G., Speiser, P., Zeillinger, R., Rodriguez, 
C., and Theillet, C. 1997. Mapping of DNA amplifications at 15 chromosomal localizations in 
1875 breast tumors: definition of phenotypic groups. Cancer Res 57:4360-4367. 
133. Jacquemier, J., Adelaide, J., Parc, P., Penault-Llorca, F., Planche, J., deLapeyriere, O., and 
Birnbaum, D. 1994. Expression of the FGFR1 gene in human breast-carcinoma cells. Int J 
Cancer 59:373-378. 
134. Reis-Filho, J.S., Simpson, P.T., Turner, N.C., Lambros, M.B., Jones, C., Mackay, A., 
Grigoriadis, A., Sarrio, D., Savage, K., Dexter, T., et al. 2006. FGFR1 emerges as a potential 
therapeutic target for lobular breast carcinomas. Clin Cancer Res 12:6652-6662. 
135. Gorringe, K.L., Jacobs, S., Thompson, E.R., Sridhar, A., Qiu, W., Choong, D.Y., and Campbell, 
References 
167 
 
I.G. 2007. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian 
cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 13:4731-4739. 
136. Simon, R., Richter, J., Wagner, U., Fijan, A., Bruderer, J., Schmid, U., Ackermann, D., Maurer, 
R., Alund, G., Knonagel, H., et al. 2001. High-throughput tissue microarray analysis of 3p25 
(RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 
61:4514-4519. 
137. Missiaglia, E., Selfe, J., Hamdi, M., Williamson, D., Schaaf, G., Fang, C., Koster, J., 
Summersgill, B., Messahel, B., Versteeg, R., et al. 2009. Genomic imbalances in 
rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: 
an approach to identify candidate genes involved in tumor development. Genes Chromosomes 
Cancer 48:455-467. 
138. Kunii, K., Davis, L., Gorenstein, J., Hatch, H., Yashiro, M., Di Bacco, A., Elbi, C., and 
Lutterbach, B. 2008. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 
signaling for growth and survival. Cancer Res 68:2340-2348. 
139. Takeda, M., Arao, T., Yokote, H., Komatsu, T., Yanagihara, K., Sasaki, H., Yamada, Y., Tamura, 
T., Fukuoka, K., Kimura, H., et al. 2007. AZD2171 shows potent antitumor activity against 
gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor 
receptor. Clin Cancer Res 13:3051-3057. 
140. Rand, V., Huang, J., Stockwell, T., Ferriera, S., Buzko, O., Levy, S., Busam, D., Li, K., 
Edwards, J.B., Eberhart, C., et al. 2005. Sequence survey of receptor tyrosine kinases reveals 
mutations in glioblastomas. Proc Natl Acad Sci U S A 102:14344-14349. 
141. Chou, A., Dekker, N., and Jordan, R.C. 2009. Identification of novel fibroblast growth factor 
receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip. Oral Surg 
Oral Med Oral Pathol Oral Radiol Endod 107:535-541. 
142. Greenman, C., Stephens, P., Smith, R., Dalgliesh, G.L., Hunter, C., Bignell, G., Davies, H., 
Teague, J., Butler, A., Stevens, C., et al. 2007. Patterns of somatic mutation in human cancer 
genomes. Nature 446:153-158. 
143. Davies, H., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G., Teague, J., Butler, A., 
Edkins, S., Stevens, C., et al. 2005. Somatic mutations of the protein kinase gene family in 
human lung cancer. Cancer Res 65:7591-7595. 
144. Ruhe, J.E., Streit, S., Hart, S., Wong, C.H., Specht, K., Knyazev, P., Knyazeva, T., Tay, L.S., 
Loo, H.L., Foo, P., et al. 2007. Genetic alterations in the tyrosine kinase transcriptome of human 
cancer cell lines. Cancer Res 67:11368-11376. 
145. Tomlinson, D.C., Hurst, C.D., and Knowles, M.A. 2007. Knockdown by shRNA identifies 
S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 26:5889-
5899. 
146. van Rhijn, B.W., van Tilborg, A.A., Lurkin, I., Bonaventure, J., de Vries, A., Thiery, J.P., van 
der Kwast, T.H., Zwarthoff, E.C., and Radvanyi, F. 2002. Novel fibroblast growth factor 
receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal 
disorders. Eur J Hum Genet 10:819-824. 
147. van Rhijn, B.W., Montironi, R., Zwarthoff, E.C., Jobsis, A.C., and van der Kwast, T.H. 2002. 
Frequent FGFR3 mutations in urothelial papilloma. J Pathol 198:245-251. 
148. Stephens, P., Edkins, S., Davies, H., Greenman, C., Cox, C., Hunter, C., Bignell, G., Teague, J., 
Smith, R., Stevens, C., et al. 2005. A screen of the complete protein kinase gene family 
identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37:590-592. 
References 
168 
 
149. Jang, J.H., Shin, K.H., and Park, J.G. 2001. Mutations in fibroblast growth factor receptor 2 and 
fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. 
Cancer Res 61:3541-3543. 
150. Hernandez, S., de Muga, S., Agell, L., Juanpere, N., Esgueva, R., Lorente, J.A., Mojal, S., 
Serrano, S., and Lloreta, J. 2009. FGFR3 mutations in prostate cancer: association with low-
grade tumors. Mod Pathol 22:848-856. 
151. Dutt, A., Salvesen, H.B., Chen, T.H., Ramos, A.H., Onofrio, R.C., Hatton, C., Nicoletti, R., 
Winckler, W., Grewal, R., Hanna, M., et al. 2008. Drug-sensitive FGFR2 mutations in 
endometrial carcinoma. Proc Natl Acad Sci U S A 105:8713-8717. 
152. Ding, L., Getz, G., Wheeler, D.A., Mardis, E.R., McLellan, M.D., Cibulskis, K., Sougnez, C., 
Greulich, H., Muzny, D.M., Morgan, M.B., et al. 2008. Somatic mutations affect key pathways 
in lung adenocarcinoma. Nature 455:1069-1075. 
153. Pollock, P.M., Gartside, M.G., Dejeza, L.C., Powell, M.A., Mallon, M.A., Davies, H., 
Mohammadi, M., Futreal, P.A., Stratton, M.R., Trent, J.M., et al. 2007. Frequent activating 
FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with 
craniosynostosis and skeletal dysplasia syndromes. Oncogene 26:7158-7162. 
154. Chesi, M., Brents, L.A., Ely, S.A., Bais, C., Robbiani, D.F., Mesri, E.A., Kuehl, W.M., and 
Bergsagel, P.L. 2001. Activated fibroblast growth factor receptor 3 is an oncogene that 
contributes to tumor progression in multiple myeloma. Blood 97:729-736. 
155. Ornitz, D.M., and Marie, P.J. 2002. FGF signaling pathways in endochondral and 
intramembranous bone development and human genetic disease. Genes Dev 16:1446-1465. 
156. Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, 
D., Thiery, J.P., and Radvanyi, F. 1999. Frequent activating mutations of FGFR3 in human 
bladder and cervix carcinomas. Nat Genet 23:18-20. 
157. Rosty, C., Aubriot, M.H., Cappellen, D., Bourdin, J., Cartier, I., Thiery, J.P., Sastre-Garau, X., 
and Radvanyi, F. 2005. Clinical and biological characteristics of cervical neoplasias with 
FGFR3 mutation. Mol Cancer 4:15. 
158. Goriely, A., Hansen, R.M., Taylor, I.B., Olesen, I.A., Jacobsen, G.K., McGowan, S.J., Pfeifer, 
S.P., McVean, G.A., Meyts, E.R., and Wilkie, A.O. 2009. Activating mutations in FGFR3 and 
HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat Genet 
41:1247-1252. 
159. Naski, M.C., Wang, Q., Xu, J., and Ornitz, D.M. 1996. Graded activation of fibroblast growth 
factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 
13:233-237. 
160. di Martino, E., L'Hote, C.G., Kennedy, W., Tomlinson, D.C., and Knowles, M.A. 2009. Mutant 
fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in 
a cell type- and mutation-specific manner. Oncogene 28:4306-4316. 
161. Taylor, J.G.t., Cheuk, A.T., Tsang, P.S., Chung, J.Y., Song, Y.K., Desai, K., Yu, Y., Chen, Q.R., 
Shah, K., Youngblood, V., et al. 2009. Identification of FGFR4-activating mutations in human 
rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 
119:3395-3407. 
162. Jackson, C.C., Medeiros, L.J., and Miranda, R.N. 2010. 8p11 myeloproliferative syndrome: a 
review. Hum Pathol 41:461-476. 
163. Patnaik, M.M., and Tefferi, A. 2009. Molecular diagnosis of myeloproliferative neoplasms. 
Expert Rev Mol Diagn 9:481-492. 
References 
169 
 
164. Avet-Loiseau, H., Facon, T., Daviet, A., Godon, C., Rapp, M.J., Harousseau, J.L., Grosbois, B., 
and Bataille, R. 1999. 14q32 translocations and monosomy 13 observed in monoclonal 
gammopathy of undetermined significance delineate a multistep process for the oncogenesis of 
multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 59:4546-4550. 
165. Marsh, S.K., Bansal, G.S., Zammit, C., Barnard, R., Coope, R., Roberts-Clarke, D., Gomm, J.J., 
Coombes, R.C., and Johnston, C.L. 1999. Increased expression of fibroblast growth factor 8 in 
human breast cancer. Oncogene 18:1053-1060. 
166. Mattila, M.M., and Harkonen, P.L. 2007. Role of fibroblast growth factor 8 in growth and 
progression of hormonal cancer. Cytokine Growth Factor Rev 18:257-266. 
167. Murphy, T., Darby, S., Mathers, M.E., and Gnanapragasam, V.J. 2010. Evidence for distinct 
alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J 
Pathol 220:452-460. 
168. Theodorou, V., Kimm, M.A., Boer, M., Wessels, L., Theelen, W., Jonkers, J., and Hilkens, J. 
2007. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in 
mammary cancer. Nat Genet 39:759-769. 
169. Daphna-Iken, D., Shankar, D.B., Lawshe, A., Ornitz, D.M., Shackleford, G.M., and MacArthur, 
C.A. 1998. MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and 
ovarian stromal hyperplasia. Oncogene 17:2711-2717. 
170. MacArthur, C.A., Shankar, D.B., and Shackleford, G.M. 1995. Fgf-8, activated by proviral 
insertion, cooperates with the Wnt-1 transgene in murine mammary tumorigenesis. J Virol 
69:2501-2507. 
171. Giri, D., Ropiquet, F., and Ittmann, M. 1999. Alterations in expression of basic fibroblast 
growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 
5:1063-1071. 
172. Ropiquet, F., Giri, D., Kwabi-Addo, B., Mansukhani, A., and Ittmann, M. 2000. Increased 
expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate 
cancer. Cancer Res 60:4245-4250. 
173. Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., 
Omeroglu, G., Meterissian, S., Omeroglu, A., et al. 2008. Stromal gene expression predicts 
clinical outcome in breast cancer. Nat Med 14:518-527. 
174. Relf, M., LeJeune, S., Scott, P.A., Fox, S., Smith, K., Leek, R., Moghaddam, A., Whitehouse, 
R., Bicknell, R., and Harris, A.L. 1997. Expression of the angiogenic factors vascular 
endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor 
beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin 
in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969. 
175. Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G.D., Pham, T.A., 
Dillard-Telm, L., Tsai, S.P., Stephan, J.P., et al. 2002. A mouse model of hepatocellular 
carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic 
mice. Am J Pathol 160:2295-2307. 
176. Wang, Y., and Becker, D. 1997. Antisense targeting of basic fibroblast growth factor and 
fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and 
tumor growth. Nat Med 3:887-893. 
177. Abdel-Rahman, W.M., Kalinina, J., Shoman, S., Eissa, S., Ollikainen, M., Elomaa, O., 
Eliseenkova, A.V., Butzow, R., Mohammadi, M., and Peltomaki, P. 2008. Somatic FGF9 
mutations in colorectal and endometrial carcinomas associated with membranous beta-catenin. 
References 
170 
 
Hum Mutat 29:390-397. 
178. Birrer, M.J., Johnson, M.E., Hao, K., Wong, K.K., Park, D.C., Bell, A., Welch, W.R., 
Berkowitz, R.S., and Mok, S.C. 2007. Whole genome oligonucleotide-based array comparative 
genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for 
advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25:2281-2287. 
179. Marek, L., Ware, K.E., Fritzsche, A., Hercule, P., Helton, W.R., Smith, J.E., McDermott, L.A., 
Coldren, C.D., Nemenoff, R.A., Merrick, D.T., et al. 2009. Fibroblast growth factor (FGF) and 
FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 
75:196-207. 
180. Cha, J.Y., Lambert, Q.T., Reuther, G.W., and Der, C.J. 2008. Involvement of fibroblast growth 
factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 6:435-445. 
181. Ezzat, S., Zheng, L., Zhu, X.F., Wu, G.E., and Asa, S.L. 2002. Targeted expression of a human 
pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin 
Invest 109:69-78. 
182. Itoh, H., Hattori, Y., Sakamoto, H., Ishii, H., Kishi, T., Sasaki, H., Yoshida, T., Koono, M., 
Sugimura, T., and Terada, M. 1994. Preferential alternative splicing in cancer generates a K-sam 
messenger RNA with higher transforming activity. Cancer Res 54:3237-3241. 
183. Cha, J.Y., Maddileti, S., Mitin, N., Harden, T.K., and Der, C.J. 2009. Aberrant receptor 
internalization and enhanced FRS2-dependent signaling contribute to the transforming activity 
of the fibroblast growth factor receptor 2 IIIb C3 isoform. J Biol Chem 284:6227-6240. 
184. Savagner, P., Valles, A.M., Jouanneau, J., Yamada, K.M., and Thiery, J.P. 1994. Alternative 
splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-
mesenchymal transition in rat bladder carcinoma cells. Mol Biol Cell 5:851-862. 
185. Yan, G., Fukabori, Y., McBride, G., Nikolaropolous, S., and McKeehan, W.L. 1993. Exon 
switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor 
genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell 
Biol 13:4513-4522. 
186. Oltean, S., Sorg, B.S., Albrecht, T., Bonano, V.I., Brazas, R.M., Dewhirst, M.W., and Garcia-
Blanco, M.A. 2006. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in 
Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad 
Sci U S A 103:14116-14121. 
187. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D., Thompson, D., Ballinger, D.G., 
Struewing, J.P., Morrison, J., Field, H., Luben, R., et al. 2007. Genome-wide association study 
identifies novel breast cancer susceptibility loci. Nature 447:1087-1093. 
188. Hunter, D.J., Kraft, P., Jacobs, K.B., Cox, D.G., Yeager, M., Hankinson, S.E., Wacholder, S., 
Wang, Z., Welch, R., Hutchinson, A., et al. 2007. A genome-wide association study identifies 
alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 
39:870-874. 
189. Garcia-Closas, M., Hall, P., Nevanlinna, H., Pooley, K., Morrison, J., Richesson, D.A., Bojesen, 
S.E., Nordestgaard, B.G., Axelsson, C.K., Arias, J.I., et al. 2008. Heterogeneity of breast cancer 
associations with five susceptibility loci by clinical and pathological characteristics. PLoS 
Genet 4:e1000054. 
190. Bange, J., Prechtl, D., Cheburkin, Y., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., 
Muller, S., Gartner, S., Sures, I., et al. 2002. Cancer progression and tumor cell motility are 
associated with the FGFR4 Arg(388) allele. Cancer Res 62:840-847. 
References 
171 
 
191. Spinola, M., Leoni, V.P., Tanuma, J., Pettinicchio, A., Frattini, M., Signoroni, S., Agresti, R., 
Giovanazzi, R., Pilotti, S., Bertario, L., et al. 2005. FGFR4 Gly388Arg polymorphism and 
prognosis of breast and colorectal cancer. Oncol Rep 14:415-419. 
192. Fritzsche, S., Kenzelmann, M., Hoffmann, M.J., Muller, M., Engers, R., Grone, H.J., and 
Schulz, W.A. 2006. Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. 
Endocr Relat Cancer 13:839-849. 
193. Darby, S., Sahadevan, K., Khan, M.M., Robson, C.N., Leung, H.Y., and Gnanapragasam, V.J. 
2006. Loss of Sef (similar expression to FGF) expression is associated with high grade and 
metastatic prostate cancer. Oncogene 25:4122-4127. 
194. Zisman-Rozen, S., Fink, D., Ben-Izhak, O., Fuchs, Y., Brodski, A., Kraus, M.H., Bejar, J., and 
Ron, D. 2007. Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is 
common to a variety of human carcinomas. Oncogene 26:6093-6098. 
195. Abate-Shen, C., and Shen, M.M. 2007. FGF signaling in prostate tumorigenesis--new insights 
into epithelial-stromal interactions. Cancer Cell 12:495-497. 
196. Zhong, C., Saribekyan, G., Liao, C.P., Cohen, M.B., and Roy-Burman, P. 2006. Cooperation 
between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res 
66:2188-2194. 
197. Pardo, O.E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., and Seckl, M.J. 2002. Fibroblast 
growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent 
pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem 277:12040-
12046. 
198. Pardo, O.E., Lesay, A., Arcaro, A., Lopes, R., Ng, B.L., Warne, P.H., McNeish, I.A., Tetley, 
T.D., Lemoine, N.R., Mehmet, H., et al. 2003. Fibroblast growth factor 2-mediated translational 
control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung 
cancer cells. Mol Cell Biol 23:7600-7610. 
199. Pardo, O.E., Wellbrock, C., Khanzada, U.K., Aubert, M., Arozarena, I., Davidson, S., Bowen, 
F., Parker, P.J., Filonenko, V.V., Gout, I.T., et al. 2006. FGF-2 protects small cell lung cancer 
cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J 
25:3078-3088. 
200. Nomura, S., Yoshitomi, H., Takano, S., Shida, T., Kobayashi, S., Ohtsuka, M., Kimura, F., 
Shimizu, H., Yoshidome, H., Kato, A., et al. 2008. FGF10/FGFR2 signal induces cell migration 
and invasion in pancreatic cancer. Br J Cancer 99:305-313. 
201. Xian, W., Schwertfeger, K.L., Vargo-Gogola, T., and Rosen, J.M. 2005. Pleiotropic effects of 
FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J 
Cell Biol 171:663-673. 
202. Acevedo, V.D., Gangula, R.D., Freeman, K.W., Li, R., Zhang, Y., Wang, F., Ayala, G.E., 
Peterson, L.E., Ittmann, M., and Spencer, D.M. 2007. Inducible FGFR-1 activation leads to 
irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 
12:559-571. 
203. Winter, S.F., Acevedo, V.D., Gangula, R.D., Freeman, K.W., Spencer, D.M., and Greenberg, 
N.M. 2007. Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis 
with concomitant differential regulation of Ang-1 and Ang-2. Oncogene 26:4897-4907. 
204. Carmeliet, P., and Jain, R.K. 2000. Angiogenesis in cancer and other diseases. Nature 407:249-
257. 
205. Javerzat, S., Auguste, P., and Bikfalvi, A. 2002. The role of fibroblast growth factors in vascular 
References 
172 
 
development. Trends Mol Med 8:483-489. 
206. Cross, M.J., and Claesson-Welsh, L. 2001. FGF and VEGF function in angiogenesis: signalling 
pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22:201-207. 
207. Auguste, P., Gursel, D.B., Lemiere, S., Reimers, D., Cuevas, P., Carceller, F., Di Santo, J.P., and 
Bikfalvi, A. 2001. Inhibition of fibroblast growth factor/fibroblast growth factor receptor 
activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -
independent mechanisms. Cancer Res 61:1717-1726. 
208. Seghezzi, G., Patel, S., Ren, C.J., Gualandris, A., Pintucci, G., Robbins, E.S., Shapiro, R.L., 
Galloway, A.C., Rifkin, D.B., and Mignatti, P. 1998. Fibroblast growth factor-2 (FGF-2) 
induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of 
forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 141:1659-
1673. 
209. Liotta, L.A., Steeg, P.S., and Stetler-Stevenson, W.G. 1991. Cancer metastasis and angiogenesis: 
an imbalance of positive and negative regulation. Cell 64:327-336. 
210. Terranova, V.P., DiFlorio, R., Lyall, R.M., Hic, S., Friesel, R., and Maciag, T. 1985. Human 
endothelial cells are chemotactic to endothelial cell growth factor and heparin. J Cell Biol 
101:2330-2334. 
211. Stokes, C.L., Rupnick, M.A., Williams, S.K., and Lauffenburger, D.A. 1990. Chemotaxis of 
human microvessel endothelial cells in response to acidic fibroblast growth factor. Lab Invest 
63:657-668. 
212. Mattila, M.M., Ruohola, J.K., Valve, E.M., Tasanen, M.J., Seppanen, J.A., and Harkonen, P.L. 
2001. FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 
breast cancer cells. Oncogene 20:2791-2804. 
213. Gillis, P., Savla, U., Volpert, O.V., Jimenez, B., Waters, C.M., Panos, R.J., and Bouck, N.P. 
1999. Keratinocyte growth factor induces angiogenesis and protects endothelial barrier 
function. J Cell Sci 112 ( Pt 12):2049-2057. 
214. Underwood, P.A., Bean, P.A., and Gamble, J.R. 2002. Rate of endothelial expansion is 
controlled by cell:cell adhesion. Int J Biochem Cell Biol 34:55-69. 
215. Ricol, D., Cappellen, D., El Marjou, A., Gil-Diez-de-Medina, S., Girault, J.M., Yoshida, T., 
Ferry, G., Tucker, G., Poupon, M.F., Chopin, D., et al. 1999. Tumour suppressive properties of 
fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 18:7234-7243. 
216. Amann, T., Bataille, F., Spruss, T., Dettmer, K., Wild, P., Liedtke, C., Muhlbauer, M., Kiefer, P., 
Oefner, P.J., Trautwein, C., et al. 2010. Reduced expression of fibroblast growth factor receptor 
2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am J Pathol 176:1433-
1442. 
217. Yasumoto, H., Matsubara, A., Mutaguchi, K., Usui, T., and McKeehan, W.L. 2004. Restoration 
of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human 
prostate carcinoma PC-3 cells. Prostate 61:236-242. 
218. Katoh, M. 2009. FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer 
pathologies. J Invest Dermatol 129:1861-1867. 
219. Yu, C.E., Oshima, J., Fu, Y.H., Wijsman, E.M., Hisama, F., Alisch, R., Matthews, S., Nakura, J., 
Miki, T., Ouais, S., et al. 1996. Positional cloning of the Werner's syndrome gene. Science 
272:258-262. 
220. Bachrati, C.Z., and Hickson, I.D. 2003. RecQ helicases: suppressors of tumorigenesis and 
premature aging. Biochem J 374:577-606. 
References 
173 
 
221. Opresko, P.L., Cheng, W.H., and Bohr, V.A. 2004. Junction of RecQ helicase biochemistry and 
human disease. J Biol Chem 279:18099-18102. 
222. Huang, S., Lee, L., Hanson, N.B., Lenaerts, C., Hoehn, H., Poot, M., Rubin, C.D., Chen, D.F., 
Yang, C.C., Juch, H., et al. 2006. The spectrum of WRN mutations in Werner syndrome 
patients. Hum Mutat 27:558-567. 
223. Uhrhammer, N.A., Lafarge, L., Dos Santos, L., Domaszewska, A., Lange, M., Yang, Y., 
Aractingi, S., Bessis, D., and Bignon, Y.J. 2006. Werner syndrome and mutations of the WRN 
and LMNA genes in France. Hum Mutat 27:718-719. 
224. Goto, M., Yamabe, Y., Shiratori, M., Okada, M., Kawabe, T., Matsumoto, T., Sugimoto, M., and 
Furuichi, Y. 1999. Immunological diagnosis of Werner syndrome by down-regulated and 
truncated gene products. Hum Genet 105:301-307. 
225. Moser, M.J., Kamath-Loeb, A.S., Jacob, J.E., Bennett, S.E., Oshima, J., and Monnat, R.J., Jr. 
2000. WRN helicase expression in Werner syndrome cell lines. Nucleic Acids Res 28:648-654. 
226. Opresko, P.L., Otterlei, M., Graakjaer, J., Bruheim, P., Dawut, L., Kolvraa, S., May, A., 
Seidman, M.M., and Bohr, V.A. 2004. The Werner syndrome helicase and exonuclease 
cooperate to resolve telomeric D loops in a manner regulated by TRF1 and TRF2. Mol Cell 
14:763-774. 
227. Chang, S., Multani, A.S., Cabrera, N.G., Naylor, M.L., Laud, P., Lombard, D., Pathak, S., 
Guarente, L., and DePinho, R.A. 2004. Essential role of limiting telomeres in the pathogenesis 
of Werner syndrome. Nat Genet 36:877-882. 
228. Du, X., Shen, J., Kugan, N., Furth, E.E., Lombard, D.B., Cheung, C., Pak, S., Luo, G., Pignolo, 
R.J., DePinho, R.A., et al. 2004. Telomere shortening exposes functions for the mouse Werner 
and Bloom syndrome genes. Mol Cell Biol 24:8437-8446. 
229. Crabbe, L., Verdun, R.E., Haggblom, C.I., and Karlseder, J. 2004. Defective telomere lagging 
strand synthesis in cells lacking WRN helicase activity. Science 306:1951-1953. 
230. Laud, P.R., Multani, A.S., Bailey, S.M., Wu, L., Ma, J., Kingsley, C., Lebel, M., Pathak, S., 
DePinho, R.A., and Chang, S. 2005. Elevated telomere-telomere recombination in WRN-
deficient, telomere dysfunctional cells promotes escape from senescence and engagement of the 
ALT pathway. Genes Dev 19:2560-2570. 
231. Eller, M.S., Liao, X., Liu, S., Hanna, K., Backvall, H., Opresko, P.L., Bohr, V.A., and Gilchrest, 
B.A. 2006. A role for WRN in telomere-based DNA damage responses. Proc Natl Acad Sci U S 
A 103:15073-15078. 
232. Lombard, D.B., Beard, C., Johnson, B., Marciniak, R.A., Dausman, J., Bronson, R., Buhlmann, 
J.E., Lipman, R., Curry, R., Sharpe, A., et al. 2000. Mutations in the WRN gene in mice 
accelerate mortality in a p53-null background. Mol Cell Biol 20:3286-3291. 
233. Lebel, M., and Leder, P. 1998. A deletion within the murine Werner syndrome helicase induces 
sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. Proc Natl 
Acad Sci U S A 95:13097-13102. 
234. Lebel, M., Cardiff, R.D., and Leder, P. 2001. Tumorigenic effect of nonfunctional p53 or p21 in 
mice mutant in the Werner syndrome helicase. Cancer Res 61:1816-1819. 
235. Wang, L., Ogburn, C.E., Ware, C.B., Ladiges, W.C., Youssoufian, H., Martin, G.M., and 
Oshima, J. 2000. Cellular Werner phenotypes in mice expressing a putative dominant-negative 
human WRN gene. Genetics 154:357-362. 
236. Smith, E.D., Kudlow, B.A., Frock, R.L., and Kennedy, B.K. 2005. A-type nuclear lamins, 
progerias and other degenerative disorders. Mech Ageing Dev 126:447-460. 
References 
174 
 
237. McKeon, F.D., Kirschner, M.W., and Caput, D. 1986. Homologies in both primary and 
secondary structure between nuclear envelope and intermediate filament proteins. Nature 
319:463-468. 
238. Stuurman, N., Heins, S., and Aebi, U. 1998. Nuclear lamins: their structure, assembly, and 
interactions. J Struct Biol 122:42-66. 
239. Spann, T.P., Goldman, A.E., Wang, C., Huang, S., and Goldman, R.D. 2002. Alteration of 
nuclear lamin organization inhibits RNA polymerase II-dependent transcription. J Cell Biol 
156:603-608. 
240. Ivorra, C., Kubicek, M., Gonzalez, J.M., Sanz-Gonzalez, S.M., Alvarez-Barrientos, A., 
O'Connor, J.E., Burke, B., and Andres, V. 2006. A mechanism of AP-1 suppression through 
interaction of c-Fos with lamin A/C. Genes Dev 20:307-320. 
241. Frock, R.L., Kudlow, B.A., Evans, A.M., Jameson, S.A., Hauschka, S.D., and Kennedy, B.K. 
2006. Lamin A/C and emerin are critical for skeletal muscle satellite cell differentiation. Genes 
Dev 20:486-500. 
242. Nitta, R.T., Jameson, S.A., Kudlow, B.A., Conlan, L.A., and Kennedy, B.K. 2006. Stabilization 
of the retinoblastoma protein by A-type nuclear lamins is required for INK4A-mediated cell 
cycle arrest. Mol Cell Biol 26:5360-5372. 
243. Rusinol, A.E., and Sinensky, M.S. 2006. Farnesylated lamins, progeroid syndromes and farnesyl 
transferase inhibitors. J Cell Sci 119:3265-3272. 
244. Hennekam, R.C. 2006. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J 
Med Genet A 140:2603-2624. 
245. Hutchinson, J. 1886. Congenital Absence of Hair and Mammary Glands with Atrophic 
Condition of the Skin and its Appendages, in a Boy whose Mother had been almost wholly Bald 
from Alopecia Areata from the age of Six. Med Chir Trans 69:473-477. 
246. Eriksson, M., Brown, W.T., Gordon, L.B., Glynn, M.W., Singer, J., Scott, L., Erdos, M.R., 
Robbins, C.M., Moses, T.Y., Berglund, P., et al. 2003. Recurrent de novo point mutations in 
lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423:293-298. 
247. De Sandre-Giovannoli, A., Bernard, R., Cau, P., Navarro, C., Amiel, J., Boccaccio, I., Lyonnet, 
S., Stewart, C.L., Munnich, A., Le Merrer, M., et al. 2003. Lamin a truncation in Hutchinson-
Gilford progeria. Science 300:2055. 
248. Cao, H., and Hegele, R.A. 2003. LMNA is mutated in Hutchinson-Gilford progeria (MIM 
176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090). J Hum 
Genet 48:271-274. 
249. Pendas, A.M., Zhou, Z., Cadinanos, J., Freije, J.M., Wang, J., Hultenby, K., Astudillo, A., 
Wernerson, A., Rodriguez, F., Tryggvason, K., et al. 2002. Defective prelamin A processing and 
muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet 
31:94-99. 
250. Kuro-o, M. 2010. A potential link between phosphate and aging--lessons from Klotho-deficient 
mice. Mech Ageing Dev 131:270-275. 
251. Razzaque, M.S., Sitara, D., Taguchi, T., St-Arnaud, R., and Lanske, B. 2006. Premature aging-
like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB 
J 20:720-722. 
252. Stubbs, J.R., Liu, S., Tang, W., Zhou, J., Wang, Y., Yao, X., and Quarles, L.D. 2007. Role of 
hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in 
fibroblastic growth factor 23 null mice. J Am Soc Nephrol 18:2116-2124. 
References 
175 
 
253. Tsujikawa, H., Kurotaki, Y., Fujimori, T., Fukuda, K., and Nabeshima, Y. 2003. Klotho, a gene 
related to a syndrome resembling human premature aging, functions in a negative regulatory 
circuit of vitamin D endocrine system. Mol Endocrinol 17:2393-2403. 
254. Ohnishi, M., Nakatani, T., Lanske, B., and Razzaque, M.S. 2009. Reversal of mineral ion 
homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 
1alpha-hydroxylase. Kidney Int 75:1166-1172. 
255. Hesse, M., Frohlich, L.F., Zeitz, U., Lanske, B., and Erben, R.G. 2007. Ablation of vitamin D 
signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 
26:75-84. 
256. Morishita, K., Shirai, A., Kubota, M., Katakura, Y., Nabeshima, Y., Takeshige, K., and Kamiya, 
T. 2001. The progression of aging in klotho mutant mice can be modified by dietary phosphorus 
and zinc. J Nutr 131:3182-3188. 
257. Ohnishi, M., and Razzaque, M.S. 2010. Dietary and genetic evidence for phosphate toxicity 
accelerating mammalian aging. FASEB J 24:3562-3571. 
258. Boer, V.M., Amini, S., and Botstein, D. 2008. Influence of genotype and nutrition on survival 
and metabolism of starving yeast. Proc Natl Acad Sci U S A 105:6930-6935. 
259. Brauer, M.J., Huttenhower, C., Airoldi, E.M., Rosenstein, R., Matese, J.C., Gresham, D., Boer, 
V.M., Troyanskaya, O.G., and Botstein, D. 2008. Coordination of growth rate, cell cycle, stress 
response, and metabolic activity in yeast. Mol Biol Cell 19:352-367. 
260. DeRisi, J.L., Iyer, V.R., and Brown, P.O. 1997. Exploring the metabolic and genetic control of 
gene expression on a genomic scale. Science 278:680-686. 
261. Cao, S.X., Dhahbi, J.M., Mote, P.L., and Spindler, S.R. 2001. Genomic profiling of short- and 
long-term caloric restriction effects in the liver of aging mice. Proc Natl Acad Sci U S A 
98:10630-10635. 
262. Kayo, T., Allison, D.B., Weindruch, R., and Prolla, T.A. 2001. Influences of aging and caloric 
restriction on the transcriptional profile of skeletal muscle from rhesus monkeys. Proc Natl 
Acad Sci U S A 98:5093-5098. 
263. Lee, C.K., Klopp, R.G., Weindruch, R., and Prolla, T.A. 1999. Gene expression profile of aging 
and its retardation by caloric restriction. Science 285:1390-1393. 
264. Masoro, E.J. 2006. Dietary restriction-induced life extension: a broadly based biological 
phenomenon. Biogerontology 7:153-155. 
265. Wetter, T.J., Gazdag, A.C., Dean, D.J., and Cartee, G.D. 1999. Effect of calorie restriction on in 
vivo glucose metabolism by individual tissues in rats. Am J Physiol 276:E728-738. 
266. Xie, W., Li, Y., Mechin, M.C., and Van De Werve, G. 1999. Up-regulation of liver glucose-6-
phosphatase in rats fed with a P(i)-deficient diet. Biochem J 343 Pt 2:393-396. 
267. Xie, W., Tran, T.L., Finegood, D.T., and van de Werve, G. 2000. Dietary P(i) deprivation in rats 
affects liver cAMP, glycogen, key steps of gluconeogenesis and glucose production. Biochem J 
352 Pt 1:227-232. 
268. Clancy, D.J., Gems, D., Harshman, L.G., Oldham, S., Stocker, H., Hafen, E., Leevers, S.J., and 
Partridge, L. 2001. Extension of life-span by loss of CHICO, a Drosophila insulin receptor 
substrate protein. Science 292:104-106. 
269. Kenyon, C. 2005. The plasticity of aging: insights from long-lived mutants. Cell 120:449-460. 
270. Kenyon, C., Chang, J., Gensch, E., Rudner, A., and Tabtiang, R. 1993. A C. elegans mutant that 
lives twice as long as wild type. Nature 366:461-464. 
271. Morris, J.Z., Tissenbaum, H.A., and Ruvkun, G. 1996. A phosphatidylinositol-3-OH kinase 
References 
176 
 
family member regulating longevity and diapause in Caenorhabditis elegans. Nature 382:536-
539. 
272. Tatar, M., Kopelman, A., Epstein, D., Tu, M.P., Yin, C.M., and Garofalo, R.S. 2001. A mutant 
Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine 
function. Science 292:107-110. 
273. Nagai, T., Yamada, K., Kim, H.C., Kim, Y.S., Noda, Y., Imura, A., Nabeshima, Y., and 
Nabeshima, T. 2003. Cognition impairment in the genetic model of aging klotho gene mutant 
mice: a role of oxidative stress. FASEB J 17:50-52. 
274. Di Marco, G.S., Hausberg, M., Hillebrand, U., Rustemeyer, P., Wittkowski, W., Lang, D., and 
Pavenstadt, H. 2008. Increased inorganic phosphate induces human endothelial cell apoptosis in 
vitro. Am J Physiol Renal Physiol 294:F1381-1387. 
275. Bose, S., French, S., Evans, F.J., Joubert, F., and Balaban, R.S. 2003. Metabolic network control 
of oxidative phosphorylation: multiple roles of inorganic phosphate. J Biol Chem 278:39155-
39165. 
276. Papa, S., and Skulachev, V.P. 1997. Reactive oxygen species, mitochondria, apoptosis and 
aging. Mol Cell Biochem 174:305-319. 
277. Utsugi, T., Ohno, T., Ohyama, Y., Uchiyama, T., Saito, Y., Matsumura, Y., Aizawa, H., Itoh, H., 
Kurabayashi, M., Kawazu, S., et al. 2000. Decreased insulin production and increased insulin 
sensitivity in the klotho mutant mouse, a novel animal model for human aging. Metabolism 
49:1118-1123. 
278. Nishimura, T., Utsunomiya, Y., Hoshikawa, M., Ohuchi, H., and Itoh, N. 1999. Structure and 
expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 
1444:148-151. 
279. Choi, M., Moschetta, A., Bookout, A.L., Peng, L., Umetani, M., Holmstrom, S.R., Suino-
Powell, K., Xu, H.E., Richardson, J.A., Gerard, R.D., et al. 2006. Identification of a hormonal 
basis for gallbladder filling. Nat Med 12:1253-1255. 
280. Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C.L., McDonald, J.G., Luo, G., Jones, 
S.A., Goodwin, B., Richardson, J.A., et al. 2005. Fibroblast growth factor 15 functions as an 
enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217-225. 
281. Ito, S., Fujimori, T., Furuya, A., Satoh, J., and Nabeshima, Y. 2005. Impaired negative feedback 
suppression of bile acid synthesis in mice lacking betaKlotho. J Clin Invest 115:2202-2208. 
282. Nishimura, T., Nakatake, Y., Konishi, M., and Itoh, N. 2000. Identification of a novel FGF, 
FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492:203-206. 
283. Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., 
Sandusky, G.E., Hammond, L.J., Moyers, J.S., Owens, R.A., et al. 2005. FGF-21 as a novel 
metabolic regulator. J Clin Invest 115:1627-1635. 
284. Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., and Maratos-Flier, E. 2007. 
Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic 
lipid metabolism in ketotic states. Cell Metab 5:426-437. 
285. Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., 
Mohammadi, M., Esser, V., et al. 2007. Endocrine regulation of the fasting response by 
PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5:415-425. 
286. Kurosu, H., Choi, M., Ogawa, Y., Dickson, A.S., Goetz, R., Eliseenkova, A.V., Mohammadi, 
M., Rosenblatt, K.P., Kliewer, S.A., and Kuro-o, M. 2007. Tissue-specific expression of 
betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity 
References 
177 
 
of FGF19 and FGF21. J Biol Chem 282:26687-26695. 
287. Ogawa, Y., Kurosu, H., Yamamoto, M., Nandi, A., Rosenblatt, K.P., Goetz, R., Eliseenkova, 
A.V., Mohammadi, M., and Kuro-o, M. 2007. BetaKlotho is required for metabolic activity of 
fibroblast growth factor 21. Proc Natl Acad Sci U S A 104:7432-7437. 
288. Quarles, L.D. 2003. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and 
skeletal mineralization. Am J Physiol Endocrinol Metab 285:E1-9. 
289. Schiavi, S.C., and Kumar, R. 2004. The phosphatonin pathway: new insights in phosphate 
homeostasis. Kidney Int 65:1-14. 
290. White, K.E., Koller, D.L., Takacs, I., Buckwalter, K.A., Foroud, T., and Econs, M.J. 1999. 
Locus heterogeneity of autosomal dominant osteopetrosis (ADO). J Clin Endocrinol Metab 
84:1047-1051. 
291. Yamashita, T., Yoshioka, M., and Itoh, N. 2000. Identification of a novel fibroblast growth 
factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. 
Biochem Biophys Res Commun 277:494-498. 
292. Yamashita, T. 2005. Structural and biochemical properties of fibroblast growth factor 23. Ther 
Apher Dial 9:313-318. 
293. Feng, J.Q., Ward, L.M., Liu, S., Lu, Y., Xie, Y., Yuan, B., Yu, X., Rauch, F., Davis, S.I., Zhang, 
S., et al. 2006. Loss of DMP1 causes rickets and osteomalacia and identifies a role for 
osteocytes in mineral metabolism. Nat Genet 38:1310-1315. 
294. Lorenz-Depiereux, B., Bastepe, M., Benet-Pages, A., Amyere, M., Wagenstaller, J., Muller-
Barth, U., Badenhoop, K., Kaiser, S.M., Rittmaster, R.S., Shlossberg, A.H., et al. 2006. DMP1 
mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the 
regulation of phosphate homeostasis. Nat Genet 38:1248-1250. 
295. Topaz, O., Indelman, M., Chefetz, I., Geiger, D., Metzker, A., Altschuler, Y., Choder, M., 
Bercovich, D., Uitto, J., Bergman, R., et al. 2006. A deleterious mutation in SAMD9 causes 
normophosphatemic familial tumoral calcinosis. Am J Hum Genet 79:759-764. 
296. Liu, S., Gupta, A., and Quarles, L.D. 2007. Emerging role of fibroblast growth factor 23 in a 
bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix 
mineralization. Curr Opin Nephrol Hypertens 16:329-335. 
297. Miller, W.L., and Portale, A.A. 2000. Vitamin D 1 alpha-hydroxylase. Trends Endocrinol Metab 
11:315-319. 
298. Henry, H.L. 2001. The 25(OH)D(3)/1alpha,25(OH)(2)D(3)-24R-hydroxylase: a catabolic or 
biosynthetic enzyme? Steroids 66:391-398. 
299. Yoshida, T., Fujimori, T., and Nabeshima, Y. 2002. Mediation of unusually high concentrations 
of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of 
renal 1alpha-hydroxylase gene. Endocrinology 143:683-689. 
300. Segawa, H., Yamanaka, S., Ohno, Y., Onitsuka, A., Shiozawa, K., Aranami, F., Furutani, J., 
Tomoe, Y., Ito, M., Kuwahata, M., et al. 2007. Correlation between hyperphosphatemia and 
type II Na-Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol 292:F769-779. 
301. Hu, M.C., Shi, M., Zhang, J., Pastor, J., Nakatani, T., Lanske, B., Razzaque, M.S., Rosenblatt, 
K.P., Baum, M.G., Kuro-o, M., et al. 2010. Klotho: a novel phosphaturic substance acting as an 
autocrine enzyme in the renal proximal tubule. FASEB J 24:3438-3450. 
302. Hurwitz, S. 1996. Homeostatic control of plasma calcium concentration. Crit Rev Biochem Mol 
Biol 31:41-100. 
303. Muller, D., Hoenderop, J.G., Merkx, G.F., van Os, C.H., and Bindels, R.J. 2000. Gene structure 
References 
178 
 
and chromosomal mapping of human epithelial calcium channel. Biochem Biophys Res 
Commun 275:47-52. 
304. Weber, K., Erben, R.G., Rump, A., and Adamski, J. 2001. Gene structure and regulation of the 
murine epithelial calcium channels ECaC1 and 2. Biochem Biophys Res Commun 289:1287-
1294. 
305. Hoenderop, J.G., Dardenne, O., Van Abel, M., Van Der Kemp, A.W., Van Os, C.H., St -Arnaud, 
R., and Bindels, R.J. 2002. Modulation of renal Ca2+ transport protein genes by dietary Ca2+ 
and 1,25-dihydroxyvitamin D3 in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice. 
FASEB J 16:1398-1406. 
306. Hoenderop, J.G., Muller, D., Van Der Kemp, A.W., Hartog, A., Suzuki, M., Ishibashi, K., Imai, 
M., Sweep, F., Willems, P.H., Van Os, C.H., et al. 2001. Calcitriol controls the epithelial 
calcium channel in kidney. J Am Soc Nephrol 12:1342-1349. 
307. Inoue, Y., Segawa, H., Kaneko, I., Yamanaka, S., Kusano, K., Kawakami, E., Furutani, J., Ito, 
M., Kuwahata, M., Saito, H., et al. 2005. Role of the vitamin D receptor in FGF23 action on 
phosphate metabolism. Biochem J 390:325-331. 
308. Shimada, T., Yamazaki, Y., Takahashi, M., Hasegawa, H., Urakawa, I., Oshima, T., Ono, K., 
Kakitani, M., Tomizuka, K., Fujita, T., et al. 2005. Vitamin D receptor-independent FGF23 
actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 
289:F1088-1095. 
309. 2000. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. 
Nat Genet 26:345-348. 
310. Bianchine, J.W., Stambler, A.A., and Harrison, H.E. 1971. Familial hypophosphatemic rickets 
showing autosomal dominant inheritance. Birth Defects Orig Artic Ser 7:287-295. 
311. Silve, C., and Beck, L. 2002. Is FGF23 the long sought after phosphaturic factor phosphatonin? 
Nephrol Dial Transplant 17:958-961. 
312. Shimada, T., Muto, T., Urakawa, I., Yoneya, T., Yamazaki, Y., Okawa, K., Takeuchi, Y., Fujita, 
T., Fukumoto, S., and Yamashita, T. 2002. Mutant FGF-23 responsible for autosomal dominant 
hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in 
vivo. Endocrinology 143:3179-3182. 
313. Jonsson, K.B., Zahradnik, R., Larsson, T., White, K.E., Sugimoto, T., Imanishi, Y., Yamamoto, 
T., Hampson, G., Koshiyama, H., Ljunggren, O., et al. 2003. Fibroblast growth factor 23 in 
oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663. 
314. Econs, M.J., and Drezner, M.K. 1994. Tumor-induced osteomalacia--unveiling a new hormone. 
N Engl J Med 330:1679-1681. 
315. Cai, Q., Hodgson, S.F., Kao, P.C., Lennon, V.A., Klee, G.G., Zinsmiester, A.R., and Kumar, R. 
1994. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with 
oncogenic osteomalacia. N Engl J Med 330:1645-1649. 
316. Rowe, P.S., de Zoysa, P.A., Dong, R., Wang, H.R., White, K.E., Econs, M.J., and Oudet, C.L. 
2000. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. 
Genomics 67:54-68. 
317. Carpenter, T.O., Ellis, B.K., Insogna, K.L., Philbrick, W.M., Sterpka, J., and Shimkets, R. 2005. 
Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic 
osteomalacia-causing tumors. J Clin Endocrinol Metab 90:1012-1020. 
318. Berndt, T., Craig, T.A., Bowe, A.E., Vassiliadis, J., Reczek, D., Finnegan, R., Jan De Beur, 
S.M., Schiavi, S.C., and Kumar, R. 2003. Secreted frizzled-related protein 4 is a potent tumor-
References 
179 
 
derived phosphaturic agent. J Clin Invest 112:785-794. 
319. Folpe, A.L., Fanburg-Smith, J.C., Billings, S.D., Bisceglia, M., Bertoni, F., Cho, J.Y., Econs, 
M.J., Inwards, C.Y., Jan de Beur, S.M., Mentzel, T., et al. 2004. Most osteomalacia-associated 
mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a 
comprehensive review of the literature. Am J Surg Pathol 28:1-30. 
320. Jan de Beur, S.M. 2005. Tumor-induced osteomalacia. JAMA 294:1260-1267. 
321. Perry, W., and Stamp, T.C. 1978. Hereditary hypophosphataemic rickets with autosomal 
recessive inheritance and severe osteosclerosis. A report of two cases. J Bone Joint Surg Br 60-
B:430-434. 
322. Scriver, C.R., Reade, T., Halal, F., Costa, T., and Cole, D.E. 1981. Autosomal 
hypophosphataemic bone disease responds to 1,25-(OH)2D3. Arch Dis Child 56:203-207. 
323. Scriver, C.R., Reade, T.M., DeLuca, H.F., and Hamstra, A.J. 1978. Serum 1,25-
dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone 
disease. N Engl J Med 299:976-979. 
324. Drezner, M.K., Lyles, K.W., Haussler, M.R., and Harrelson, J.M. 1980. Evaluation of a role for 
1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic 
rickets and osteomalacia. J Clin Invest 66:1020-1032. 
325. Fukase, M., Avioli, L.V., Birge, S.J., and Chase, L.R. 1984. Abnormal regulation of 25-
hydroxyvitamin D3-1 alpha-hydroxylase activity by calcium and calcitonin in renal cortex from 
hypophosphatemic (Hyp) mice. Endocrinology 114:1203-1207. 
326. Tenenhouse, H.S., and Jones, G. 1990. Abnormal regulation of renal vitamin D catabolism by 
dietary phosphate in murine X-linked hypophosphatemic rickets. J Clin Invest 85:1450-1455. 
327. Ichikawa, S., Imel, E.A., Kreiter, M.L., Yu, X., Mackenzie, D.S., Sorenson, A.H., Goetz, R., 
Mohammadi, M., White, K.E., and Econs, M.J. 2007. A homozygous missense mutation in 
human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117:2684-2691. 
328. Lyles, K.W., Burkes, E.J., Ellis, G.J., Lucas, K.J., Dolan, E.A., and Drezner, M.K. 1985. Genetic 
transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity. J 
Clin Endocrinol Metab 60:1093-1096. 
329. Topaz, O., Shurman, D.L., Bergman, R., Indelman, M., Ratajczak, P., Mizrachi, M., Khamaysi, 
Z., Behar, D., Petronius, D., Friedman, V., et al. 2004. Mutations in GALNT3, encoding a 
protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 
36:579-581. 
330. Fukagawa, M., and Kazama, J.J. 2005. With or without the kidney: the role of FGF23 in CKD. 
Nephrol Dial Transplant 20:1295-1298. 
331. Ben-Dov, I.Z., Galitzer, H., Lavi-Moshayoff, V., Goetz, R., Kuro-o, M., Mohammadi, M., 
Sirkis, R., Naveh-Many, T., and Silver, J. 2007. The parathyroid is a target organ for FGF23 in 
rats. J Clin Invest 117:4003-4008. 
332. Nakanishi, S., Kazama, J.J., Nii-Kono, T., Omori, K., Yamashita, T., Fukumoto, S., Gejyo, F., 
Shigematsu, T., and Fukagawa, M. 2005. Serum fibroblast growth factor-23 levels predict the 
future refractory hyperparathyroidism in dialysis patients. Kidney Int 67:1171-1178. 
333. Kazama, J.J., Sato, F., Omori, K., Hama, H., Yamamoto, S., Maruyama, H., Narita, I., Gejyo, F., 
Yamashita, T., Fukumoto, S., et al. 2005. Pretreatment serum FGF-23 levels predict the efficacy 
of calcitriol therapy in dialysis patients. Kidney Int 67:1120-1125. 
334. Matsumura, Y., Aizawa, H., Shiraki-Iida, T., Nagai, R., Kuro-o, M., and Nabeshima, Y. 1998. 
Identification of the human klotho gene and its two transcripts encoding membrane and secreted 
References 
180 
 
klotho protein. Biochem Biophys Res Commun 242:626-630. 
335. Ohyama, Y., Kurabayashi, M., Masuda, H., Nakamura, T., Aihara, Y., Kaname, T., Suga, T., 
Arai, M., Aizawa, H., Matsumura, Y., et al. 1998. Molecular cloning of rat klotho cDNA: 
markedly decreased expression of klotho by acute inflammatory stress. Biochem Biophys Res 
Commun 251:920-925. 
336. Shiraki-Iida, T., Aizawa, H., Matsumura, Y., Sekine, S., Iida, A., Anazawa, H., Nagai, R., Kuro-
o, M., and Nabeshima, Y. 1998. Structure of the mouse klotho gene and its two transcripts 
encoding membrane and secreted protein. FEBS Lett 424:6-10. 
337. Imura, A., Iwano, A., Tohyama, O., Tsuji, Y., Nozaki, K., Hashimoto, N., Fujimori, T., and 
Nabeshima, Y. 2004. Secreted Klotho protein in sera and CSF: implication for post-translational 
cleavage in release of Klotho protein from cell membrane. FEBS Lett 565:143-147. 
338. Takeshita, K., Fujimori, T., Kurotaki, Y., Honjo, H., Tsujikawa, H., Yasui, K., Lee, J.K., 
Kamiya, K., Kitaichi, K., Yamamoto, K., et al. 2004. Sinoatrial node dysfunction and early 
unexpected death of mice with a defect of klotho gene expression. Circulation 109:1776-1782. 
339. Kumar, R., and Thompson, J.R. 2011. The regulation of parathyroid hormone secretion and 
synthesis. J Am Soc Nephrol 22:216-224. 
340. de Groot, T., Bindels, R.J., and Hoenderop, J.G. 2008. TRPV5: an ingeniously controlled 
calcium channel. Kidney Int 74:1241-1246. 
341. Cha, S.K., Ortega, B., Kurosu, H., Rosenblatt, K.P., Kuro, O.M., and Huang, C.L. 2008. 
Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via 
binding to galectin-1. Proc Natl Acad Sci U S A 105:9805-9810. 
342. Imura, A., Tsuji, Y., Murata, M., Maeda, R., Kubota, K., Iwano, A., Obuse, C., Togashi, K., 
Tominaga, M., Kita, N., et al. 2007. alpha-Klotho as a regulator of calcium homeostasis. 
Science 316:1615-1618. 
343. Tohyama, O., Imura, A., Iwano, A., Freund, J.N., Henrissat, B., Fujimori, T., and Nabeshima, Y. 
2004. Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J 
Biol Chem 279:9777-9784. 
344. Hayes, G., Busch, A., Lotscher, M., Waldegger, S., Lang, F., Verrey, F., Biber, J., and Murer, H. 
1994. Role of N-linked glycosylation in rat renal Na/Pi-cotransport. J Biol Chem 269:24143-
24149. 
345. Virkki, L.V., Biber, J., Murer, H., and Forster, I.C. 2007. Phosphate transporters: a tale of two 
solute carrier families. Am J Physiol Renal Physiol 293:F643-654. 
346. Pfister, M.F., Ruf, I., Stange, G., Ziegler, U., Lederer, E., Biber, J., and Murer, H. 1998. 
Parathyroid hormone leads to the lysosomal degradation of the renal type II Na/Pi cotransporter. 
Proc Natl Acad Sci U S A 95:1909-1914. 
347. Kurosu, H., Yamamoto, M., Clark, J.D., Pastor, J.V., Nandi, A., Gurnani, P., McGuinness, O.P., 
Chikuda, H., Yamaguchi, M., Kawaguchi, H., et al. 2005. Suppression of aging in mice by the 
hormone Klotho. Science 309:1829-1833. 
348. Chateau, M.T., Araiz, C., Descamps, S., and Galas, S. 2010. Klotho interferes with a novel 
FGF-signalling pathway and insulin/Igf-like signalling to improve longevity and stress 
resistance in Caenorhabditis elegans. Aging (Albany NY) 2:567-581. 
349. Lorenzi, O., Veyrat-Durebex, C., Wollheim, C.B., Villemin, P., Rohner-Jeanrenaud, F., Zanchi, 
A., and Vischer, U.M. 2010. Evidence against a direct role of klotho in insulin resistance. 
Pflugers Arch 459:465-473. 
350. Wolf, I., Levanon-Cohen, S., Bose, S., Ligumsky, H., Sredni, B., Kanety, H., Kuro-o, M., 
References 
181 
 
Karlan, B., Kaufman, B., Koeffler, H.P., et al. 2008. Klotho: a tumor suppressor and a 
modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 27:7094-7105. 
351. Hsieh, C.C., Kuro-o, M., Rosenblatt, K.P., Brobey, R., and Papaconstantinou, J. 2010. The 
ASK1-Signalosome regulates p38 MAPK activity in response to levels of endogenous oxidative 
stress in the Klotho mouse models of aging. Aging (Albany NY) 2:597-611. 
352. Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, M., 
Miyazono, K., and Ichijo, H. 1998. Mammalian thioredoxin is a direct inhibitor of apoptosis 
signal-regulating kinase (ASK) 1. EMBO J 17:2596-2606. 
353. Liu, H., Nishitoh, H., Ichijo, H., and Kyriakis, J.M. 2000. Activation of apoptosis signal-
regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior 
dissociation of the ASK1 inhibitor thioredoxin. Mol Cell Biol 20:2198-2208. 
354. Papaconstantinou, J., and Hsieh, C.C. 2010. Activation of senescence and aging characteristics 
by mitochondrially generated ROS: how are they linked? Cell Cycle 9:3831-3833. 
355. Nishitoh, H., Saitoh, M., Mochida, Y., Takeda, K., Nakano, H., Rothe, M., Miyazono, K., and 
Ichijo, H. 1998. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 2:389-395. 
356. Matsuzawa, A., and Ichijo, H. 2005. Stress-responsive protein kinases in redox-regulated 
apoptosis signaling. Antioxid Redox Signal 7:472-481. 
357. Sumbayev, V.V., and Yasinska, I.M. 2005. Regulation of MAP kinase-dependent apoptotic 
pathway: implication of reactive oxygen and nitrogen species. Arch Biochem Biophys 436:406-
412. 
358. Toyama, R., Fujimori, T., Nabeshima, Y., Itoh, Y., Tsuji, Y., and Osamura, R.Y. 2006. Impaired 
regulation of gonadotropins leads to the atrophy of the female reproductive system in klotho-
deficient mice. Endocrinology 147:120-129. 
359. Kamemori, M., Ohyama, Y., Kurabayashi, M., Takahashi, K., Nagai, R., and Furuya, N. 2002. 
Expression of Klotho protein in the inner ear. Hear Res 171:103-110. 
360. Anamizu, Y., Kawaguchi, H., Seichi, A., Yamaguchi, S., Kawakami, E., Kanda, N., Matsubara, 
S., Kuro-o, M., Nabeshima, Y., Nakamura, K., et al. 2005. Klotho insufficiency causes decrease 
of ribosomal RNA gene transcription activity, cytoplasmic RNA and rough ER in the spinal 
anterior horn cells. Acta Neuropathol 109:457-466. 
361. Min, D., Panoskaltsis-Mortari, A., Kuro, O.M., Hollander, G.A., Blazar, B.R., and Weinberg, 
K.I. 2007. Sustained thymopoiesis and improvement in functional immunity induced by 
exogenous KGF administration in murine models of aging. Blood 109:2529-2537. 
362. Kawaguchi, H., Manabe, N., Miyaura, C., Chikuda, H., Nakamura, K., and Kuro-o, M. 1999. 
Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting 
low-turnover osteopenia. J Clin Invest 104:229-237. 
363. Ishii, M., Yamaguchi, Y., Yamamoto, H., Hanaoka, Y., and Ouchi, Y. 2008. Airspace 
enlargement with airway cell apoptosis in klotho mice: a model of aging lung. J Gerontol A Biol 
Sci Med Sci 63:1289-1298. 
364. Sato, A., Hirai, T., Imura, A., Kita, N., Iwano, A., Muro, S., Nabeshima, Y., Suki, B., and 
Mishima, M. 2007. Morphological mechanism of the development of pulmonary emphysema in 
klotho mice. Proc Natl Acad Sci U S A 104:2361-2365. 
365. Suga, T., Kurabayashi, M., Sando, Y., Ohyama, Y., Maeno, T., Maeno, Y., Aizawa, H., 
Matsumura, Y., Kuwaki, T., Kuro, O.M., et al. 2000. Disruption of the klotho gene causes 
pulmonary emphysema in mice. Defect in maintenance of pulmonary integrity during postnatal 
life. Am J Respir Cell Mol Biol 22:26-33. 
References 
182 
 
366. Gery, S., Tanosaki, S., Bose, S., Bose, N., Vadgama, J., and Koeffler, H.P. 2005. Down-
regulation and growth inhibitory role of C/EBPalpha in breast cancer. Clin Cancer Res 11:3184-
3190. 
367. Gomis, R.R., Alarcon, C., Nadal, C., Van Poznak, C., and Massague, J. 2006. C/EBPbeta at the 
core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer 
Cell 10:203-214. 
368. Wolf, I., O'Kelly, J., Rubinek, T., Tong, M., Nguyen, A., Lin, B.T., Tai, H.H., Karlan, B.Y., and 
Koeffler, H.P. 2006. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human 
breast cancer. Cancer Res 66:7818-7823. 
369. Wolf, I., Laitman, Y., Rubinek, T., Abramovitz, L., Novikov, I., Beeri, R., Kuro, O.M., Koeffler, 
H.P., Catane, R., Freedman, L.S., et al. 2010. Functional variant of KLOTHO: a breast cancer 
risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Oncogene 29:26-33. 
370. Hudelist, G., Wagner, T., Rosner, M., Fink-Retter, A., Gschwantler-Kaulich, D., Czerwenka, K., 
Kroiss, R., Tea, M., Pischinger, K., Kostler, W.J., et al. 2007. Intratumoral IGF-I protein 
expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. Endocr 
Relat Cancer 14:1053-1062. 
371. Maor, S., Yosepovich, A., Papa, M.Z., Yarden, R.I., Mayer, D., Friedman, E., and Werner, H. 
2007. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors 
associated with BRCA1 mutations. Cancer Lett 257:236-243. 
372. Gattineni, J., Bates, C., Twombley, K., Dwarakanath, V., Robinson, M.L., Goetz, R., 
Mohammadi, M., and Baum, M. 2009. FGF23 decreases renal NaPi-2a and NaPi-2c expression 
and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal 
Physiol 297:F282-291. 
373. Ranch, D., Zhang, M.Y., Portale, A.A., and Perwad, F. 2011. Fibroblast growth factor 23 
regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase 
signaling pathway in Hyp mice. J Bone Miner Res 26:1883-1890. 
374. Weisman, Y., Harell, A., Edelstein, S., David, M., Spirer, Z., and Golander, A. 1979. 1 alpha, 
25-Dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua 
and placenta. Nature 281:317-319. 
375. Gray, T.K., Lester, G.E., and Lorenc, R.S. 1979. Evidence for extra-renal 1 alpha-hydroxylation 
of 25-hydroxyvitamin D3 in pregnancy. Science 204:1311-1313. 
376. Stoffels, K., Overbergh, L., Bouillon, R., and Mathieu, C. 2007. Immune regulation of 1alpha-
hydroxylase in murine peritoneal macrophages: unravelling the IFNgamma pathway. J Steroid 
Biochem Mol Biol 103:567-571. 
377. Esteban, L., Vidal, M., and Dusso, A. 2004. 1alpha-Hydroxylase transactivation by gamma-
interferon in murine macrophages requires enhanced C/EBPbeta expression and activation. J 
Steroid Biochem Mol Biol 89-90:131-137. 
378. Dusso, A.S., Brown, A.J., and Slatopolsky, E. 2005. Vitamin D. Am J Physiol Renal Physiol 
289:F8-28. 
379. Gorham, E.D., Garland, C.F., Garland, F.C., Grant, W.B., Mohr, S.B., Lipkin, M., Newmark, 
H.L., Giovannucci, E., Wei, M., and Holick, M.F. 2007. Optimal vitamin D status for colorectal 
cancer prevention: a quantitative meta analysis. Am J Prev Med 32:210-216. 
380. Skinner, H.G., Michaud, D.S., Giovannucci, E., Willett, W.C., Colditz, G.A., and Fuchs, C.S. 
2006. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer 
Epidemiol Biomarkers Prev 15:1688-1695. 
References 
183 
 
381. Giovannucci, E., Liu, Y., Rimm, E.B., Hollis, B.W., Fuchs, C.S., Stampfer, M.J., and Willett, 
W.C. 2006. Prospective study of predictors of vitamin D status and cancer incidence and 
mortality in men. J Natl Cancer Inst 98:451-459. 
382. Giovannucci, E. 2009. Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol 
19:84-88. 
383. Forster, R.E., Jurutka, P.W., Hsieh, J.C., Haussler, C.A., Lowmiller, C.L., Kaneko, I., Haussler, 
M.R., and Kerr Whitfield, G. 2011. Vitamin D receptor controls expression of the anti-aging 
klotho gene in mouse and human renal cells. Biochem Biophys Res Commun 414:557-562. 
384. Forster, I.C., Hernando, N., Biber, J., and Murer, H. 2006. Proximal tubular handling of 
phosphate: A molecular perspective. Kidney Int 70:1548-1559. 
385. Panda, D.K., Miao, D., Tremblay, M.L., Sirois, J., Farookhi, R., Hendy, G.N., and Goltzman, D. 
2001. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for 
skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A 98:7498-7503. 
386. Segawa, H., Onitsuka, A., Furutani, J., Kaneko, I., Aranami, F., Matsumoto, N., Tomoe, Y., 
Kuwahata, M., Ito, M., Matsumoto, M., et al. 2009. Npt2a and Npt2c in mice play distinct and 
synergistic roles in inorganic phosphate metabolism and skeletal development. Am J Physiol 
Renal Physiol 297:F671-678. 
387. Wohrle, S., Bonny, O., Beluch, N., Gaulis, S., Stamm, C., Scheibler, M., Muller, M., Kinzel, B., 
Thuery, A., Brueggen, J., et al. 2011. FGF receptors control vitamin D and phosphate 
homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J 
Bone Miner Res 26:2486-2497. 
388. Keisala, T., Minasyan, A., Lou, Y.R., Zou, J., Kalueff, A.V., Pyykko, I., and Tuohimaa, P. 2009. 
Premature aging in vitamin D receptor mutant mice. J Steroid Biochem Mol Biol 115:91-97. 
389. Kato, S., Takeyama, K., Kitanaka, S., Murayama, A., Sekine, K., and Yoshizawa, T. 1999. In 
vivo function of VDR in gene expression-VDR knock-out mice. J Steroid Biochem Mol Biol 
69:247-251. 
390. Eicher, E.M., Southard, J.L., Scriver, C.R., and Glorieux, F.H. 1976. Hypophosphatemia: mouse 
model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci 
U S A 73:4667-4671. 
391. Aono, Y., Yamazaki, Y., Yasutake, J., Kawata, T., Hasegawa, H., Urakawa, I., Fujita, T., Wada, 
M., Yamashita, T., Fukumoto, S., et al. 2009. Therapeutic effects of anti-FGF23 antibodies in 
hypophosphatemic rickets/osteomalacia. J Bone Miner Res 24:1879-1888. 
392. Matsuda, Y., Schlange, T., Oakeley, E.J., Boulay, A., and Hynes, N.E. 2009. WNT signaling 
enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses 
MDA-MB-231 xenograft growth. Breast Cancer Res 11:R32. 
393. Biber, J., Stieger, B., Stange, G., and Murer, H. 2007. Isolation of renal proximal tubular brush-
border membranes. Nat Protoc 2:1356-1359. 
394. Tallquist, M.D., and Soriano, P. 2000. Epiblast-restricted Cre expression in MORE mice: a tool 
to distinguish embryonic vs. extra-embryonic gene function. Genesis 26:113-115. 
395. Guo, C., Yang, W., and Lobe, C.G. 2002. A Cre recombinase transgene with mosaic, widespread 
tamoxifen-inducible action. Genesis 32:8-18. 
396. Traykova-Brauch, M., Schonig, K., Greiner, O., Miloud, T., Jauch, A., Bode, M., Felsher, D.W., 
Glick, A.B., Kwiatkowski, D.J., Bujard, H., et al. 2008. An efficient and versatile system for 
acute and chronic modulation of renal tubular function in transgenic mice. Nat Med 14:979-984. 
397. Schonig, K., Schwenk, F., Rajewsky, K., and Bujard, H. 2002. Stringent doxycycline dependent 
References 
184 
 
control of CRE recombinase in vivo. Nucleic Acids Res 30:e134. 
398. Aslakson, C.J., and Miller, F.R. 1992. Selective events in the metastatic process defined by 
analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer 
Res 52:1399-1405. 
399. Dey, J.H., Bianchi, F., Voshol, J., Bonenfant, D., Oakeley, E.J., and Hynes, N.E. 2010. Targeting 
fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs 
mammary tumor outgrowth and metastasis. Cancer Res 70:4151-4162. 
400. Tobiume, K., Matsuzawa, A., Takahashi, T., Nishitoh, H., Morita, K., Takeda, K., Minowa, O., 
Miyazono, K., Noda, T., and Ichijo, H. 2001. ASK1 is required for sustained activations of 
JNK/p38 MAP kinases and apoptosis. EMBO Rep 2:222-228. 
401. Knaup, K.X., Jozefowski, K., Schmidt, R., Bernhardt, W.M., Weidemann, A., Juergensen, J.S., 
Warnecke, C., Eckardt, K.U., and Wiesener, M.S. 2009. Mutual regulation of hypoxia-inducible 
factor and mammalian target of rapamycin as a function of oxygen availability. Mol Cancer Res 
7:88-98. 
402. Ferrara, N. 1995. The role of vascular endothelial growth factor in pathological angiogenesis. 
Breast Cancer Res Treat 36:127-137. 
403. Lambert, G., Traebert, M., Biber, J., and Murer, H. 2000. Cleavage of disulfide bonds leads to 
inactivation and degradation of the type IIa, but not type IIb sodium phosphate cotransporter 
expressed in Xenopus laevis oocytes. J Membr Biol 176:143-149. 
404. Chang, Q., Hoefs, S., van der Kemp, A.W., Topala, C.N., Bindels, R.J., and Hoenderop, J.G. 
2005. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 
310:490-493. 
405. Bryant, D.M., and Stow, J.L. 2005. Nuclear translocation of cell-surface receptors: lessons from 
fibroblast growth factor. Traffic 6:947-954. 
406. Wu, Y., Chen, Z., and Ullrich, A. 2003. EGFR and FGFR signaling through FRS2 is subject to 
negative feedback control by ERK1/2. Biol Chem 384:1215-1226. 
407. Murakami, M., Elfenbein, A., and Simons, M. 2008. Non-canonical fibroblast growth factor 
signalling in angiogenesis. Cardiovasc Res 78:223-231. 
408. Thomas, G.V., Tran, C., Mellinghoff, I.K., Welsbie, D.S., Chan, E., Fueger, B., Czernin, J., and 
Sawyers, C.L. 2006. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in 
kidney cancer. Nat Med 12:122-127. 
409. Pende, M., Um, S.H., Mieulet, V., Sticker, M., Goss, V.L., Mestan, J., Mueller, M., Fumagalli, 
S., Kozma, S.C., and Thomas, G. 2004. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and 
rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-
activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24:3112-3124. 
410. Ruvinsky, I., Sharon, N., Lerer, T., Cohen, H., Stolovich-Rain, M., Nir, T., Dor, Y., Zisman, P., 
and Meyuhas, O. 2005. Ribosomal protein S6 phosphorylation is a determinant of cell size and 
glucose homeostasis. Genes Dev 19:2199-2211. 
411. Razzaque, M.S., and Lanske, B. 2006. Hypervitaminosis D and premature aging: lessons 
learned from Fgf23 and Klotho mutant mice. Trends Mol Med 12:298-305. 
 
Abbreviations 
185 
 
10 Abbreviations 
1,25(OH)2D) active vitamin D 
AC  adenylat cyclase 
ADAM  a disintegrin and 
metalloproteinase domain 
ADHR autosomal dominant 
hypophoshatemic rickets 
ANG  angiopoeitin 
AREG  epiregulin, amphiregulin 
ARHR autosomal recessive 
hypophosphatemic rickets 
BBM brush border membrane 
BCL  b-cell lymphoma 
BCR  breakpoint cluster region 
BLM Bloom’s syndrome (known as 
Bloom-Torre-Machacek 
syndrome) 
BTC  betacellulin 
BUN  blood urea nitrogen 
CaR  Calcium-sensing receptor 
CB28  Calbindin 1 
CBL  casitas B-lineage lymphoma 
C/EBP CCAAT/enhancer-binding 
protein 
CKD  chronic kidney disease 
cKO  conditional knock-out 
CoCl2  cobalt chloride 
COFS cerebro-oculo-facio-skeletal 
syndrome 
Cyp7A1 cholesterol 7α-hydroxylase 
DAG  diacylglycerol 
DMP1  Dentin Matrix Protein-1 
DSB  double-strand break 
ECM  extracellular matrix 
EGF/EGFR epidermal growth factor/ 
receptor 
EMT epithelial-mesenchymal-
transition 
ER  estrogen receptor 
ErbB1-4 epidermal growth factor receptor 
(EGFR) family (avian 
erythroblastosis oncogene B) 
ERK1/2  extracellular signal-regulated 
kinase 
ES   embryonic cells 
FAK  Focal adhesion kinase 
FD  Fibrous dysplasia 
FEPO4  Fractional excretion of 
phosphate 
FGF/FGFR fibroblast growth factor / 
receptor 
FGFBP FGF-binding protein 
FLRT3 Fibronectin leucin-rich 
transmembrane protein 3 
FOP  FGFR1 oncogene partner 
FRS2  FGF receptor substrate 2 
GAPDH Glycerinaldehyd-3-phosphat-
Dehydrogenase 
GAB1 GRB2-associated binding 
protein 1 
GALNT3 UDP-N-acetyl-a-D-
galactosamine/polypeptide N-
acetylgalactosaminyl 
transferase-3 
GFR glomerular filtration rate 
GRB2  growth factor receptor-bound 2 
HB-EGF heparin binding EGF-like 
growth factor 
HBS heparan sulphate 
glycosaminoglycan binding site 
HGF  hepatocyte growth factor 
HGPS Hutchinson-Gilford progeria 
syndrome 
HIF1α  hypoxia inducible factor 1α 
HR  homologous recombination 
HS  heparan sulphate 
HSGAG heparan sulphate 
glycosaminoglycan 
HSS hyperostosis-hyperphosphatemia 
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syndrome 
IAP1  Inhibitor of apoptosis 
ICL  interstrand crosslinks 
Ig  Immunoglobulin 
IGH  Immunoglobulin heavy chain 
JNK  Jun N-terminal kinase 
KD  knock-down 
kDa  kilo Dalton 
KGF  keratinocyte growth factor 
KO  knock-out 
KsM kidney specific Memo knock-out 
LC-MSMS Liquid Chromatography/Mass 
Spectrometry/Mass 
Spectrometry 
LDL low density lipoprotein 
LMNA the lamin A/C gene 
MAPK Mitogen activated protein kinase 
MEF  mouse embryonic fibroblast 
Memo Mediator of ErbB-driven cell 
motility 
MEPE a gene expressed in bone 
marrow and tumors causing 
osteomalacia 
MKP3  MAPK phosphatase 3 
MMP  matrix metalloproteinase 
Na-Pi  sodium phosphate cotransporter 
NCAM neural cell adhesion molecule 
NGAL  Neutrophil gelatinase-associated 
lipocalin 
NHERF1 Na/H-exchanger regulatory 
factors 
NRG  neuregulin 
NTRK1 neurotrophic tyrosine kinase 
receptor type 1 
NCX1 sodium-calcium exchanger 
PDZ PSD-95, Discs-large and ZO-1 
PHEX phosphate regulating gene with 
homologies to endopeptidases 
on the X chromosome 
PI  phosphatidylinositol 
PI3K  Phosphatidylinositol-3 kinase 
PIP3 phosphatidylinositol-3,4,5-
triphosphate 
Pit-2 a type III Na-Pi cotransporter, 
that belongs to the SLC20 gene 
family 
PKA Protein kinase A 
PKC  Protein kinase C 
PLC  Phospholipase C 
PMCA  plasma membrane Ca2+ ATPase 
PTB  phosphotyrosine binding 
PTEN   phosphatase and tensin homolog 
PTH  parathyroid hormone 
PTHR1 parathyroid hormone receptor 1 
PTHrP  PTH-related peptide 
PZHR1 PZH/PTHrP-receptor 
QPCR  quantitative real time PCR 
RET  rearranged during transfection 
RMS  rhabdomyosarcoma 
RXR  retinoid receptor 
S6K/RSK S6 kinase/ribosomal S6 Kinase 
SCLL  stem cell leukemia/lymphoma
  syndrome 
SEF   similar expression to fgf genes 
Ser  serine 
sFRP-4 secreted frizzled-related protein-
4 
SH2 src homology 2 
SHP2  src homology phosphatase 2 
SIBLING  small integrin binding ligand n-
linked glycoprotein 
SNP  single nucleotide polymorphism 
SOS  son of sevenless 
STAT transducer and activator of 
transcription proteins 
TC-NER transcripton-coupled nucleotide 
excision repair 
TGF  Transforming growth factor 
TIO Tumor-induced 
rickets/osteomalacia 
TOP 5’ terminal oligopyrimidine tract  
TOR  Target of rapamycin 
TrkA/TrkB tropomyosine receptor kinase 
A/B 
TRP   Tubular reabsorption of 
phosphate 
TRPV5 transient receptor potential 
vanilloid 5 
Tyr  tyrosine 
VDR  vitamin D receptor 
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VDRE  vitamin D response element 
VEGF vascular endothelial growth 
factor 
WCE  whole cell extract 
Wrn/WS Werner gene 
XFE  Epf-Errcc1 syndrome 
XIAP  X-linked inhibitor of apoptosis 
XLH X-linked hypophosphatemic 
rickets 
ZNF  zinkfinger 
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